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ABBREVIATIONS  
ACC  Acinic cell carcinoma 
ACT  Adenoid cystic carcinoma 
APP Adhesion promoting protein 
BAL  Broncheoalveolar lavage 
CE Capillary electrophoresis  
CHAPS 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulphonate 
CUB  C1r/C1s Uegf Bmp1 
DMBT1  Deleted in Malignant Brain Tumors 1 
DMBT1pbs1 DMBT1 pathogen binding site 1 
DNA Deoxyribonucleic acid 
DSS Dextran sulfate  
EcAf Eikenella corrodens aggregating factor 
ECM  Extra cellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FPLC Fast protein liquid chromatography 
gp-340  glycoprotein 340 
HPLC High pressure liquid chromatography 
IgG Immunoglobulin G 
Lab Labial 
LPS  Lipopolysaccharide 
LTA  Lipoteichoic acid 
mAb  Monoclonal antibody 
MARCO Macrophage scavenger receptor with collagenous structure 
MEC  Mucoepidermoid carcinoma 
MSR1 Macrophage scavenger receptor 
PA Pleomorphic adenoma 
PAMP Pathogen associated molecular structure 
PAR Parotid 
PBS Phosphate buffered saline 
PRG Proline-rich glycoprotein 
PRR  Pattern recognition receptor 
Q-TOF Quadrupole time of flight 
SAG  Salivary agglutinin 
SDS-PAGE  Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
S-IgA Secretory immunoglobulin A 
SID  SRCR interspersed domain 
SL  Sublingual 
SM Submandibular 
SP A, D  Surfactant protein A, D 
SRCR  Scavenger receptor cysteine-rich 
SRCRP SRCR peptide 
TBS  Tris buffered saline 
TMB 3,3’,5,5’ tertamethylbenzidine 
TT TBS + tween 
TTC TT + calcium 
VUMC Free university medical center 
ZP  Zona pellucida 
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Background 
The oral cavity is a common portal for microbe entry and harbors an enormous variety of micro-organisms. 
The mouth is readily accessible and may be useful to monitor microbe-microbe and host-microbe interactions, 
such as colonization processes of the teeth and mucosal surfaces, and the protective functions of saliva. Saliva 
has been regarded as a representative mucosal secretory product. Proteins that are present in saliva serve 
similar functions when present in other mucosal fluids including sweat, tears, nose fluid, bronchoalveolar 
lavage, seminal plasma, and the mucus of the gastrointestinal tract. Therefore, the oral cavity and saliva as a 
whole is considered as a suitable and representative model system to study host (mucosal) defense systems. 
(1;2). 
 
The salivary glands 
Human saliva is a product of various salivary glands. These include the major salivary glands: the paired 
parotid, submandibular and sublingual glands (Fig. 1), and approximately 450-750 minor salivary glands, 
which are scattered through the inner surface of the oral mucosa, lips, palate, cheeks and tongue (3;4).  
 
Figure 1. Anatomic location of the major human 
salivary glands. PAR, parotid gland; SL, sublingual 
gland; SM, submandibular gland. (Adapted from Netter 
F. H. (1959). The Ciba collection of medical 
illustrations. Vol. 3, pt 1). 
 
 
 
 
 
 
 
 
The terminal parts of the salivary secretory system are the acinar cells, which are grouped in lobes (acini) (Fig. 
2). The acinar cells are divided into serous and mucous cells, essentially on basis of whether they secrete high 
molecular weight mucins or not (5;6). For example, the secretions of sublingual and palatinal glands are rich 
in high molecular weight mucins. These mucins determine the visco-elastic or mucous properties of saliva (6). 
On the other hand, the secretory product of the parotid glands is devoid of mucins, and therefore has a more 
watery or serous characteristic. 
Each salivary gland type is composed of a typical combination of serous acini and mucous acini. For example, 
the parotid gland contains exclusively serous acini, whereas both sublingual and labial salivary glands contain 
exclusively mucous acini. The submandibular gland is a mixed gland since it is composed of both serous and 
  GENERAL INTRODUCTION 
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mucous acini. The properties and protein composition is unique for each glandular secretion and a result of the 
particular cellular composition of each salivary gland. 
The sublingual, submandibular and the minor salivary glands secrete continuously at 0-0,5 ml/min. The 
sublingual and submandibular salivary glands can increase their secreted volume to eight and ten times, 
respectively, when stimulated appropriately (7). The parotid glands have, when unstimulated, no measurable 
secretion, but become the major source of oral fluid, when stimulated (7). So, unstimulated whole saliva is 
dominated by the sublingual and submandibular components, whilst acid- and mechanically stimulated saliva 
has a composition close to that of parotid saliva. Therefore, the composition of saliva varies according to the 
particular mixture of secretions from the different glands elicited by the degree of stimulation.   
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Anatomy of a typical salivary gland. On secretion by the acini (Ac), the salivary fluid, first passes through 
the intercalated ducts (ICD; cross section, ICD’). Of the entire ductal system, these ducts contain the smallest diameter 
and are formed by cubical-shaped epithelial cells. Situated at the terminal part of the acini are the demilune cells (DC). 
The intercalated ducts pass on to the striated ducts (SD; cross section, SD’). These ducts are lined by columnar-shaped 
cells. The most prominent characteristic of these cells is the presence of striations at the basal ends of these cells, caused 
by the presence of numerous mitochondria. Finally, the salivary fluid is secreted into the oral cavity through the terminal 
excretory ducts (ED). 
 
The protective functions of saliva  
Saliva contains a large number of proteins, which may effectuate different functions simultaneously. For 
example, the salivary mucins are involved in lubrication but also prevent desiccation of the oral mucosa, and 
furthermore, they are involved in antimicrobial defense (8). Figure 3 provides an overview of the 
multifunctionality of salivary proteins. On the other hand, various salivary proteins fulfill similar functions. 
For example, a number of proteins including immunoglobulins, histatins, lysozyme, lactoferrin, 
lactoperoxidase, cystatins, mucins and salivary agglutinin (SAG) are all involved in the protection of the oral 
cavity by exhibiting antimicrobial activity (1). 
CHAPTER 1   
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Figure 3. The functions of saliva. (Adapted from Levine M. J. (1993). Am. NY Acad. Sci. 694: 11-16). 
 
The protective role of saliva is best demonstrated in patients suffering from hyposalivation, i.e. reduction of 
salivary flow rate below physiological values. Hyposalivation may be caused by stress, medication use or 
destruction of the salivary gland tissues (9-11). The latter phenomenon can be a consequence of radiotherapy 
in the head-neck region or an autoimmune disease like the Sjögren syndrome (12). In general, patients 
suffering from hyposalivation have difficulties in chewing and swallowing food, problems in speaking and 
articulation, and suffer from pain sensations of the tongue and oral mucosa (13). Also, these patients display a 
higher risk of microbial colonization of oral tissues and opportunistic infections e.g. by Streptococcus mutans, 
Lactobacillus spp and Candida albicans (14-16). 
Saliva regulates the colonization of endogenous and exogenous micro-organisms via various mechanisms 
(17). On the one hand, saliva may enhance bacterial colonization by forming receptors on the dental or 
mucosal surfaces and serving as a microbial nutrient. Salivary proteins, which are coated the dental surface, 
the acquired pellicle, functions as a substratum for adhering bacteria. Proline-rich proteins and statherins are 
major initial constituents and mucins are major mature constituents of the acquired pellicle; they are important 
receptors for adhesion of oral bacteria (18-21). Besides, the salivary mucins, which contain a great variety of 
carbohydrate residues, are considered as the major source of salivary nutrients for micro-organisms. Micro-
organisms express only a limited set of carbohydrate degrading enzymes. This means that the complex 
carbohydrate moiety of the salivary mucins gives rise to great variety of micro-organisms with complimentary 
enzyme activities (22-24).  
On the other hand, saliva contains several proteins in soluble phase, which inhibit the colonization of bacteria 
to oral surfaces by exposing antimicrobial activity or by inhibiting adherence. Antimicrobial proteins 
  GENERAL INTRODUCTION 
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exhibiting bactericidal and candidacidal activity include lysozyme, lactoperoxidase, lactoferrin and histatins 
(1). Though, considering the number of bacteria (108/ml) and the variety of species (>400) that are present in 
the oral cavity, the effect of these antimicrobial proteins in vivo appears to be limited. In addition, other 
salivary proteins have the ability to bind and agglutinate bacteria in saliva. These proteins interfere with 
ligands on the microbial cell wall and inhibit the adherence of bacteria to the dental and mucosal surfaces, for 
example by mimicking adhesive sites on oral tissues. In this way these proteins have been implicated to play a 
role in caries resistance (25;26). The major aggregating proteins in saliva are the immunoglobulins (mainly S-
IgA), mucins (MUC5B and in particular MUC7) and SAG (1). The aim of our study was to unravel 
structurally related protective functions of SAG in the oral cavity. Primarily we focused on SAG-bacterial 
interactions and the localization of SAG in the salivary glands and in glandular salivas. 
 
SAG  
Searching for S. mutans agglutinating components in saliva, Ericson and Rundegren isolated twenty years ago 
a 300-400 kDa glycoprotein, SAG, by affinity adsorption with S. mutans (27). Polyacrylamide gel 
electrophoresis, analytical centrifugation, and analyses of amino acids and carbohydrates showed that the 
native SAG was a fucose-rich glycoprotein with a carbohydrate content of approximately 25% - 40%. It was 
found that the carbohydrate moiety consisted of 6% sialic acid residues and 12% fucose (28-30). The 
concentration of SAG in parotid saliva was determined to be less than 0.5% of the total protein content (27). 
This might be a reason that SAG was neglected in several studies on bacteria binding salivary proteins 
(31;32). Besides, other studies described a protein with comparable characteristics and a comparable 
molecular weight with that of SAG, designated Eikenella corrodens aggregating factor (EcAf) (33) and APP 
(adhesion promoting protein) (34). However, none of these studies explored the protein on a molecular level, 
thus conclusive evidence about the identity of these proteins remained unknown. 
More effort was put into the characterization of SAG-bacterial interactions. Due to its S. mutans binding 
properties SAG had been implicated to play a role in the protection against dental caries (35;36). It was shown 
that SAG binds in a calcium dependent manner to antigen I/II, a surface receptor on streptococci (37-39). 
Moreover, SAG showed a calcium dependent binding to S-IgA, resulting in synergy of bacterial binding 
(29;40). In line with these results it was demonstrated that high salt concentrations and EDTA  inhibited 
adhesion of S. mutans to SAG-coated microtiterplates (41;42). 
Studies that were focused on bacterial receptors on SAG mainly described the characterization of carbohydrate 
ligands (29;38;42;43). For example, SAG-mediated agglutination of S. mutans was most potently inhibited 
with high concentrations of fucose and lactose. S. sanguis was found to be exclusively mediated by sialic acid 
residues (38). Besides,  Ligtenberg and co-workers demonstrated by immunoblotting that SAG contained 
blood group reactive antigens and Lewis (Le) antigens (42). It was shown that the Le a-antigen (Gal β 1,3(Fuc 
α 1,4)GlcNAc), was involved in S. mutans binding, harboring an essential role for the terminal fucose.  
A large number of studies revealed that carbohydrate residues on SAG play only a partial role in binding and 
agglutination of bacteria. For example, competitive inhibition assays with monovalent carbohydrates gave 
CHAPTER 1   
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inconsistent results (29;38;42). Moreover, chemical modification of the carbohydrate residues of SAG only 
slightly impaired its agglutinating properties (43). On the other hand, treatments affecting the polypeptide 
moiety abolished binding to S. mutans and IgA completely, suggesting a dominant role for the peptide 
domains in ligand binding (29;42;43). However, the precise role of the polypeptide chain in bacterial binding 
remained unknown.  
 
SAG is more than a salivary protein 
Thus, SAG has intensely been investigated with regard to its role in binding and agglutination of cariogenic 
bacteria in the oral cavity. Recent discoveries have expanded both the available data and the view on this 
molecule in an explosive manner. Genetic and biochemical analysis revealed that SAG and gp-340 contain an 
identical amino acid sequence and represent the isoforms of Deleted in Malignant Brain Tumors 1 (DMBT1) 
secreted in saliva (DMBT1SAG) and lung fluid (DMBT1GP340), respectively (44). DMBT1 was first studied in 
brain tissue, where its loss of heterozygosity was related to the development of brain cancer. DMBT1 is 
located on chromosome 10q25.3-26.1 and contains 59 highly homologous introns, which possibly cause the 
genetic instability of DMBT1 (44;45). Furthermore, DMBT1 was proposed to be involved in epithelial 
differentiation and as putative tumor-suppressor in the gastrointestinal tract and the lung (46;47).  
 
OUTLINE OF THIS THESIS 
 
Focusing on the polypeptide chain of SAG, the aim of this study was to unravel the role of SAG in the innate 
immune system, using the oral cavity and saliva as model systems. 
* In chapter 2 we show that SAG and gp-340, a lung isoform of DMBT1 and a member of the SRCR 
superfamily, contain an identical amino acid sequence. These molecules both interact with S. mutans and 
surfactant protein D. 
* In chapter 3 we characterize two mAbs that were raised against gp-340. These mAbs were used to localize 
SAG/DMBT1 in the human parotid, submandibular and labial salivary glands by immunohistochemistry. 
* In chapter 4 SAG/DMBT1 is localized in salivary gland tumors and tumor surrounding tissues by 
immunohistochemistry. 
* In chapter 5 the identification of the bacterial-binding site of SAG/DMBT1 is described. 
* In chapter 6 it is postulated that bacterial binding by the bacterial-binding site on SAG/DMBT1 is unique for 
SAG/DMBT1 and DMBT1 orthologs  
* In chapter 7 it is shown that the scavenging capacity (bacterial binding) of SAG/DMBT1 is impaired by 
germline deletions. 
* In chapter 8 SAG/DMBT1 is shown to bind sulfated and phosphorylated ligands, including typical PAMPs, 
such as lipopolysaccharide and lipoteichoic acid.  
* In chapter 9 an overview of the whole study is presented and critically discussed giving an outlook for 
further research. 
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Human Salivary Agglutinin Binds to Lung Surfactant Protein-D and is Identical to Scavenger Receptor 
Protein gp-340/DMBT1 
 
Antoon J.M. Ligtenberg, Floris J. Bikker, Jasper Groenink, Ida Tornoe, Rikke Leth-Larsen, Enno C.I. 
Veerman, Arie V. Nieuw Amerongen and Uffe Holmskov 
 
Biochem. J. 359, 243-248 (2001) 
 
Salivary agglutinin (SAG) is a 300-400 kDa salivary glycoprotein that binds to antigen B polypeptides of oral 
streptococci thereby playing a role in their colonization and the development of caries. Of a trypsin digest of 
SAG a mass spectrum was recorded. A dominant peak of 1460 Da was sequenced by Quadrupole time of 
flight (Q-TOF) tandem mass spectrometry. The sequence showed 100 % identity with part of a scavenger 
receptor cysteine rich (SRCR) domain found in gp-340/DMBT1. The mass spectrum revealed 11 peaks with 
an identical mass as a computer-simulated trypsin digest of gp-340.  
gp-340 is a 340 kDa glycoprotein isolated from bronchoalveolar lavage fluid that binds specifically to lung 
surfactant protein D. gp-340 is encoded by DMBT1 (Deleted in Malignant Brain Tumors 1) and is a candidate 
tumor suppressor gene. A search in the human genome revealed only one copy of the gene. The molecular 
mass as judged by SDS-PAGE and the amino acid composition of SAG were found to be nearly identical to 
that of gp-340. By Western blotting it was shown that monoclonal antibodies directed against gp-340 reacted 
with SAG and monoclonal antibodies directed against SAG reacted with gp-340. It was demonstrated that gp-
340 and SAG bound in a similar way to S. mutans and surfactant protein D. Histochemically, gp-340 
distribution in the submandibular salivary glands was identical to the SAG distribution as reported elsewhere 
(Takano et al., 1991). We conclude that SAG is identical to gp-340 and that this molecule interacts with S. 
mutans and surfactant protein D. 
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INTRODUCTION 
 
Salivary agglutinin (SAG) is a 300-400 kDa glycoprotein that originally was isolated by affinity adsorption of 
parotid saliva to Streptococcus mutans (1). It induces aggregation of S. mutans (1;2) and was shown to be 
present in the salivary pellicle on the tooth surface (3). Immobilized on hydroxylapatite it promotes adhesion 
of S. mutans (3-6). In addition, SAG mediates binding between S. mutans and Streptococcus sanguis, which is 
one of the first colonizers of the dental surface (7). It forms heterotypic complexes with IgA (8-10). This 
complex formation is calcium-dependent (8-10) and disrupted by reduction (9).   
The primary structure of gp-340, a glycoprotein purified from lung washings with a molecular weight that is 
comparable to SAG, has recently been described (9;11;12). gp-340 co-purified with surfactant protein D (SP-
D) from bronchoalveolar lavage (BAL) on carbohydrate affinity columns and purified SP-D binds gp-340 
through a protein-protein interaction in a calcium dependent manner (9;11). SP-D is a member of the collectin 
family. Collectins play an important role in the innate immunity by binding to specific carbohydrate structures 
on the surfaces of pathogenic microorganisms, including bacteria, viruses, yeasts, and parasitic protozoa. This 
binding enhances phagocytosis and killing of microorganisms by neutrophils and alveolar macrophages 
(13;14). The gp-340 molecules exist both in a soluble form and in a form associated with the alveolar 
macrophage and it has been suggested as a potential opsonin receptor for SP-D.  
gp-340 is an alternatively spliced form of DMBT1, a gene identified as a candidate tumor suppressor gene for 
tumors of the central nervous system (15). It is a member of the scavenger receptor cysteine-rich (SRCR) 
superfamily, a group of molecules that are primarily involved in various types of ligand binding in the innate 
immune system. gp-340 is composed of 13 SRCR domains, two CUB domains separated by a 14th SRCR 
domain and a zona pellucida (ZP) domain and a short sequence with no known homology. It was 
demonstrated by RT-PCR that gp-340 is also expressed in salivary gland tissue and immunoreactive gp-340 
was also found in the salivary ducts (12).  
Until recently, nothing was known about the molecular structure of SAG making it difficult to do functional 
studies. Recently it has been demonstrated that the polypeptide chain of SAG is identical to that of gp-
340/DMBT1 (16). Here we report data corroborating this observation and demonstrate that both proteins are 
not only identical on a genetic level, but also show similar binding characteristics for monoclonal antibodies, 
S. mutans and SP-D. Immunohistochemically gp-340 expression is demonstrated in the salivary gland.  
 
EXPERIMENTAL PROCEDURES 
 
Antibodies  
Monoclonal antibody against SAG (mAb143) with a specificity as described previously (17;18) was kindly 
provided by dr. D. Malamud (University of Pennsylvania). Antibodies against gp-340 (Hyb213-1 and 
Hyb213-6) have been described previously (11;19). Alkaline phosphatase conjugated goat anti-rabbit IgG 
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antibody (whole molecule) (A-8025) and alkaline phosphatase conjugated goat anti-mouse IgG antibody 
(whole molecule) (A-2527) were obtained from Sigma (St. Louis, MO, USA).  
 
Purification of SAG  
Parotid saliva was collected with a Lashley cup under stimulation with sugar-free candies and incubated on ice 
water resulting in the formation of precipitates containing SAG. After centrifugation (15 min, 5000 x g, 4oC) 
the pellet was resuspended in 1/10 volume of buffer A (10 mM Tris, 10 mM EDTA, pH 6.9, 0.05% CHAPS). 
Samples were applied on an Uno Q-6 column (BioRad Laboratories, Hercules, CA). Retained proteins were 
eluted with a linear gradient from 0 to 0.5 M NaCl in buffer A. SAG containing fractions were pooled and 
purity was checked by electrophoresis. This sample was used for binding studies with SP-D.  
 
Isolation of gp-340 and SP-D 
gp-340 was isolated from human bronchoalveolar lavage (BAL) as described previously (11). SP-D was 
purified from BAL as described by Strong et al. (20). 
 
SDS-PAGE and Western blotting 
SDS-PAGE was conducted on a Pharmacia Phast System (Pharmacia-LKB, Uppsala, Sweden) according to 
the manufacturers instructions. Proteins were dissolved in sample buffer containing 15 mM Tris-HCl, pH 6.8, 
0.5 % SDS, 2.5 % glycerol and 0.05 % bromophenol blue. For reduction samples were incubated with 25 mM 
dithiothreitol (ICN Biomedicals, Aurora, Ohio). Samples were separated on 4-15 % (w/v) or 7.5 % 
polyacrylamide gels. For Western blotting proteins were transferred to nitrocellulose membranes by diffusion 
blotting. Nitrocellulose membranes were blocked with PBS containing 2% bovine serum albumin (BSA) and 
0.1 % Tween 20 (PBS-T-BSA). Incubation with antibodies was also conducted in PBS-T-BSA. Bound 
antibodies were detected with alkaline phosphatase conjugated goat anti-mouse immunoglobulins (whole 
molecule) (A-2527, Sigma) and 5-bromo-4-chloro-3-indolyl-phosphate (Roche Diagnostics, Mannheim, 
Germany) was used as substrate.  
 
Determination of internal sequence 
SAG-enriched saliva was separated on 4-15% Tris -acetate gels (Novex, San Diego, CA, USA). The gels were 
stained with Coomassie Brilliant Blue R250 (Sigma, St.Louis, MO, USA) in 10 % acetic acid and 25 % 
methanol and destained in the same solution without Coomassie Brilliant Blue. The SAG band was excised 
and incubated for 10 min with 100 µl acetonitrile. After removing acetonitrile, gel fragments were dried for 30 
min in a vacuum centrifuge. Trypsin digestion was conducted by overnight incubation in 20 µl trypsin 
sequence grade (Roche Diagnostics) solution (20 ng/ml in 50 mM NH4HCO3). Peptide fragments were 
subsequently extracted and wash fluid was pooled and concentrated to a volume of 30 µl. The sample was 
applied on a Poros 50 column. The column was washed with 5% formic acid/5 % methanol. The sample was 
extracted in 10 µl 5% formic acid/60% methanol and applied on a Quadrupole Time Of Flight (Q-TOF; 
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Micromass UK Ltd) hybrid tandem mass spectrometer. In the MS mode a mass spectrum of the total peptide 
mixture was recorded. A dominant peptide peak was selected and an MS-MS spectrum was recorded by which 
the amino acid sequence was determined. Sequence similarity was searched with a Protein Data Bank. Amino 
acid composition and location of determined sequences were determined with the Protean program of DNA 
Star (DNA Star Inc., USA). The DMBT1 sequence (15) was used to do a database search on the human 
genome with the BLAST program at http://www.ncbi.nlm.nih.gov (21).  
 
Bacterial binding assay  
Binding experiments were conducted with S. mutans strain Ingbritt. The strain was stored frozen in Protect 
bacterial preservers (Technical Service Consultants Ltd., Bury. U.K.). Bacteria were cultured on blood agar 
plates and grown for 48 h at 37°C under micro-aerophilic conditions. One colony was used for inoculation in 
Todd Hewitt broth (Difco Laboratories, Detroit, MI, U.S.A.) and cultures were grown overnight at 37°C in 
completely filled 100 ml flasks under air without shaking. Cells were harvested by centrifugation (3000 x g at 
4°C for 10 min), washed in PBS, and resuspended in PBS to an optical density at 700 nm of 1.0 (109 cells/ml). 
The bacterial suspension (0.5 ml) was pelleted by centrifugation for 2 min at 10.000 x g. The pellet was 
resuspended in 40 µl gp-340 solution (OD280 = 0.014), SAG or BAL fluid. After one hour of incubation at 
37°C, bacteria were pelleted by centrifugation and washed with PBS. Hereafter, bacteria were resuspended in 
sample buffer and incubated for one hour at room temperature. After centrifugation the supernatant was 
prepared for SDS-PAGE by boiling for 5 min.  
  
Analysis of SP–D binding to SAG and gp–340 
Microtiter plates (Polysorp, Nunc, Kamstrup, Denmark) were coated with SAG or gp–340 (300 ng/ml) in 
coating buffer (60 mM Na2CO3, 35 mM NaHCO3, 0.02% (w/v) NaN3, pH 9.6) by overnight incubation. This 
incubation and all the following steps were carried out in a volume of 100 µl per well at room temperature, 
and all washes and incubations were carried out with TBS-T (Tris-buffered saline (TBS): 140 mM NaCl, 10 
mM Tris-HCl, 0.02% (w/v) NaN3, pH 7.4; TBS-T: TBS containing 0.05% (v/v) Tween 20 (polyoxyethylene 
sorbitan monolaurate, Merck-Schuchardt, Germany) containing 5 mM CaCl2 unless otherwise stated. The 
plates were washed and incubated with 200 µg of human serum albumin (Statens Seruminstitut) in 200 µl TBS 
for 2 h. After washing, the plates were incubated with dilutions of SP–D, or SP–D containing 100 mM 
maltose. As a control the SP–D was also applied in buffer containing 10 mM EDTA instead of calcium. The 
plates were incubated overnight at 4ºC and washed. They were then incubated for 2 h with rabbit anti–human 
SP–D antiserum diluted 1:500 in TBS-T. After washing, the plates were incubated for 2 h with alkaline–
phosphatase–coupled goat anti–rabbit Ig diluted 1:2000. After a final wash, the bound enzyme was estimated 
by adding para–nitrophenyl phosphate disodium salt (1 mg/ml) (Roche Diagnostics) in diethanolamine buffer. 
The absorbance of the 96 wells was read at 405 nm by means of a multichannel spectrophotometer.  
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Immunohistochemistry 
Four sections were cut from neutral–buffered formaldehyde–fixed paraffin–embedded tissue blocks. Sections 
were mounted at ChemMate Capillary Gap Slides (DAKO, Glostrup, Denmark) dried at 60° C, deparaffinized 
and hydrated. Antigen retrieval was performed using microwave heating in Target Retrieval Solution (DAKO, 
Glostrup, Denmark). Three Tissue–Tek containers (Miles Inc, Elkhart, IN USA), each with 24 slides in 250 ml 
buffer, were placed on the edge of a turntable inside the microwave oven. Slides were heated 11 min at full 
power (900W), then for 15 min at 400W. After heating, slides remained in buffer for 15 min. Antigen retrieval 
was followed by blocking of endogenous biotin, using Dako Biotin–Blocking System (DAKO, Glostrup, 
Denmark). Incubation with Hyb 213–6 (17 µg/ml) was done for 25 min at room temperature. Immunostaining 
was automated using the ChemMate HRP/DAB detection kit, K5001 (DAKO, Glostrup, Denmark) on the 
TechMate 1000 instrument (DAKO, Glostrup, Denmark). Immunostaining was followed by brief nuclear 
counter staining in Mayers hematoxylin. Finally, cover slips were mounted with AquaTex (Merck, Darmstadt, 
Germany). Controls were performed by replacing the primary monoclonal antibody with an unrelated 
monoclonal antibody of the same subclass as the gp–340 antibodies. 
 
RESULTS 
 
Amino acid composition and sequence 
SAG was separated by SDS-PAGE under reducing conditions. A band was excised and digested with trypsin 
and analyzed by Q-TOF mass spectrometry. The amino acid sequence of a 1460 Da peak of the mass spectrum 
was determined by tandem mass spectrometry (Fig. 1). This sequence showed 100% homology with a part of 
a scavenger receptor cysteine-rich (SRCR) domain of gp-340 and DMBT1. Peaks of the mass spectrum were 
compared with a trypsin digest of gp-340 (Table 1) and revealed 11 peaks with the same mass. The amino acid 
composition as determined by Ericson and Rundegren (1) for SAG was compared with the amino acid 
composition as determined by Holmskov et al. (12) and the composition developed from the amino acid 
sequence (11) (Table 2). A high degree of similarity was observed.  
 
Human genome search 
The sequence of the DMBT1 gene was used to search for homology in the human genome. No other candidate 
gene was found for a glycoprotein of 300-400 kDa containing this sequence than the DMBT1 gene itself. This 
means that the SAG must be expressed by the DMBT1 gene. 
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Figure 1. Mass spectrum of a 
trypsin digest of SAG as determined 
by Q-TOF mass spectrometry. 
Analysis of the spectrum revealed a 
particular strong peak at 1459.9 
Dalton. This peak was sequenced by 
tandem mass spectrometry and 
showed 100 % homology with a part 
of the SRCR domain of gp-
340/DMBT1 (FGQGSGPIVLDDVR). 
The marked peaks are also found in a 
computer simulated trypsin digest of 
gp-340. 100% on the y-axis represents 
the most intense peak currently on the 
display. 
 
Table 1. Comparison of a trypsin digest of SAG with a computer simulated digest of gp-340. SAG was digested with 
trypsin and a mass spectrum was run on a Q-TOF mass spectrometer. The peptide mass was compared with the mass of 
peptides of gp-340. The marked peptide-fragment was sequenced and showed 100 % homology with a fragment of the SRCR 
domains of gp-340. This fragment was 10 x present in gp-340.   
 
Mass spectrum peak of SAG  Computer-simulated 
digest of gp-340 
Fragment in gp-340 sequence 
535.245 535.31 2108 –2111 
795.428 795.36 2367-2373 
1005.673 1005.57 1804-1812 
1115.611 1115.55 1846-1854 
1420.823 1420.65 2086-2098 
1457.851 1457.65 2326-2338 
1459.914 1459.75 418-431, 549-562, 657-670, 
788-801, 917-930, 1048-1061 
1177-1190, 1306-1319, 1435-1448,  
1695-1708  
1501.787 1502.66 1033-1047 
2254.195 2254.14 2034-2051 
2477.365 2477.19 2086-2107 
2813.615 2813.49 708-734 
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Table 2. Comparison of the amino acid composition of SAG and gp-340. The amino acid composition as determined 
for SAG (9) was compared with the amino acid composition of gp-340 as determined by amino acid analysis (17) and as 
determined from the polypeptide sequence (18).  
Amino acid SAG 
mol/mol protein (9) 
gp-340 
mol/mol protein (17) 
gp-340 
mol/mol protein (18) 
Ala 8.6 6.3 6.05 
Cys  2.4 5.43 
Asx 12.5 12.7 6.46 
Glx 8.6 6.1 3.61(Glu) 
Phe 2.3 3.2 2.11 
Gly 11.4 11 10.73 
His 2.5 2.4 3.11 
Ile 4.4 3.2 3.03 
Lys 1.2 4.3 0.41 
Leu 8.0 8.5 7.05 
Met 0.5 ND 5.14 
Pro 4.3 6.2 5.30 
Arg 6.2 6.1 3.27 
Ser 11.6 10.7 12.06 
Thr 6.0 6.0 5.72 
Val 6.1 7.0 7.09 
Trp  ND 3.69 
Tyr 3.4 3.4 3.07 
Hyp 0.3 0.3  
 
Western blotting with antibodies directed against SAG and gp-340 
SAG and gp-340 were compared on Western blots of parotid saliva and BAL fluid (Fig. 2). The antibody 
against SAG (mAb143) and the antibodies directed against gp-340 (Hyb213-1) reacted with the same bands in 
saliva as well as in BAL. Heterogeneity of the band pattern was observed in both saliva and BAL with some 
people showing two bands (band A and B) for both SAG and gp-340. 
 
Binding of gp-340 and SAG to S. mutans 
Binding of gp-340 and SAG to S. mutans was tested in a soluble phase assay. After incubation bacterial 
extracts were analyzed by Western blotting (Fig. 3). In the presence of calcium both band A and band B of gp-
340 from BAL fluid bind to S. mutans in solution (Fig. 3A). Purified gp-340, containing only one band, and 
SAG both showed binding to S. mutans (Fig. 3C). Binding of gp-340 was inhibited by EDTA (Fig. 3D), as 
previously described for SAG (22). 
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Figure 2. Specificities of monoclonal antibodies directed against SAG and gp-340 analyzed by Western blotting. 
Parotid saliva from seven different persons (left boxes) and BAL samples from five different persons (right boxes) were 
probed by Western blotting with monoclonal anti-SAG antibody (143) and with monoclonal anti-gp-340 antibodies (213-
6 and 213-1). The bound antibodies were visualized by means of alkaline phosphatase-labeled goat anti-mouse IgG and 
substrate as described in Experimental Procedures. 
 
 
Figure 3. Binding of gp-340 and SAG to S. mutans as analyzed by Western 
blotting. Bacterial pellets were suspended and incubated for one hour in panel A, 
crude BAL; panel B, purified gp-340; panel C, purified gp-340 in the presence of 
EDTA; panel D, partially purified SAG. After incubation the bacteria were washed 
and the pellet subjected to SDS-PAGE in the unreduced state followed by Western 
blotting. Lanes 1, starting material before and, lanes 2, after incubation with S. 
mutans. Lanes 3, washed bacterial pellet after incubation with different solutions. 
The blots were incubated with monoclonal anti-gp-340 antibody (Hyb213-1). The 
bound antibody was visualized by means of alkaline phosphatase-labeled goat anti-
mouse IgG and substrate as described in Experimental Procedures. 
 
Binding of SAG and gp-340 to SP-D 
In the presence of calcium, SP-D binds to microtiter plates coated with SAG (Fig. 4). The binding was 
dependent on the concentration of SP-D and on the amount of SAG coated on the plate (not shown). The 
binding was not influenced by the presence of maltose but totally inhibited by the chelation of calcium by 
EDTA. The same binding pattern was found for SP-D binding to gp-340 coated microtiter plates. 
 
Immunohistochemical analysis of gp-340 
Immunohistochemical analysis was conducted with antibody 213-6 against gp-340. In the submandibular 
salivary gland the serous acini and demilune cells were strongly stained. The ducts and mucous acini stained 
negative (Fig. 5). Staining of controls was negative. 
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Figure 4. Binding of SP-D to gp-340 and 
SAG. SAG (open symbols) or gp-340 (filled 
symbols) coated microtiter plates were 
incubated with serial dilutions SP-D in the 
presence of calcium ( -), calcium and 100 
mM maltose (◊ - ◊), or with 10 mM EDTA (∆ - 
∆). Bound SP-D was visualized by means of a 
polyclonal rabbit anti-human SP-D antiserum, 
alkaline phosphatase-labeled goat anti-rabbit 
IgG and substrate as described in Experimental 
Procedures. 
 
 
 
 
 
 
Figure 5. Immunohistochemical 
localization of SAG/gp-340 in the 
submandibular gland. The tissues 
were stained by an indirect 
immunoperoxidase technique and 
counterstained with Mayer’s 
hematoxylin as described in 
Experimental Procedures. Original 
magnification, x 400. 
 
 
 
DISCUSSION 
 
The present report demonstrates that human SAG is identical to gp-340 and that both proteins show similar 
binding characteristics for antibodies, S. mutans and SP-D. SAG is a 300- 400 kDa glycoprotein that was 
originally isolated from parotid saliva by affinity adsorption to S. mutans (1). It has been described as an 
aggregating factor for S. mutans and S. sanguis (23) the binding being mediated via the antigen B polypeptides 
on the surface of these bacteria (24). It showed also complexation with S-IgA and bound to complement factor 
C1q, thereby activating C1 (25).  
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A mass spectrum of a trypsin digest of SAG revealed 11 peaks that were also present in a computer-simulated 
digest of gp-340. Three were fragments of SRCR domains, one fragment of a SID domain, 5 fragments of 
CUB domains and two fragments of the C-terminal region of gp-340 that shows no homology with other 
proteins. One fragment was sequenced and the sequence showed 100% identity in a span of 14 residues with a 
fragment of a SRCR domain of gp-340. The amino acid composition of SAG and gp-340 were also similar.  
It is however known that high homologies are found between members of the SRCR superfamily both within 
and between species and therefore the binding characteristics of gp-340 and SAG were examined. The 
specificity of three monoclonal antibodies raised against SAG and gp-340 were then compared and the 
reaction pattern of these antibodies was nearly identical. Western blot analysis of crude parotid saliva and 
BAL fluid revealed inter-individual heterogeneity in the band pattern both in saliva and in BAL. This has 
previously been shown for both gp-340 and SAG. Two high molecular weight bands with an average 
molecular mass of 340 kDa and an additional band of 300 kDa have been described for gp-340 (12;26) and 
three variant forms of a 300 kDa protein present in saliva that all bound to S. mutans have previously been 
described (27). The heterogeneity of the molecule can be due to alternative splicing of the gene; at least three 
different splice forms have been cloned and sequenced for the DMBT1 gene (12;15;28). The variations in 
molecular weight can also be explained by differences in glycosylation, like for example blood group 
dependent differences. The presence of blood group antigens has previously been demonstrated on SAG (22).  
Not only the binding of antibodies, but also the binding of SP-D and S. mutans was identical. gp-340 binds 
calcium-dependently to S. mutans in a similar way as SAG and SP-D bound to SAG in a similar way as to gp-
340. This interaction was calcium-dependent, but was not inhibited by maltose. 
It has previously been shown by reverse transcriptase PCR that a mRNA for gp-340 was expressed in the 
salivary gland (12). Immunohistochemical localization using specific monoclonal antibodies directed against 
gp-340 revealed strong and distinct granular staining of the serous acini and demilune cells in the 
submandibular gland. In a previous paper, for the submandibular gland of the serous acinar cells and demilune 
cells staining for SAG was described (18). Thus, identical staining patterns are found with antibodies against 
gp-340 and SAG.  
Structural data have indicated that Ebnerin (29) and CRP-ductin (30), also called Vomeroglandin (31), are the 
rat and mouse homologue protein to gp-340. Recently it was shown that purified CRP-ductin binds SP-D in a 
similar way as gp-340. Both Ebnerin and CRP-ductin are found in soluble as well as membrane associated 
form and they were cloned from the Ebnerin and vomero glands respectively and both molecules have both 
been implied to be involved in pheromone/taste perception (31). It is thus likely that Ebnerin and CRP-ductin 
are the murine and rat homologue molecules to SAG. 
Based on the structural as well as the functional data we conclude that SAG is identical to gp-340/DMBT1. 
Up to now, SAG was described as a protein involved in the regulation of dental bacterial colonization and gp-
340 was known as a SP-D binding molecule. The presented data show that SAG can interact with 
microorganisms and SP-D emphasizing this molecules possible role in innate mucosal immunity. 
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Chapter 3 
 
Immunohistochemical Detection of Salivary Agglutinin in Human Parotid, Submandibular and Labial 
Salivary Glands 
 
Floris J. Bikker, Antoon J. M. Ligtenberg, Jacqueline E. van der Wal, Petra A. M. van den Keijbus, Uffe 
Holmskov, Enno C. I. Veerman, and Arie V. Nieuw Amerongen  
 
J. Dent. Res. 81, 134-139 (2002) 
 
Salivary agglutinin (SAG) is a Streptococcus mutans binding protein and a member of the scavenger receptor 
cysteine-rich superfamily. It is identical to lung gp-340 and brain DMBT1, which possibly play a role in 
innate immunity and tumor suppression, respectively.  
The goal of this study was to localize SAG in human salivary glands. Two monoclonal antibodies, directed 
against gp-340, were characterized. mAb 213-1 reacted with sialic acid epitopes and cross-reacted with 
MUC7. The reaction with mAb 213-6 disappeared after reduction suggesting a protein epitope was 
recognized.  
In the parotid gland immunohistochemical labeling with mAb 213-6 was found in the duct cells. In the 
submandibular gland and labial gland both serous acini and demilune cells were labeled. In the labial gland 
labeling was found at the luminal side of the duct cells.  
SAG was distinctly localized in salivary glands but in distinct glandular secretions no differences in 
electrophoretic behavior were observed. 
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INTRODUCTION 
 
Salivary agglutinin (SAG) is a 300-400 kDa glycoprotein that originally was identified as the protein 
responsible for the Streptococcus mutans-aggregating properties of parotid saliva (1). Binding of SAG to the 
cariogenic S. mutans occurs through antigen B (2), also known as antigen I/II, PAc and MSL-1 (3;4). In saliva 
SAG is present in complex with s-IgA (5-7).  
Recently it has been shown that SAG is identical to the lung glycoprotein gp-340 a member of the scavenger 
receptor cysteine-rich (SRCR) superfamily (8-10). SRCR domains are found widely in cell surface molecules 
and in some secreted proteins where they are thought to mediate ligand binding (11-13).  
gp-340 is a product of an alternatively spliced form of the DMBT1 gene (14;15), which codes for 3 distinct 
conserved protein domains, SRCR, CUB domains, and a zona pellucida (ZP) domain. These domains are 
involved in embryogenesis and development (16-18). DMBT1, which is involved in epithelial differentiation, 
is a candidate tumor suppressor gene in medulloblastoma, glioblastoma multiforme, lung and gastrointestinal 
tumors caused by homozygous deletions or by a lack of expression (15;19-22). 
Relatively little is known about the localization of SAG in salivary glands. In one study using a monoclonal 
antibody directed against a Lewis Y (LeY) epitope, SAG has been localized in the Golgi apparatus and in 
secretory granules of ductal and acinar cells of human parotid and submandibular salivary glands (23). 
However, the LeY antigen is also present on the Proline-Rich Glycoprotein (24), which hampers an 
unambiguous interpretation. In the present study we used monoclonal antibodies that originally had been 
raised against lung gp-340. Different localization patterns of SAG were found in the serous parotid gland, the 
seromucous submandibular glands and the minor, primarily mucous labial gland.  
 
EXPERIMENTAL PROCEDURES 
 
Collection of human saliva 
Parotid secretions were collected with a Lashley cup under stimulation with sugar-free candies. 
Submandibular secretions were collected without conscious stimulation, using a custom fitted device (25). 
Unstimulated labial saliva was collected by pipetting the saliva directly from the labial mucosa after the 
mucosa of the lower lip was dried. The study was approved by the Institutional Ethical Board of the VUMC at 
Amsterdam and informed consent was obtained from all saliva donors. After collection, samples were directly 
processed for SDS-PAGE analysis. 
 
Antibodies and lectins 
Monoclonal antibody (mAb) 213-1 (8;14) and mAb 213-6, both IgG1 subclass, were raised against gp-340 as 
described (8). mAb 5E9 recognizes sialidase-sensitive carbohydrate epitope expressed on salivary mucins 
(26;27). Rabbit polyclonal antibody CpMG2, evoked against a synthetic peptide corresponding to the C-
terminal region of salivary mucin MUC7, recognizes native MUC7 in saliva (28). Digoxigenin–labeled MAA 
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(Maackia amurensis agglutinin) is specific to N-acetylneuraminic acid (sialic acid) α-2,3-linked to galactose 
and digoxigenin-labeled SNA (Sambucus nigra agglutinin) is specific to N-acetylneuraminic acid α-2,6-linked 
to galactose. (Boehringer, Mannheim, Germany). Alkaline phosphatase conjugated to goat anti-rabbit IgG 
antibody and alkaline phosphatase conjugated to goat anti-mouse IgG antibody were obtained from Sigma (St. 
Louis, MO, USA). 
 
SDS-PAGE and Western blotting 
Saliva samples were incubated at 100°C for 10 min in sample buffer containing 15 mM Tris-HCl, pH 6.8, 0.5 
% SDS, 2.5 % glycerol and 0.05 % bromophenol blue. Reduced samples were prepared by incubation in 
sample buffer supplemented with 25mM dithiothreitol (ICN Biomedicals, Aurora, Ohio). SDS-PAGE was 
conducted on a Pharmacia Phast System (Pharmacia-LKB, Uppsala, Sweden) using 7.5 % or 4-15 % 
polyacrylamide gels, according to the manufacturers protocol.  
Immunodetection of proteins after SDS PAGE was essentially as described (28). Nitrocellulose membranes 
were incubated with antibodies or digoxigenin labeled lectins. Bound antibodies were detected with alkaline 
phosphatase-conjugated to rabbit anti-mouse immunoglobulins (DAKO, Glostrup, Denmark) using 5-bromo-
4-chloro-3-indolyl-phosphate (X-P) and nitro blue tetrazolium chloride (NBT) (Boehringer Mannheim, 
Germany) as substrate. Bound lectins were detected with anti-digoxigenin conjugated to alkaline phosphatase, 
in combination with X-P and NBT.  
 
Glycan affecting treatments  
The carbohydrate residues of SAG on Western blots were oxidized by an incubation with 20 mM sodium-
meta-periodate (Merck, Darmstadt, Germany) in a 100 mM sodium acetate buffer, pH 4.2 (29). Sialic acid 
residues were removed by incubation with Vibrio cholerae neuraminidase (0.1 U/ml) (Roche) in 50 mM 
sodium acetate buffer containing 4 mM calcium chloride, pH 5.5, at 37°C for 16 hr. 
 
Immunohistochemistry on human tissues specimen 
Sections for immunohistochemistry were obtained from human salivary gland tissues that had been removed 
for therapeutic or diagnostic purposes by the Department of Oral & Maxillofacial Surgery/Oral Pathology, 
(VUMC). For parotid tissue: N = 2 (male, 46 yrs; female 65 yrs), labial tissue; N = 3 (male, 55 yrs; female 47 
and 60 yrs) and submandibular tissue: N = 2 (male, 69 yrs; female 72 yrs). The study was approved by the 
Institutional Ethical Board of the VUMC at Amsterdam and informed consent was obtained from all tissue 
donors.  
Sections were cut from neutral-buffered formaldehyde-fixed paraffin-embedded tissue blocks and were 
mounted on ChemMate Capillary Gap Slides (DAKO, Glostrup, Denmark) dried at 60°C, deparaffinized and 
hydrated. Antigen retrieval was performed using microwave heating in Target Retrieval Solution (DAKO, 
Glostrup, Denmark) for 11 min at full power (900 W), and 15 min at 400 W. After heating, slides remained in 
the buffer for 15 min. Antigen retrieval was followed by blocking of endogenous biotin, using Dako Biotin-
CHAPTER 3   
 38
Blocking System (DAKO, Glostrup, Denmark). Incubation with mAb 213-1 and mAb 213-6 (17 µg/ml) was 
done for 25 min at room temperature. Immunostaining was automated using the ChemMate HRP/DAB 
detection kit, K5001 (DAKO, Glostrup, Denmark) on the TechMate 1000 instrument (DAKO, Glostrup, 
Denmark). Immunostaining was followed by brief nuclear counter staining in Mayers hematoxylin. Finally, 
cover slips were mounted with AquaTex (Merck, Darmstadt, Germany). Controls were performed by 
replacing the primary monoclonal antibody with an unrelated monoclonal antibody of the same subclass as the 
gp–340 antibodies (IgG1). 
 
RESULTS 
 
Immunoblotting of parotid, submandibular and labial salivary secretions  
To compare the electrophoretic behavior of SAG from different salivary secretions, saliva from the parotid, 
submandibular and labial glandular secretions were analyzed by Western blotting with mAb 213-6. Since 
mAb 213-1 also recognizes MUC7-epitopes (next paragraph), in these experiments only mAb 213-6 was used. 
All salivary secretions contained SAG, but no differences in electrophoretic behavior were found (Fig. 1).  
 
Figure 1. Detection of SAG in various glandular secretions. 
Human saliva was separated on 7.5 % polyacrylamide gels, 
transferred to nitrocellulose and immunoblotted with mAb 213-6. 
Lane 1, parotid saliva; lane 2, submandibular saliva; lane 3, labial 
saliva. SAG was detected in all samples, but no differences in 
electrophoretic behaviour were observed. 
 
Characterization of monoclonal antibodies 
To characterize further the epitopes recognized by mAbs 213-1 and 213-6, the effects of various chemical and 
enzymatic treatments of SAG on recognition by these antibodies was analyzed by Western blotting. In the 
control blots, a positive reaction was seen with mAb 213-1, mAb 213-6, mAb 5E9 and the lectin MAA. (Fig. 
2, lane C). The reaction with SNA lectin, recognizing N-acetylneuraminic acid α-2,6-linked to galactose, was 
negative (not shown), suggesting SAG only contains α-2,3-linked sialic acid residues. After treatment of the 
membrane with meta-periodate, the recognition by mAb 213-1, lectin MAA and mAb 5E9 was destroyed, 
whereas the epitope recognized by mAb 213-6 remained intact (Fig. 2, lane P). These results indicate that 
mAb 213-1, like lectin MAA and mAb 5E9, is directed against a carbohydrate epitope. When sialic acid 
residues were removed by treatment of the nitrocellulose membranes with neuraminidase, the binding of mAb 
213-1, lectin MAA and mAb 5E was lost. This suggests that the presence of sialic acid residues is required for 
recognition by mAb 213-1. In contrast the epitope recognized by mAb 213-6 remained intact (Fig. 2, lane N). 
After reduction the signal with mAb 213-6 was abolished (Fig. 2). This shows that the epitope recognition of 
mAb 213-6 is dependent on the presence of intact disulfide bonds and thereby subject to the native, three-
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dimensional structure of the protein. Periodate and neuraminidase treatment of SAG did not abolish the 
recognition by mAb 213-6 (Fig. 2). These data suggest that mAb 213-6 is directed to peptide domains of SAG.  
To examine whether mAb 213-1 and mAb 213-6 cross-react with other salivary proteins, parotid and 
submandibular saliva were immunoblotted with mAb 213-1 and mAb 213-6. In parotid saliva both mAbs only 
labeled SAG. (Fig 3, lanes 1, 3). Immunoblotting of submandibular saliva with mAb 213-1 revealed an 
additional band at lower Mr position. (Fig.3, lane 2). Immunoblotting with polyclonal antibody CpMG2, 
suggested that this band corresponded to MUC7 (Fig. 3, lane 6).  
 
Figure 2. Immunoreactivity of mAbs 213-1 and 213-6 
with glycan affected salivary proteins. Parotid saliva 
was separated on 7.5 % polyacrylamide gels and 
transferred to nitrocellulose. Subsequently, blots were 
treated by periodate (P) or neuraminidase (N), column 2 
and 3, respectively. Control blots (C) remained unaffected. - : unreduced; + : reduced. After reduction, the recognition by 
mAb 213-6 is lost. Periodate and neuraminidase treatment abolished recognition by mAbs 213-1 and 5E9 as well as lectin 
MAA. mAb 213-6 was unaffected by these treatments. 
 
 
Figure 3. Immunoreactivity of mAbs 213-1 and 213-6 with various 
glandular secretions. Parotid and submandibular saliva were 
separated on 4-15% polyacrylamide gels, transferred to nitrocellulose 
and immunoblotted with various mAbs. Parotid saliva, lanes 1, 3 and 
5; submandibular saliva, lanes 2, 4 and 6. mAb 213-1 and mAb 213-6 
were raised against lung gp-340, CpMG2 was raised against a MUC7 
peptide. In contrast to mAb 213-6, mAb 213-1 showed cross-
reactivity with MUC7. 
 
 
 
 
 
Immunohistochemical localization of SAG in human parotid, submandibular and labial salivary tissue 
To study the localization of SAG / gp-340 in human parotid, submandibular and labial salivary glands, 
paraffin embedded human glandular tissues were probed with either mAb 213-1 or mAb 213-6 for parotid 
tissue, and mAb 213-6 only for submandibular and labial tissue. MAb 213-1 was omitted for detection of SAG 
in labial and submandibular tissues because of its cross-reactivity with MUC7 (Fig. 3).  
It was found that SAG was differentially localized in distinct salivary gland tissues (Fig. 4). Both mAbs gave 
very similar staining patterns in the serous parotid glandular tissue. Strong cytoplasmic labeling was found in 
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the striated duct cells. The excretory and intercalated ducts were stained as well, albeit less intense. The serous 
acini were negative (Fig. 4A-D). 
In the submandibular gland the majority of the serous acini, and the demilune cells, capping the mucous acini, 
were labeled by mAb 213-6 (Fig. 4E, F). In acinar cells a diffuse cytoplasmic staining was noted. In addition 
cytoplasmic granules were stained. The serous cells that were not labeled did not contain cytoplasmic 
granules. The duct cells and the mucous acini, which consist of larger cells that are more transparent than the 
serous acinar cells, were negative. 
In the labial gland, mainly the serous demilune and serous acini were stained (Fig. 4G, H). Furthermore, 
staining was also found at the luminal side of duct cells. Again, the mucous acini were negative. The typical 
localization patterns were observed in all glandular tissues studied. Controls were negative.  
 
DISCUSSION 
 
In this study the localization of SAG in different human salivary glandular tissue was studied by using two 
monoclonal antibodies, mAb 213-1 and mAb 213-6, which were partly characterized.  
Previously it has been found that removal of N-linked carbohydrates from SAG, did not affect the binding of 
mAb 213-1 (14). The present finding that mAb 213-1 reacts with a neuraminidase-sensitive epitope (Fig. 2) 
indicates that the epitope of mAb 213-1 is associated with O-linked oligosaccharide chains. Potential O-
glycosylation sites, serine and threonin, are abundantly present in SAG.  
mAb 213-6, recognizes a conformational epitope that is sensitive for reduction of disulfide bonds. SAG 
consists of numerous domains containing disulfide bonds, including SRCR domains, CUB domains and a ZP 
domain (17;30;31).  
SAG could be demonstrated in parotid, submandibular and labial salivary secretions (Fig. 1). Histochemistry 
revealed a differential localization pattern of SAG in these glands. In all tissues studied, SAG was 
demonstrated in serous cells. However, in parotid gland tissue, SAG was only present in striated duct cells, 
while the serous acini were negative. This result is different from those of Takano and co-workers (23). They 
localized SAG in both acini and ducts in parotid glandular tissue by using mAb 303, recognizing a LeY 
epitope. As stated by Gillece-Castro and co-workers (24), proline-rich glycoproteins (PRG) also contain the 
LeY epitope. Besides, Lantini and Cossu (32) studied the distribution of Le-antigens in salivary tissue and 
found LeY reactivity in both duct cells and acini. Thus, it is possible that the acinar labeling found by Takano 
et al. (23) reflected the presence of PRG.  
In the submandibular gland, staining for SAG was found in serous acinar cells and demilune cells, while in 
this tissue the duct cells were negative. Acini that were negative were devoid of granules, suggesting that in 
these cells release of the intra-cellular components had taken place, possibly during the processing of the 
tissue for histochemical examination. In contrast to Takano and co-workers, we did not observe labeling of  
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Figure 4. Immunohistochemical localization of SAG / gp-340 in human parotid, submandibular and labial salivary 
tissue. A - D, Serous parotid gland tissue: duct cells are labelled by mAb 213-1 (A and B) and mAb 213-6 (C and D). 
The strongest labelling was observed in the striated ducts but also the excretory and intercalated ducts were stained, albeit 
less intense. The serous acini were all negative. E and F, seromucous submandibular gland tissue: serous acini (s) and 
demilune cells (d) are labelled by mAb 213-6. The mucous acini (m) and duct cells were negative. G and H, labial gland 
tissue: demilune cells (d, inset), serous acini (s) and the luminal site of the duct cells (l) are labelled by mAb 213-6. 
Again, all mucous cells (m) were found negative. Magnification A, C, E, and G: 100x, B, D, F, and H: 400x. 
 
submandibular duct cells. Again, the discrepancy between their study and the present one might be due to the 
broader specificity of the anti-LeY antiserum they used. This is corroborated by the finding of Lantini and 
Cossu (32) who found anti-LeYimmunoreactivity in both duct cells and acinar cells of the submandibular 
gland.  
In the labial gland, mainly serous cells, including the acinar cells, demilune cells and duct cells were positive 
for SAG, while mucous cells were negative. Similar differences between glandular localization patterns have 
been reported for lysozyme. It has been demonstrated that in the parotid gland lysozyme was expressed only in 
the intercalated duct cells, not in the acinar cells. On the other hand in the sublingual glands and in the minor 
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oral glands, both the serous acini and the ducts were positive (33). This suggest that the serous acinar cells of 
the (sero)mucous glands are less differentiated than those of the parotid gland.  
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Chapter 4 
 
Salivary Agglutinin/DMBT1 Expression is Upregulated in the Presence of Salivary Gland Tumors 
 
Floris J. Bikker, Jacqueline. E. van der Wal, Antoon J.M. Ligtenberg, Jan Mollenhauer, Jolanda M.A. de 
Blieck-Hogervorst, Isaac van der Waal, Annemarie Poustka, and Arie V. Nieuw Amerongen 
 
J. Dent. Res., accepted 
 
Salivary agglutinin (SAG) is encoded by the gene Deleted in Malignant Brain Tumors 1 (DMBT1) and 
represents the salivary variant of DMBT1 (DMBT1SAG). While SAG is a bona fide anti-caries factor, DMBT1 
was proposed as candidate tumor-suppressor for brain, digestive tract, and lung cancer. Though DMBT1SAG is 
expressed in the salivary glands, its expression in salivary gland tumors is unknown. Here we analyzed 
DMBT1SAG expression in 20 salivary gland tumors and 14 tumor-flanking tissues by immunohistochemistry. 
All 20 salivary gland tumors displayed decreased DMBT1SAG expression compared to positive structures in 
either the tumor-flanking tissues or healthy tissues. Besides DMBT1SAG is upregulated in 10/14 tumor-
flanking tissues and a strong staining of the luminal content in the tumor and/or the tumor-flanking tissue is 
observed in 14/20 cases. This suggests, that in addition to its role in caries defense, SAG may serve as 
potential tumor indicator and/or tumor suppressor in salivary gland tissue. 
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INTRODUCTION 
 
Salivary agglutinin (SAG) is a 300-400 kDa glycoprotein that was originally identified as the protein 
responsible for the calcium-dependent Streptococcus mutans-aggregating properties of parotid saliva (1;2). 
For this reason, it has been implicated in the protection against caries (3). 
The amino acid sequence of SAG is identical to that of gp-340, a respiratory tract glycoprotein. Both SAG and 
gp-340 are encoded by the gene Deleted in Malignant Brain Tumors 1 (DMBT1) at chromosome 10q25.3-
q26.1 and thus represent the DMBT1-isoforms secreted to the saliva and the lung surfactant, respectively (4-
7). DMBT1GP340 is putatively involved in respiratory tract protection, because it interacts with the defense 
collectins surfactant protein D (SP-D) and A (SP-A) and is able to stimulate alveolar macrophage migration 
(4;8).  
While these data suggest a certain functional overlap between DMBT1SAG and DMBT1GP340, i.e. in pathogen 
defense, further, quite distinct functions have been attached to DMBT1 as well. In vitro studies demonstrated 
that the rabbit homologue of DMBT1 (and therefore SAG) triggers epithelial differentiation, when interacting 
with galectin-3 in the extra cellular matrix (ECM; 9-12). Furthermore, different tumors were shown to display 
loss of DMBT1 expression, apparently depending on the time point of DMBT1 localization in the ECM (9;11-
14). Unifying concepts have postulated that both its protective functions, especially its role in pathogen-
defense and its putative functions in cellular differentiation are of importance to counteract tumorigenesis 
(4;10;11;13-20).  
Based on these concepts, it appeared tempting to investigate whether SAG, which previously was exclusively 
linked to caries defense, is subjected to the same principles in salivary gland tumors as DMBT1 in tumors at 
various other sites in the human body. Here we report on the DMBT1SAG expression pattern in salivary gland 
tumors and tumor-flanking tissue. 
 
EXPERIMENTAL PROCEDURES 
 
Tumor and normal samples 
Sections of normal, labial glandular tissue (Lab, n = 3), parotid glandular tissues (PAR, n = 4), normal 
submandibular glandular tissues (SM, n = 2), and sections of adenoid cystic carcinomas (ACT, n = 5), 
mucoepidermoid carcinomas (MEC, n = 5), acinic cell carcinomas (ACC, n = 5), which are malignant 
carcinomas, and pleomorphic adenomas (PA, n = 5), which are benign carcinomas, were used for 
immunostaining with DMBT1SAG (Table 1). 14/20 tissues studied (parotid and submandibular) contained 
tumor-flanking normal tissue, i.e. tissue immediately adjacent to the tumor (Table 1, examples Fig. 1C, (14). 
The sections were obtained from human salivary gland tissues that had been removed for therapeutic or 
diagnostic purposes by the Department of Oral & Maxillofacial Surgery and Oral Pathology. Because of the 
small size of the biopsies in 6/20 cases no tumor-flanking tissue removed. The study was approved by the 
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Institutional Ethical Board of the VUMC at Amsterdam and informed consent was obtained from all tissue 
donors.  
 
Table 1. Specification of tumor samples. PAR, parotid gland; SM, submandibular gland; Pal, palatal gland, Lab; labial 
gland, ACC, acinic cell carcinoma; ACT, adenoid cystic carcinoma; MEC, mucoepidermoid carcinoma; and PA, 
pleomorphic adenoma.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
aTotal number of tumor specimens / specimens that contained tumor flanking tissue 
 
Antibodies  
For immunohistochemical detection of DMBT1SAG tissue specimen were probed with monoclonal antibody 
(mAb) 213-6, that recognizes a peptide epitope of DMBT1 (4;20). For healthy parotid tissue we used mAb 
213-6 and mAb 213-1 (4;20). The mAbs were kindly provided by Dr Uffe Holmskov (University of Southern 
Denmark, Odense, Denmark).  
 
Immunohistochemistry on human tissues specimen 
Sections were cut from neutral-buffered formaldehyde-fixed paraffin-embedded tissue blocks and were 
mounted on ChemMate Capillary Gap Slides (DAKO, Glostrup, Denmark) dried at 60°C, deparaffinized and 
hydrated. Antigen retrieval was performed using microwave heating in Target Retrieval Solution (DAKO) for 
11 min at full power (900 W), and 15 min at 400 W. After heating, slides remained in the buffer for 15 min. 
Antigen retrieval was followed by blocking of endogenous biotin, using Dako Biotin-Blocking System 
(DAKO). Incubation with mAb 213-6 and 213-1 (17 µg/ml) was done for 25 min at room temperature. 
Immunostaining was automated using the ChemMate HRP/DAB detection kit, K5001 (DAKO, Glostrup, 
Denmark) on the TechMate 1000 instrument (DAKO, Glostrup, Denmark). Immunostaining was followed by 
Glandular source Tumor type Totala 
   
PAR ACC 3/2, ACT 4/4, MEC 1/1, PA 4/4 12/11 
   
SM ACC 1/1, MEC 1/1, PA 1/1 3/3 
   
Pal MEC 3/0 3/0 
   
Lab ACC 1/0 1/0 
   
Tongue ATC 1/0 1/0 
   
Total  20/14 
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brief nuclear counter staining in Mayers hematoxyline/eosine. Finally, cover slips were mounted with 
AquaTex (Merck, Darmstadt, Germany). Controls were performed by replacing the primary monoclonal 
antibody with an unrelated monoclonal antibody of the same subclass as mAb 213-6 (IgG1). 
 
RESULTS  
 
Figure 1. Immunohistochemical localization of DMBT1SAG in human healthy salivary gland tissue, tumor 
surrounding tissue and salivary gland tumors. The sections were counterstained with hematoxyline/eosine. (A) 
Healthy parotid tissue: DMBT1SAG is localized in the ducts. (B) Parotid tumor surrounding tissue (ACC), DMBT1SAG is 
localized in the intercalated ducts (icd) and serous acini (a). (C) ACC surrounding tissue (right upper side) showing 
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strong staining of luminal content of striated ducts is next to ACC (left down side). (D) Healthy submandibular gland 
tissue. Serous acini (a) and demilune cells (d) were DMBT1SAG positive. (E) Submandibular tumor surrounding tissue 
(PA), DMBT1SAG is localized in the intercalated ducts and strongly present in the luminal content (lc). (F) Healthy labial 
tissue: DMBT1SAG is localized in the ducts, demilune cells (d) and serous acini (a). (G) ACC, no DMBT1SAG was found 
in ACC’s. (H and I) MEC, the secretory cells were DMBT1SAG positive (m). The epidermoid-cell and intermediate-cell 
components were totally negative. Moreover, the luminal content (lc) stained strongly positive (H). (J) ATC, showing no 
DMBT1SAG expression. (K) ACT, A minor subset of tumor cells showing DMBT1SAG expression. (L), PA. DMBT1SAG 
staining strongly positive in the secretory product and focally some tumor cells surrounding the secretory product. 
Magnification A, B, F, G, H and L = 100x ; E = 200x; C, D, I , J, and K = 400 x. 
 
Table 2. DMBT1SAG expression in normal and tumor-flanking tissues.  
Gland Structure Normal tissuea Tumor-flanking tissuea  
   ACC ACT MEC PA Total upb 
        
Lab Serous acini 3/3 (+++)      
 Demilune cells 3/3 (+++)      
 Ducts 3/3 (+++)      
        
PAR Intercalated ducts 4/4 (+++) 2/2 (+++) 3/4 (+++) 1/1 (+++) 4/4 (+++)  
    1/4 (++)   0/11 
 Serous acini 0/4 1/2 (++) 1/4 (++) 1/1 (++)   
   1/2 (+) 1/4 (+)  2/4 (+) 7/11 
 Luminal content 0/4 1/2 3/4 1/1 2/4  7/11 
        
SM Intercalated ducts 0/2 1/1 (+++)  1/1 (+++) 1/1 (+++) 3/3 
 Serous acini 2/2 (+++) 0/1  0/1 0/1 0/3 
 Demilune cells 2/2 (+++) 0/1  0/1 0/1 0/3 
 Luminal content 0/2 0/1  1/1 1/1 2/3 
        
Total upc   3/3 2/4 2/2 3/5 10/14 
Luminal content upd  1/3 3/4 2/2 3/5 9/14 
aNumber of DMBT1SAG positive cases per cases analyzed; the percentage of DMBT1SAG positive cells is given in 
brackets: (-) 0%; (+) < 30%; (++) 30-60%; (+++) 60-90% 
bTotal number of DMBT1SAG positive tumor cases per cases analyzed within a particular gland 
cTotal number of DMBT1SAG cases per cases analyzed of the respective tumor types 
dTotal number of cases with DMBT1SAG staining of luminal content per cases analyzed 
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Table 3: DMBT1SAG expression in salivary gland tumors 
Gland Structure Salivary Gland Tumorsa 
  ACC ACT MECb PA Totalc 
       
Lab Tumor cells 1/1 (-)a    1/1 (-) 
 Luminal content 0/1    0/1 
       
Pal Tumor cells   2/3 (+)a  2/3 (+) 
    1/3 (++)a  1/3 (++) 
 Luminal content   3/3  3/3 
       
PAR Tumor cells 3/3 (-) 3/4 (-)  1/4 (-) 7/12 (-) 
    1/1 (+)a 3/4 (+) 4/12 (+) 
   1/4 (++)   1/12 (++) 
 Luminal content 0/3 1/4 1/1 3/4 5/12 
       
SM Tumor cells 1/1 (-)  1/1 (-)  2/3 (-) 
     1/1 (+) 1/3 (+) 
 Luminal content 0/1  0/1 1/1 1/3 
       
Tongue Tumor cells  1/1 (+)   1/1 (+) 
 Luminal content  0/1   0/1 
       
Totald Tumor cells 5/5 (-) 3/5 (-) 1/5 (-) 1/5 (-) 10/20 (-) 
  0/5(+) 1/5 (+) 3/5 (+) 4/5 (+) 8/20 (+) 
  0/5(++) 1/5 (++) 1/5 (++) 0/5(++) 2/20 (++) 
 Luminal content 0/5 1/5 4/5 4/5 9/20 
aNumber of DMBT1SAG positive cases per cases analyzed; the percentage of DMBT1SAG positive cells is given in 
brackets: (-) 0%; (+) < 30%; (++) 30-60%; (+++) 60-90% 
bExclusively mucus-producing cells were DMBT1SAG positive 
cTotal number of tumor cases with DMBT1SAG expression per cases analyzed within a particular gland 
dTotal number of tumor cases with DMBT1SAG expression per cases analyzed of the respective tumor types 
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DMBT1SAG expression in normal and tumor-flanking tissue 
Recent studies suggested that DMBT1 is upregulated in tumor-flanking tissues in liver, lung, and breast cancer 
(13;14). In order to test whether this might also attribute to DMBT1SAG in the salivary gland, we compared its 
expression in tumor-flanking tissues to data previously obtained for the normal salivary gland (Table 2, 20). 
The tumor-flanking parotid gland tissue showed staining of the luminal aspects of intercalated duct cells in 
11/11 cases similar to the pattern observed in the healthy tissue (Table 1 and 2; Figs. 1A and 1B). Seven cases 
displayed upregulation in the serous acini (Fig. 1B), and seven cases revealed substantial staining of the 
luminal content (Fig. 1C), which was not observed in healthy tissues (Fig. 1A). In contrast to healthy 
submandibular gland tissue (Table 1 and 2, Fig. 1D), 3/3 tumor-flanking submandibular gland tissues showed 
upregulation of DMBT1SAG in the intercalated ducts and two of these displayed a corresponding strong 
staining of the luminal content as well (Table 2; Fig. 1E). Remarkably, DMBT1SAG was completely 
downregulated in the demilune cells in the tumor-flanking tissue of the submandibular gland (3/3 cases; Table 
2; Fig. 1E). In healthy labial tissue, staining was observed in ducts, demilune cells and serous acini (Fig. 1F). 
Due to the lack of either tumor-flanking tissue or corresponding normal tissue from healthy glands, no 
comparisons could be made for tongue and the labial and palatal gland tumors 
Taken together, the analyses uncovered upregulation of DMBT1SAG by secretory cells in 10/14 (71%) tumor-
flanking tissues. Compared to normal tissues, staining for DMBT1SAG in the luminal content of tumor-flanking 
normal tissues was observed (9/14 tumor-flanking tissues versus 0/9 normal tissues; p = 0.003 according to the 
two-tailed Fisher’s exact test). Moreover, a switch of the cell types that express DMBT1SAG appeared to take 
place. In the parotid and submandibular gland tissue, expression is induced in serous acini and in the 
intercalated ducts, respectively, while it is silenced in demilune cells. Consistently, expression and/or secretion 
of DMBT1SAG is enhanced in the presence of a tumor. This can at least partly be traced back to the 
upregulation of DMBT1SAG expression in the serous acini and intercalated ducts. 
 
DMBT1SAG expression in salivary gland tumors 
Studies of other tumor types arising from monolayered epithelia or exocrine glands indicated a 
downregulation of DMBT1 in the tumor cells compared to the tumor-flanking tissues (13;14). All 20 salivary 
gland tumors displayed decreased DMBT1SAG expression compared to positive structures in either the tumor-
flanking tissues or healthy tissues (Table 2 and 3; 11/12 tumor-flanking and 9/9 normal tissues with 60-90% 
positive cells, respectively vs. 0/20 tumors; p < 0.00001 for both comparisons according to the two-tailed 
Fisher’s exact test). The five ACCs were negative for DMBT1SAG (Table 3; Fig. 1G). Four of five MECs 
showed strong staining of the luminal content of the ducts (Table 3; Fig. 1H). In these tumors, the epidermoid- 
and intermediate-cell components consistently were negative, while a variable fraction (<5% to 60%) of the 
mucus-producing cells was strongly positive in 3/5 cases (Figs. 1H and I). One of the five MECs totally lacked 
DMBT1SAG expression. Likewise, 3/5 ATCs were negative (Table 3; Fig. 1J). In the remaining two cases, 
focal staining of parts that maintained a ductular structure was observed (Fig. 1K). One case showed signals in 
the luminal content. Four of the five PAs displayed strong staining of the secretory product with focal positive 
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surrounding tumor cells (Table 3; Fig. 1L). Moreover, secretory cells that preserved a luminal context mostly 
were DMBT1SAG positive while the solid parts did not reveal signals (examples in Figs. 1H, I, K, L). 
Accordingly, nine out of 20 tumors showed strong DMBT1SAG staining of the luminal content, while this was 
not the case in any of the nine normal tissues (Table 2 and Table 3; p = 0.03 according to the two-tailed 
Fisher’s exact test). 
 
DISCUSSION 
 
For about two decades, SAG has intensely been investigated in regard to its role in binding and aggregation of 
cariogenic bacteria in the oral cavity. Recent discoveries have expanded both the available data and the view 
on this molecule in an explosive manner. We and others reported that SAG is identical to DMBT1 (5;7). 
DMBT1 was detected in the salivary glands with an expression pattern virtually indistinguishable from SAG 
(13).  
These findings had reciprocal impacts. On the one hand, the role of DMBT1 in the prevention of infection-
induced cancer has come into focus, especially, because direct interaction with the gastric cancer-causing 
Helicobacter pylori was demonstrated and traced back by us to the polymorphic scavenger receptor cysteine-
rich (SRCR) domains of DMBT1 (7;15). On the other hand, the relationship to DMBT1 extremely broadened 
the view on SAG, because one now has to anticipate that it plays a role in the defense against various 
epidemiologically relevant pathogens in various organs and not only in the oral cavity (4;7;10;13). In 
particular, however, this relationship also means that SAG is potentially linked to tumorigenesis 
(4;7;10;11;13;14;17-19;21). Studies on DMBT1 indicated that it represents a highly unusual molecule for a 
potential tumor suppressor (10;11;13;14;17). Because several reports pointed to a lack of inactivating 
mutations, but frequent loss of expression in cancer, we focused on expression studies of DMBT1SAG in 
salivary gland tumors. 
With few exceptions, DMBT1 is secreted luminally by monolayered epithelia and glands and luminal 
secretion is commonly assumed to be associated with protective functions (4;13-15). In tissues with 
constitutive DMBT1 expression, loss of expression may directly take place after resolution of the 
monolayered structure and secretion of DMBT1 to the ECM. In contrast, tissues without or with low DMBT1 
expression may experience induction of DMBT1 expression at early stages of tumorigenesis, which is then 
followed by a resolution of the monolayered structure, translocation of DMBT1 to the ECM and finally again 
by a loss of its expression (13;14). These and further data suggested that DMBT1 translocation to the ECM 
may be unfavorable for tumor growth, which is strongly supported by the fact that its rabbit homologue is able 
to trigger cell differentiation when locating to the ECM (9). Our present data may provide support for these 
models and might extend them to DMBT1SAG.  
We can confirm that also in the salivary gland an induction of DMBT1SAG takes place in the presence of 
tumors. Ten of 14 tumor-flanking tissues showed de novo expression of DMBT1SAG in structures that are 
negative in the respective healthy tissues. Remarkably, other cell types, i.e. demilune cells, show an 
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accompanying silencing of DMBT1SAG, which raises the questions whether different cell types might produce 
different variants and whether these might exert different functions. 
In agreement with the hypothesis that DMBT1 might be less compatible with tumor growth when locating to 
the ECM, only tumor parts that maintained a luminal context showed expression, while solid parts without 
luminal context were devoid of DMBT1SAG. Also, in MEC, the better differentiated secretory cells retained 
DMBT1SAG expression, while the less differentiated epidermoid and intermediate cells were negative. Most 
remarkably, however, 14/20 salivary gland tumors displayed a strong staining for DMBT1SAG in the luminal 
content in either the tumor-flanking tissue and/or the tumor itself, which most likely both contribute to this 
effect. As a consequence, this could mean that the anti-caries factor SAG might advance to a potential tumor 
marker in the oral cavity. Increased DMBT1SAG Increased levels in saliva or saliva collected from a particular 
salivary gland could represent an indicator for the onset or the presence of a salivary gland tumor. This defines 
a clear need for further studies that aim at quantification of DMBT1SAG in the saliva of cancer patients and at 
comparison to other diseases such as oral infection and inflammation. 
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Chapter 5 
 
Identification of the Bacteria-binding Peptide Domain on Salivary Agglutinin/DMBT1, a Member of the 
Scavenger Receptor-Cysteine Rich Superfamily 
 
Floris J. Bikker, Antoon J. M. Ligtenberg, Kamran Nazmi, Enno C. I. Veerman, Wim van ’t Hof, Jan G. M. 
Bolscher, Annemarie Poustka, Arie V. Nieuw Amerongen, and Jan Mollenhauer 
 
 J. Biol. Chem. 277, 32109-32115 (2002) 
 
Salivary agglutinin (SAG) is encoded by DMBT1 and identical to gp-340, a member of the Scavenger 
Receptor Cysteine-Rich (SRCR) superfamily. SAG/DMBT1 is known for its Streptococcus mutans 
agglutinating properties. This 300-400 kDa glycoprotein is composed of conserved peptide motifs: fourteen 
SRCR domains that are separated by SRCR-interspersed domains (SIDs), two CUB (C1r/C1s Uegf Bmp1) 
domains and a Zona Pellucida domain. 
We have searched for the peptide domains of SAG/DMBT1 responsible for bacterial binding. Digestion with 
endoproteinase Lys-C resulted in a protein fragment containing exclusively SRCR and SID domains that 
bound to S. mutans. To define more closely the S. mutans-binding domain consensus-based peptides of the 
SRCR domains and SIDs were designed and synthesized. Only one of the SRCR peptides, designated 
SRCRP2 and none of the SID peptides bound to S. mutans. Strikingly, this peptide was also able to induce 
agglutination of S. mutans and a number of other bacteria. The repeated presence of this peptide in the native 
molecule endows SAG/DMBT1 with a general bacterial binding feature with a multivalent character. 
Moreover, our studies demonstrate for the first time that the polymorphic SRCR domains of SAG/DMBT1 
mediate ligand interactions. 
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INTRODUCTION 
 
Salivary agglutinin (SAG) is a 300-400 kDa blood group reactive glycoprotein (1), which has been implicated 
in the oral clearance of microorganisms because of its bacteria-agglutinating properties (2;3). Due to its ability 
to bind and agglutinate the cariogenic bacterium Streptococcus mutans, SAG has been considered to play an 
important role in the innate protection against dental caries (4;5). SAG, which is encoded by the same gene as 
DMBT-1 and the lung protein gp-340 (6-11), binds also to surfactant protein-D (8). Genetic and analysis has 
demonstrated that SAG/DMBT1 is a member of the Scavenger Receptor Cysteine-Rich (SRCR) superfamily 
(6; 9), which is highly conserved crossing species boundaries. This group of glycoproteins comprises cell 
surface molecules as well as secreted proteins that are characterized by the presence of multiple SRCR 
domains showing broad ligand binding spectra (12). SRCR-proteins, e.g. the macrophage scavenger receptor, 
Mac2-binding protein, CD5, CD6, WC1, Ebnerin, CRP-ductin, and lung gp-340, are associated with host 
defense systems (7; 8; 11-17).  
Until now, studies dealing with SAG-bacteria interactions have been focused mainly on the characterization of 
bacterial receptors (18;19), and identification of their cognate carbohydrate ligands on SAG (1;20-22). These 
studies revealed that carbohydrate residues play only a partial role in binding and aggregation of bacteria by 
SAG (1;19, 20). For example, chemical modification of the carbohydrate residues of SAG only slightly 
impaired its agglutinating properties (20). On the other hand, treatments affecting the polypeptide moiety 
abolished binding to S. mutans completely, suggesting a dominant role for peptide domains (1;20;22). The 
present study was directed on identification of the peptide domains on SAG that are responsible for its bacteria 
agglutinating properties. 
From the DNA sequence of the gene encoding SAG, DMBT1 (9;10), the architecture of the polypeptide chain 
of SAG was deduced. SAG (Fig. 1A) is composed of 13 highly homologous SRCR domains (13;23), separated 
by SIDs (SRCR-interspersed domains), two CUB (C1r/C1s Uegf Bmp1) domains (24;25), separated by a 14th 
SRCR domain, and a ZP domain (Zona Pellucida) (26). The biological function of the highly conserved SRCR 
domains has not yet been established, but their presence in proteins with broad spectrum binding properties 
suggests a role in ligand binding or adhesion. We recently noted genetic polymorphism within DMBT1. These 
polymorphisms lead to DMBT1-alleles giving rise to polypeptides with interindividually different numbers of 
SRCR domains and SIDs. Based on analogies to mucins, we have proposed that these polymorphisms may 
lead to a differential efficacy in mucosal protection  (10;27). However, the major drawback of this hypothesis 
is that it remains to be shown that the SRCR domains and/or SIDs are involved in ligand-binding.  
The search for the peptide domains on SAG/DMBT1 involved in bacteria binding was therefore initially 
directed to this part of the molecule. On basis of the deduced amino acid sequence of SAG, we designed a 
digestion strategy to obtain a fragment consisting exclusively of SRCR and SID domains. This fragment 
preserved the S. mutans binding properties. To characterize the binding domain in greater detail, peptides were 
synthesized covering the complete SRCR and SID consensus sequence, and their binding to S. mutans was 
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analyzed. Only one 16-mer peptide (QGRVEVLYRGSWGTVC) of the SRCR domain was found to bind to S. 
mutans and to mediate agglutination. 
 
EXPERIMENTAL PROCEDURES 
 
Purification of SAG 
Human parotid saliva was collected with a Lashley cup. Twenty five ml of parotid saliva was kept on ice 
water for 30 min, to promote the formation of a precipitate. This precipitate was collected by centrifugation at 
5,000 x g for 20 min at 4 ºC. The resulting pellet was dissolved in 2.5 ml PBS. The pellet was approximately 
ten-fold enriched in SAG. This crude SAG fraction was used as starting material for digestion studies and in 
the various binding studies. For further purification the pellet was dissolved in buffer A (10 mM Tris, 10 mM 
EDTA, pH 6.9, 0.05% CHAPS) and applied on an UNO Q-6 column (Bio-Rad Laboratories, Hercules, CA) 
equilibrated in buffer A, linked to FPLC equipment (Amersham Pharmacia Biotech Benelux, Roosendaal, The 
Netherlands). Proteins were eluted with a linear gradient from 0 to 0.5 M NaCl in buffer A. The eluate was 
monitored at 280 nm and analyzed by SDS-PAGE and Western blotting. The isolated SAG preparation 
contained no detectable protein impurities (less than 5%). Protein concentrations were determined with the 
BCA Protein Assay Kit (Pierce, Rockford, IL) according to the manufacturers instructions. 
 
SDS-PAGE and Western blotting 
SDS-PAGE, conducted on a Pharmacia Phast System (Amersham Pharmacia Biotech) using 4-15% 
polyacrylamide gels, and Western blotting were performed as described (28). Blots were probed with 
monoclonal antibody (mAb) 213-6 directed against gp-340 (6;29), kindly provided by Dr Uffe Holmskov 
(University of Southern Denmark, Odense, Denmark), using immunoenzymatic detection. 
 
Bacteria 
Streptococcus mutans (Ingbritt), Streptococcus gordonii (HG 222), Streptococcus sanguis (NY 584), 
Streptococcus oralis (NY 582), Streptococcus sobrinus (HG 456), Streptococcus mitis I (SK 271), 
Streptococcus mitis II (HG 168), Actinobacillus actinomycetemcomitans (NY 673), Prevotella intermedia (OB 
51), Escherichia coli (F7), Bacteroides fragilis (clinical isolate), Moraxella catarrhalis (clinical isolate), 
Peptostreptococcus micros (clinical isolate) and Staphylococcus aureus (clinical isolate) were cultured on 
blood agar plates under anaerobic conditions with 5% CO2 for 48 h at 37 ºC. Lactobacillus caseï (clinical 
isolate) was cultured on blood agar plates under micro-aerophilic conditions for 48 h at 37 ºC. Helicobacter 
pylori (ATCC 43504) was cultured on selective Dent plates (Oxoid, Hampshire, United Kingdom) for 72 h at 
37 ºC. Other bacteria strains were cultured in Brain Heart Infusion (Difco Laboratories, Detroit, MI) or Todd 
Hewitt medium (Oxoid, Hampshire, United Kingdom) overnight in air/CO2 (19:1), at 37 ºC. Cells were 
harvested and washed twice in PBS or Tris-buffered saline (TBS, 50 mM Tris, pH 7.5, containing 150 mM 
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sodium chloride). Bacteria were diluted in buffer to a final OD700 of 0.5 or 1.0, corresponding with 
approximately 5 x 108 and 109 cells/ml, respectively. 
 
Protein digestion 
0.5 µg endoproteinase Lys-C, sequencing grade from Lysobacter enzymogenes, (Roche Diagnostics GmbH, 
Mannheim, Germany) was added to 50 µl of crude SAG (50 µg/ml), dissolved in 25 mM Tris, 1 mM EDTA 
(pH 8.5). After 18 hours of incubation at 37 ºC, digestion was stopped by adding a cocktail of proteinase 
inhibitors (Complete Mini tablets, Roche Diagnostics). For reduction SAG was incubated with 10 mM 
dithiothreitol for 4 h at 4 ºC, and subsequent carboxymethylated with 20 mM 2-iodoacetamide for 4 h at 4 ºC. 
 
Exclusion of genetic polymorphism for K1812 
The triplet coding for K1812 locates at the splice fusion site of exons 45 and 46. In order to exclude that 
partial digestion at residue K1812 originates from genetic polymorphism, the respective exons and their 
immediately flanking intronic sequences were amplified by PCR using the primers dmbt1ex45dsf2 5`-
GTGCAGAAGATGAAACTGGATG-3` and dmbt1ex45dsr2 5`-GCCCAGGACACAGTCTAAAC-3` (exon 
45) and dmbt1ex46dsf2                                  5`-ACCTGTATTCAATGGCATCCC-3` and dmbt1ex46dsr2             
5`-TGCCCCCAAAGAGGCAGC-3` (exon 46) under the conditions described elsewhere (30). Forward and 
reverse strands were sequenced with the primers as depicted herein.  
 
Liquid-phase binding assay 
Two hundred µl of a S. mutans suspension (109 bacteria/ml in PBS) was centrifuged at 3,000 x g for 10 min. 
The pellet was mixed with 100 µl of digested SAG (50 µg/ml) supplemented with 5 mM calcium chloride, and 
incubated for 1 h at 37 °C. Next, bacteria were collected by centrifugation at 3,000 x g for 2 min, washed 
twice in PBS and transferred to a new vial. Bacteria-bound components were extracted by incubation with 10 
mM EDTA in PBS for 1 h at 37 °C. The extracts were examined by SDS-PAGE and Western analysis. 
Control extracts were obtained from bacteria that had not been incubated with (digested) SAG. 
 
Overlay adherence assay 
Adhesion of S. mutans to the Lys-C proteinase-digested crude SAG immobilized on nitrocellulose was studied 
using an overlay adhesion assay. Briefly, 40 µl samples of digested SAG (50 µg/ml) were separated by SDS-
PAGE and blotted onto nitrocellulose membranes. The membranes were blocked with PBS supplemented with 
0.1% Tween 20 and 2% bovine serum albumin (PBS-T-BSA) and incubated with S. mutans (109 bacteria in 
PBS-T-BSA) for 16 h at 4 °C. The nitrocellulose membranes were washed twice with PBS-T-BSA. Bound 
bacteria were visualized with mAb OMVU37, directed against S. mutans (31), alkaline phosphatase-
conjugated rabbit anti-mouse immunoglobulins (DAKO, Glostrup, Denmark) as chromogenic substrate. 
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Peptide design and synthesis 
Based on the published amino acid sequence of gp-340 (7), consensus sequences of the 13 SRCR domains and 
11 SIDs was determined using alignment software (Vector NTI, InforMax Inc., Oxford, United Kingdom). 
Nine peptides, together spanning the complete sequence (Table 1), were synthesized by solid phase peptide 
synthesis using the T-bag method adapted for Fmoc-chemistry (32). 
 
Table 1. SRCR domain and SID consensus sequence based peptides. SRCR  peptides 1-7 (SRCRP1-7) cover the 
consensus sequence of 13 SRCR domains and peptides SID20 and SID22 cover the consensus sequence of the SIDs. 
 
 
Peptide purification 
Peptides were purified by Reversed Phase HPLC on a JASCO HPLC System (Tokyo, Japan). Peptides were 
dissolved in 0.1% trifluoroacetic acid (TFA) and applied on a VYDAC C18-column (218TP, 1.0 x 25 cm, 10 
µm particles, Hesperia, CA), equilibrated in 0.1% TFA. Elution was performed with a linear gradient, from 
30-45% acetonitrile containing 0.1% TFA in 20 min at a flow rate of 4 ml/min. The absorbance of the column 
effluent was monitored at 214 nm and peak fractions were pooled, lyophilized, and reanalyzed by RP-HPLC 
and by capillary electrophoresis on a Biofocus 2000 apparatus (Bio-Rad Laboratories). The authenticity of the 
(monomeric) peptides was confirmed by quadrupole-time of flight mass spectrometry (Q-TOF MS) on a 
tandem mass spectrometer (Micromass Inc., Manchester, United Kingdom) as described previously (33). 
Despite the presence of cysteine residues, exclusively monomeric peptides were detected, indicating that 
peptide multimerization by disulfide bond formation had not occurred. The purity of the peptides was at least 
90%. 
 
 
Peptide Amino Acid Sequence Amino Acids Residue of SRCR domain 
consensus sequence 
SRCRP1 GSESSLALRLVNGGDRC 17 1 – 17 
SRCRP2 QGRVEVLYRGSWGTVC 16 18 – 33 
SRCRP3 DDSWDTNDANVVCRQLGC 18 34 – 51 
SRCRP4 GWAMSAPGNARFGQGSGPIVLDDVRC 26 52 – 77 
SRCRP5 SGHESYLWSC 10 78 – 87 
SRCRP6 PHNGWLSHNC 10 88 – 97 
SRCRP7 GHHEDAGVICSA 12 98 – 109 
SID20 SQSQPTPSPDTWPTSHASTA 20  
SID22 AQSWSTPRPDTLPTITLPASTV 22  
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Adhesion assays 
Bacterial adhesion was examined using a microtiter plate method based on labeling of microorganisms with 
cell-permeable DNA-binding probes. Microtiterplates Fluotrac 600, (Greiner, Recklinghausen, Germany) 
were coated with various amounts of either synthetic peptides, crude SAG, or purified SAG. For reduction the 
peptides and SAG were incubated with 10 mM dithiothreitol for 4 h at 4 ºC, and subsequent 
carboxymethylated with 20 mM 2-iodoacetamide for 4 h at 4 ºC. The peptides were dissolved in coating 
buffer (100 mM sodium carbonate, pH 9.6) to a starting concentration of 40 µg/ml and diluted serially. After 
incubation at 4 ºC for 16 h, plates were washed twice with TBS containing 0.1% Tween 20 and 1 mM Ca2+ 
(TTC). Subsequently, 100 µl of a S. mutans suspension (5 x 108 bacteria/ml TTC) were added to each well and 
incubated for 2 h at 37 ºC. Plates were washed three times with 0.1% Tween 20 using a plate washer 
(Mikrotek EL 403, Winooski, VT). Bound bacteria were detected using 100 µl/well of 1 mM SYTO-9 solution 
(Molecular Probes, Leiden, The Netherlands), a cell-permeable fluorescent DNA-binding probe. Plates were 
incubated in the dark for 15 min at ambient temperature and washed three times with 0.1% Tween-20. 
Fluorescence was measured in a fluorescence microtiter plate reader (Fluostar Galaxy, BMG Laboratories, 
Offenburg, Germany) at 488 nm excitation and 509 nm emission wavelength. 
 
Agglutination assays 
150 µl of an S. mutans suspension (5 x 108 bacteria/ml TTC) were mixed with 150 µl peptide solution at final 
peptide concentrations of 0-200 µg/ml in a 96-wells microtiter plate (Low affinity, PS Microlon-F, Greiner), 
and incubated for 2 h at 37 °C. After agglutination and subsequent sedimentation of the bacteria, 10 µl of the 
sediment was transferred on a microscopic slide. After heat-fixation, bacteria were stained with a 20 % crystal 
violet solution (Merck) and examined by light microscopy. Turbidometric analysis of the agglutination 
process was carried out using a spectrophotometer (UVICON 930, Kontron Instruments, Watford, United 
Kingdom). Bacterial suspensions (5 x 108 bacteria/ ml TTC) supplemented with either calcium chloride or 
EDTA, were pre-incubated for 2 h at 37 °C before peptides were added. The optical density of the bacterial 
suspensions was monitored at 700 nm for 100 min at 37 ºC. These experiments were repeated at least three 
times. 
 
RESULTS 
 
Lys-C cleavage of SAG/DMBT1 
To investigate the role of the repeating SRCR and SID domains of SAG/DMBT1 with respect to S. mutans 
binding, a selective proteolytic cleavage procedure was conducted, using endoproteinase Lys-C (34-36). 
SAG/DMBT1 contains 10 lysine residues, which are all located in the C-terminal region (Fig. 1A). One lysine 
residue is located in the 13th SRCR domain, three are located in the first CUB domain, one in the second CUB 
domain, four in the ZP domain and one in the unique sequence, located C-terminally of the ZP domain. 
Hydrolysis after the first and second lysine residues (K1722, K1791) will not yield distinct cleavage products, 
because the resulting fragments are held together by disulfide linkages between C1665 and C1729 and 
CHAPTER 5             
 62
between C1766 and C1792, respectively (23;37). Hydrolysis at K1812 will generate a fragment that contains 
13 of the 14 SRCR domains as well as the interspersing SID domains (Fig. 1A). The remaining C-proximal ZP 
and CUB domains contain additional Lys-C cleavage sites. Thus Lys-C digestion would liberate a large 
SRCR/SID-stretch, in addition to a number of smaller fragments. SDS-PAGE analysis of the Lys-C treated 
SAG revealed a new protein band with slightly lower molecular mass than the native SAG/DMBT1 (Fig. 2A). 
This band, the putative SRCR/SID-stretch of SAG/DMBT1, was recognized by mAb 213-6 directed against a 
peptide epitope of SAG/DMBT1 (29) (Fig. 2A, lane 2). Immunoreactive protein bands of lower molecular 
mass were not detected. Reduction and subsequent carboxymethylation did virtually not show different protein 
patterns on Western blot (not shown).   Next to the putative SRCR/SID-stretch, the native SAG/DMBT1 was 
still present, even after prolonged incubation with excess Lys-C, or addition of 0.01 % SDS. The triplet 
encoding for K1812 spans the fusion site of exons 45 and 46 after splicing. Sequencing did not reveal 
heterozygosity of the saliva donor in the exon or intron seqeunces. Thus, partial digestion of SAG/DMBT1 is 
not based on genetic polymorphism. Sequencing of 25 cDNA clones further ruled out that alternative splicing 
leads to omission of K1812 (not shown). 
 
Effect of Lys-C digestion on binding of SAG to S. mutans 
Whether binding sites for S. mutans were still present after digestion was examined using an overlay 
adherence-assay and a soluble phase binding-assay (Fig. 2). Nitrocellulose membranes containing native SAG 
and Lys-C digested SAG overlaid with bacteria showed that S. mutans adhered to both SAG bands (Fig. 2B). 
This demonstrates that Lys-C digestion had not destroyed the binding domains for this bacterium. Controls, in 
which either bacteria incubation or antibody incubation was omitted, were negative. This was confirmed by 
the results of liquid-phase binding assays, in which bacteria were incubated with a solution containing the 
digested SAG (Fig. 2C). Western analysis of the bacterial extracts and the corresponding supernatants 
demonstrated that both native SAG and the digested fragment were found in the bacterial pellets (Fig. 2C, lane 
2). In contrast, the supernatants were completely devoid of SAG (Fig. 2C, lane 3). In control experiments in 
which the bacteria were omitted, SAG and the digested fragment were only present in the supernatants. 
 
 
 
 
 
 
 
 
 
Figure 2. Lys-C digestion of SAG and S. mutans binding to the digested fragment. A, Crude SAG was treated with 
endoproteinase Lys-C and proteins were separated on 4-15% SDS-PAGE, transferred to nitrocellulose and 
immunoblotted with mAb 213-6 (A and C). A, lane 1, crude SAG; lane 2, Lys-C digested SAG. After digestion a new 
band appeared with a lower apparent molecular weight than the parent protein, representing a fragment that most 
probably contains predominantly SRCR domains and SIDs (amino acid 1-1812). B, Digested SAG was blotted onto a 
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nitrocellulose membrane and subjected to an overlay binding assay with S. mutans. After incubation with S. mutans 
bound bacteria were visualized with an antibody directed against S. mutans. Bacteria were found at both bands, 
suggesting that S. mutans bound to both SAG and the Lys-C digested fragment. C, The digested SAG was subjected to a 
liquid phase binding assay with S. mutans. Lane 1: starting material; lane 2: bound fraction; lane 3: unbound fraction. 
Both SAG and the digested fragment were found in the bound fraction but not in the unbound fraction, demonstrating that 
S. mutans binds both SAG and the Lys-C digested fragment. As a molecular marker we used the high range molecular 
standards (Bio-Rad): myosin (208 kDa), α-galactosidase (116 kDa), bovine serum albumin (84 kDa), ovalbumin (47 
kDa). 
 
Determination of consensus sequence of SIDs and SRCR domains 
To more specifically characterize the bacteria-binding region, we synthesized a series of peptides spanning the 
SIDs and SRCR domains of SAG. Using alignment software the consensus sequences of the SIDs and SRCR 
domains were determined. This resulted in two consensus sequences for the SIDs, one 20 residue-long and one 
22 residue-long sequence (Fig. 1B and C). Peptides representing these sequences were synthesized (designated 
SID20 and SID22, Table 1). The consensus sequence of the SRCR domain had a length of 109 amino acids 
(Fig. 1D). To cover this sequence, seven synthetic peptides were synthesized, representing loops in the native 
protein that run in-between disulfide bridges (23;37) (SRCR Peptide (SRCRP) 1-7, Table 1). 
 
Bacteria binding properties of synthetic SID and SRCR peptides 
Binding of S. mutans to these peptides was determined in a solid-phase adherence assay, in which adhered 
bacteria were quantified using a fluorescent DNA stain. Crude and purified SAG were included as controls. 
Besides binding to SAG, S. mutans adhered to only one of the nine peptides tested, SRCRP2 (Fig. 3). None of 
the other peptides tested, viz. SRCRP1, SRCRP3-7, SID20, and SID22, mediated adhesion of S. mutans. To 
examine the specificity of the adherence, inhibition studies were conducted by pre-incubating S. mutans 
suspensions with all peptides at various concentrations. Also in these experiments, only SRCRP2 inhibited 
adhesion of S. mutans to SAG (Fig. 4), suggesting that the binding sites on S. mutans for SRCRP2 and SAG 
are identical or are located in close vicinity.  
Since the SRCRP2 fragment contains a cysteine residue, this peptide potentially forms disulfide-bonded 
species. Several results, however, indicate that monomeric SRCRP2 was the active species in our experiments. 
Mass analysis revealed that the SRCRP2 preparation used in the binding studies was composed of a single 
species with a molecular mass of the monomer. Furthermore, neither reduction/carboxymethylation of 
SRCRP2, nor substitution of its cysteine to alanine, to prevent formation of disulfide-bonded species, had any 
effect on its bacteria binding properties (not shown).   
Other bacteria, including S. gordonii, S. sanguis, S. oralis, S. sobrinus, S. mitis I, S. mitis II, A. 
actinomycetemcomitans, P. intermedia, E. coli, B. fragilis, M. catarrhalis, P. micros, S. aureus, L. caseï, and 
H. pylori were also bound by SAG as well as by SRCRP2, but not by the other peptides tested (results not 
shown). These findings suggest that the SRCRP2 domain endows SAG with broad-spectrum binding 
properties. 
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Figure 3. S. mutans binding to SAG derived peptides. 
Peptide coated microplates were incubated with a S. mutans 
suspension. Bound bacteria were detected with a cell 
permeable DNA-binding fluorescent stain at 509 nm. S. 
mutans bound to crude SAG (▲) and a single peptide tested, 
namely SRCRP2 (●). All other peptides tested did not show 
this behavior. Typical examples of non-binding peptides are 
SRCRP1 (), SRCRP4 (○), and SID20 (∆). These 
experiments were performed at least in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Inhibition of S. mutans binding to SAG by peptide SRCRP2. Purified SAG coated microplates (20 µg/ml) 
was incubated with a S. mutans suspension that was pre-incubated with various concentrations of peptide SRCRP2 (50 
µg/ml, white bar; 100 µg/ml, grey bar; 200 µg/ml, black bar). Increased concentrations peptide SRCRP2 decreased the 
amount of bound bacteria to SAG demonstrating a competitive inhibition of peptide SRCRP2. All other peptides tested 
did not inhibit S. mutans binding to SAG at a concentration of 200 µg/ml: typical examples are peptides SRCRP1, 
SRCRP3, SID20, and SID22. 
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Agglutination assays 
Varying peptide concentrations were mixed with S. mutans suspensions and incubated for 2 hr, in order to 
allow precipitation of aggregates formed. Precipitates were examined by light microscopy revealing that only 
SRCRP2 induced agglutination of S. mutans (Fig. 5). At increased calcium concentrations, lower peptide 
concentrations were required to induce agglutination and the aggregates formed were clearly larger in size 
(Fig. 5C). In contrast, incubation in EDTA-containing buffer required higher concentrations of SRCRP2, and 
resulted in smaller aggregates (Fig. 5A). A similar dependence of calcium was found for the SAG-mediated 
bacteria agglutination. These findings were confirmed by the turbidometric assay (Fig. 6).  
 
 
Figure 5. Calcium–dependent agglutination of S. mutans 
by peptide SRCRP2. Peptide SRCRP2 was added in 
various concentrations (50, 100, and 200 µg/ml) to S. 
mutans in the presence of A, 5 mM EDTA; B, 1 mM 
calcium, and C, 10 mM calcium. In the presence of 5 mM 
EDTA aggregation was weaker compared to aggregation 
the presence of 1 mM calcium. In the presence of 10 mM 
calcium chloride, aggregation is even stronger and starts at 
lower concentrations peptide SRCRP2. All other peptides 
tested did not aggregate S. mutans. Typical examples of 
non-agglutinating peptides are D: SRCRP5; E: SRCRP6; 
and F: SID20 (each 200 µg/ml and in the presence of 1 mM 
calcium). These experiments were performed at least in 
triplicate.  
 
 
 
 
 
Figure 6. Turbidometric agglutination of S. mutans by peptide SRCRP2. S. mutans suspensions were mixed with 
various concentrations peptide SRCRP2 (50, 100, and 200 µg/ml) and the OD700 of the remaining suspension was 
measured in time. A, In the presence of 5 mM EDTA agglutination is much weaker than in the presence of B, 10 mM 
calcium. These experiments were performed at least in triplicate. 
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DISCUSSION 
 
In the present study we have identified a peptide domain on SAG/DMBT1 that is involved in bacteria binding 
and agglutination. To confine the binding domain we proteolytically cleaved the protein into smaller parts. 
The low prevalence of lysine residues in the repeating SID/SRCR domains, one single lysine at the C-terminus 
of the 13th SRCR domain, allowed the use of Lys-C to separate the SID/SRCR part from the rest of the 
molecule. A complicating factor is the presence of disulfide bridges spanning potential Lys-C cleavage sites, 
which prevents liberation of the hydrolysis products. Residue K1812 is the first Lys-C cleavage site resulting 
in distinct cleavage fragments. The SID/SRCR stretch of SAG/DMBT1 obtained after Lys-C digestion most 
probably contains a part of the first CUB domain. In theory, by reduction of the disulfide bridges this small 
CUB fragment could be removed. However, also the bacteria binding properties of SAG/DMBT1 are lost (22), 
hampering further identification of the binding domain using this approach. Next to the band for the putative 
SID/SRCR stretch, the native SAG/DMBT1 was still present (Fig. 2A), even after prolonged incubation with 
excess Lys-C, with addition of 0.01% SDS or after reduction and carboxymethylation of SAG/DMBT1 prior 
to digestion. This was not due to genetic heterogeneity of SAG/DMBT1, since it was obtained from a donor 
who was homozygous within the respective exons. Alternative splicing using donor/acceptor sites varying by 
one or few nucleotides cannot explicitly be ruled out, but is unlikely to occur, because none of 25 cDNA 
clones sequenced over the site showed a corresponding phenomenon. We speculate that the propensity of 
SAG/DMBT1 to form complexes may render a part of the lysine residues inaccessible to Lys-C. This is 
reasonable, because if the SRCR domains are involved in ligand-binding it is likely that the constant carboxy-
terminus, i.e., the CUB and ZP domains are responsible for oligomerization. Alternatively, resistance to Lys-C 
digestion may be caused by differential N-, and O-glycosylation of potential glycosylation sites close to the 
presumed cleavage site. In this context it should be noted that CUB1 contains 21 potential O-glycosylation 
sites, and 3 potential N-glycosylation sites (7). 
Only one of the SRCR consensus peptides, SRCRP2, bound to a wide variety of Gram-positive and Gram-
negative bacteria. Absence of binding by the other peptides does not necessarily mean that the corresponding 
domains are not involved in bacteria adherence to SAG/DMBT1 per se. It is possible that these peptides are 
derived from conformational domains of SAG/DMBT1 and that their lack of conformational restraints leads to 
poor binding of the bacteria tested. 
A puzzling finding is that, while the bacteria binding properties of SAG/DMBT1 are destroyed upon 
reduction, the putative binding domain (the SRCRP2 peptide) is part of a disulfide bridged loop. Secondary 
structure analysis using protein analysis software (Vector NTI) predicts that the SRCRP2 peptide is composed 
of two short β-sheets, separated by a β-turn (not shown). Strikingly, based on crystallographic analysis the 
same secondary structure has been proposed for the corresponding sequence in the SRCR domain of the 
highly homologous Mac-2 binding protein (23) (Fig. 7). This indicates that formation of the disulfide bond 
does not introduce significant constraints on the SRCRP2 structure. Hence, the effect of reduction on the 
bacteria-binding properties of the SRCRP2 stretch must be communicated by conformational changes 
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elsewhere in the SAG/DMBT1 molecule. E.g., it can be envisaged that upon breaking of disulfide bonds, the 
SRCR domains become shielded, thereby rendering them inaccessible to bacteria and antibodies (29). 
The role of the carbohydrate moiety, which comprises 25% of the whole molecule on weight basis (22), 
remains to be elucidated. Glycosylated regions will be present predominantly in the SIDS, which compared to 
SRCR domains, contain a high density of potential O-glycosylation sites. The high density of glycans forces 
these regions in an extended conformation, thus creating a molecule with alternating stretched SIDS and 
globular SRCR domains, promoting multivalent interaction. In addition, the oligosaccharides may provide 
(low affinity) binding sites for microbial receptors, which in the mature SAG/DMBT1 may act in concert with 
the SRCR peptide domains.  
 
Figure 7. Schematic representation of the SRCR domain of the 
Mac-2 binding protein, highlighting the putative bacteria-binding 
domain of SAG/DMBT1. A model of the SRCR domain of the Mac-
2 binding protein (Protein Data Bank accession code 1BY2) was 
constructed using RasWin Molecular Graphics. The stretch that 
corresponds to SRCRP2 is composed of two short β-sheets joined by 
a β-turn, (marked) and highly homologous (> 80%) to the Mac-2 
binding protein amino acid sequence. The QXR motif (Q18 and R20 
are indicated) is located at the surface of the SRCR domain. 
 
 
 
A study on bacteria binding of the human macrophage MARCO receptor (38), another member of the SRCR-
superfamily, has demonstrated that a peptide encompassing residues 431-441 (RGRAEVYYSGT) was 
responsible for binding of MARCO to S. aureus and E. coli (39). This region corresponds to residues 1-11 of 
SRCRP2 with 55% homology. Detailed analysis of MARCO variants demonstrated a crucial role for an 
arginine-rich segment for this function (40). More precisely, the motif RXR was identified as an essential 
element for high-affinity bacterial binding. Strikingly, the consensus sequence SRCRP2 does not contain such 
an RXR motif, but a QXR motif. The present finding that only this peptide mediates binding to a wide variety 
of bacteria, suggests that both motifs, RXR and QXR, could play a role in bacteria binding. 
In summary, we propose that the SRCR domains of SAG/DMBT1 are involved in bacteria binding. 
Furthermore we find that only one SRCR domain consensus-based synthetic peptide of 16 amino acids, which 
is 100% identical to the actual amino acid sequence of eight out of thirteen SRCR domains, is responsible for 
the broad ligand binding behavior. The repeated presence of this peptide in the native molecule endows 
SAG/DMBT1 with a general bacterial binding feature with a multivalent character. This lends support for the 
hypothesis that numeric variations of the SRCR domains of SAG/DMBT1 may interfere with efficient 
protection. Crucial next steps will be to determine which pathogen-binding activities are qualitatively or 
quantitatively affected by these polymorphisms. 
 
CHAPTER 5             
 68
ACKNOWLEDGEMENTS 
 
We thank Harold Bark for skillful practical assistance and Roel van der Schors for mass-spectrometric 
analysis of the peptides for his excellent Q-TOF work.  
 
REFERENCES 
 
1. Ligtenberg, A. J., Veerman, E. C., and Nieuw Amerongen, A. V. (2000) Ant. Leeuwenh.   
       77, 21- 30 
 2.   Ericson, T., and Rundegren, J. (1983) Eur. J.Biochem. 133, 255-261 
 3.   Rundegren, J., and Ericson, T. (1981) J.Oral Pathol. 10, 269-275 
 4.   Bleiweis, A. S. (1993) Adhesion and cohesion of plaque microflora: a function of  microbial fimbriae and fibril , 
University of Rochester Press, Rochester 
5.   Stenudd, C., Nordlund, A., Ryberg, M., Johansson, I., Kallestal, C., and Stromberg, N. (2001) J.  Dent. Res. 80, 
2005-2010 
6.   Holmskov, U., Lawson, P., Teisner, B., Tornoe, I., Willis, A. C., Morgan, C., Koch, C.,  and Reid,K. B. (1997) 
J. Biol. Chem. 272, 13743-13749 
7. Holmskov, U., Mollenhauer, J., Madsen, J., Vitved, L., Gronlund, J., Tornoe, I., Kliem,  A., Reid, K. B., 
Poustka, A., and Skjodt, K. (1999) Proc. Natl. Acad. Sci.U. S. A. 96, 10794-10799 
8. Ligtenberg, T. J., Bikker, F. J., Groenink, J., Tornoe, I., Leth-Larsen, R., Veerman, E. C., Nieuw  Amerongen, A. 
V., and Holmskov, U. (2001) Biochem. J. 359, 243-248 
9. Mollenhauer, J., Wiemann, S., Scheurlen, W., Korn, B., Hayashi, Y., Wilgenbus, K. K., von Deimling, A., and 
Poustka, A. (1997) Nat. Genet. 17, 32-39 
10. Mollenhauer, J., Herbertz, S., Holmskov, U., Tolnay, M., Krebs, I., Merlo, A., Schroder, H. D., Maier, D., 
Breitling, F., Wiemann, S., Grone, H. J., and Poustka, A. (2000) Cancer Res. 60, 1704-1710 
11. Prakobphol, A., Xu, F., Hoang, V. M., Larsson, T., Bergstrom, J., Johansson, I., Frangsmyr, L., Holmskov, U., 
Leffler, H., Nilsson, C., Boren, T., Wright, J. R., Stromberg, N., and Fisher, S. J. (2000) J. Biol. Chem. 275, 
39860-39866 
12.   Resnick, D., Pearson, A., and Krieger, M. (1994) Trends Biochem. Sci. 19, 5-8 
13.   Aruffo, A., Bowen, M. A., Patel, D. D., Haynes, B. F., Starling, G. C., Gebe, J. A., and Bajorath, J. (1997) 
Immunol. Today 18, 498-504 
14.   Freeman, M., Ashkenas, J., Rees, D. J., Kingsley, D. M., Copeland, N. G., Jenkins, N. A., and Krieger, M. 
(1990) Proc. Natl. Acad. Sci.U. S. A. 87, 8810-8814 
15.    Gough, P. J., and Gordon, S. (2000) Microbes. Infect. 2, 305-311    
16.   Holmskov, U. L. (2000) APMIS Suppl 100, 1-59 
17.   Tino, M. J., and Wright, J. R. (1999) Am. J. Respir. Cell Mol. Biol. 20, 759-768 
18.   Crowley, P. J., Brady, L. J., Piacentini, D. A., and Bleiweis, A. S. (1993) Infect. Immun. 61, 1547-1552 
19.   Demuth, D. R., Lammey, M. S., Huck, M., Lally, E. T., and Malamud, D. (1990) Microb. Pathog. 9, 199-211 
20.   Courtney, H. S., and Hasty, D. L. (1991) Infect. Immun. 59, 1661-1666 
21.   Demuth, D. R., Golub, E. E., and Malamud, D. (1990) J. Biol. Chem. 265, 7120-7126 
22.   Oho, T., Yu, H., Yamashita, Y., and Koga, T. (1998) Infect. Immun. 66, 115-121 
 IDENTIFICATION OF THE BACTERIA-BINDING PEPTIDE DOMAIN ON SAG / DMBT1 
 69
23.   Hohenester, E., Sasaki, T., and Timpl, R. (1999) Nat. Struct. Biol. 6, 228-232 
24.   Bork, P., and Beckmann, G. (1993) J. Mol. Biol. 231, 539-545 
25.   Romero, A., Romao, M. J., Varela, P. F., Kolln, I., Dias, J. M., Carvalho, A. L., Sanz, L., Topfer-Petersen, E., 
and Calvete, J. J. (1997) Nat. Struct. Biol. 4, 783-788 
26.   Sinowatz, F., Kolle, S., and Topfer-Petersen, E. (2001) Cells Tissues. Organs 168, 24-35 
27.  Mollenhauer, J., Herbertz, S., Helmke, B., Kollender, G., Krebs, I., Madsen, J., Holmskov, U., Sorger, K., 
Schmitt, L., Wiemann, S., Otto, H. F., Grone, H. J., and Poustka, A. (2001) Cancer Res. 61, 8880-8886 
28.   Bolscher, J. G., Groenink, J., van der Kwaak, J. S., van den Keijbus, P. A., van 't Hof, W., Veerman, E. C., and 
Nieuw Amerongen, A. V. (1999) J. Dent. Res. 78, 1362-1369 
29.   Bikker, F. J., Ligtenberg, A. J., van der Wal, J. E., van den Keijbus, P. A., Holmskov, U., Veerman, E. C., and 
Nieuw Amerongen, A. V. (2002) J. Dent. Res. 81, 134-139 
30.   Mollenhauer, J., Müller, H., Kollender, G., Lyer, S., Diedrichs, L., Helmke, B., Holmskov, U., Ligtenberg,  T., 
Herbertz, S., Krebs, I., Madsen, J., Bikker, F., Schmitt, L., Wiemann, S., Scheurlen, W., Otto, H.F., von  
Deimling, A., and Poustka, A. Genes Chromosomes Cancer, 35, 164-169 
31.   de Soet, J. J., van Dalen, P. J., Pavicic, M. J., and de Graaff, J. (1990) J. Clin. Microbiol. 28, 2467-2472 
32.   van 't Hof, W., Driedijk, P. C., van den Berg, M., Beck-Sickinger, A. G., Jung, G., and Aalberse, R. C. (1991) 
Mol. Immunol. 28, 1225-1232 
33.   Nagle, G. T., Jong-Brink, M., Painter, S. D., and Li, K. W. (2001) Eur. J. Biochem. 268, 1213-1221 
34.  Bank, R. A., Crusius, B. C., Zwiers, T., Meuwissen, S. G., Arwert, F., and Pronk, J. C. (1988) FEBS Lett. 238, 
105-108 
35.  Coronel, C. E., Winnica, D. E., Novella, M. L., and Lardy, H. A. (1992) J. Biol. Chem. 267, 20909-20915 
36.  Erickson, P. R., and Herzberg, M. C. (1993) J. Biol. Chem. 268, 1646-1649 
37.  McAlister, M. S., Brown, M. H., Willis, A. C., Rudd, P. M., Harvey, D. J., Aplin, R., Shotton, D. M., Dwek, R. 
A., Barclay, A. N., and Driscoll, P. C. (1998) Eur. J. Biochem. 257, 131-141 
38.  Kraal, G., van der Laan, L. J., Elomaa, O., and Tryggvason, K. (2000) Microbes. Infect. 2, 313-316 
39.  Elomaa, O., Sankala, M., Pikkarainen, T., Bergmann, U., Tuuttila, A., Raatikainen-Ahokas, A., Sariola, H., and 
Tryggvason, K. (1998) J. Biol. Chem. 273, 4530-4538 
40.  Brannstrom, A., Sankala, M., Tryggvason, K., and Pikkarainen, T. (2002) Biochem. Biophys. Res. Commun. 290, 
1462-1469 
 
 
 
 
 
 
 
 
CHAPTER 5             
 70
 IDENTIFICATION OF THE BACTERIA-BINDING PEPTIDE DOMAIN ON SAG / DMBT1 
 71
Chapter 6 
 
The Scavenging Capacity of DMBT1/agglutinin Is Impaired by Germline Deletions 
 
Based on:  
DMBT1 Is a Dual-Specific Pattern Recognition Receptor, which Pathogen-Scavenging Efficacy Is Impaired 
by Germline Deletions 
 
Floris J. Bikker, Caroline End, Antoon J. M. Ligtenberg, Stephanie Blaich, Kamran Nazmi, Stefan Lyer, Enno 
C. I. Veerman, Marcus Renner, Gaby Bergmann, Jolanda M. A. de Blieck-Hogervorst, Rainer Wittig, Petra 
Kioschis, Mathias Haffner, Arie V. Nieuw Amerongen, Annemarie Poustka, and Jan Mollenhauer 
 
Submitted 
 
The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of proteins exclusively 
occurring in multicellular animal organisms with earliest appearance in the sea urchin, which are generally 
related to host defense systems. SRCR proteins are characterized by the presence of multiple SRCR domains, 
but based on their genetic organization SRCR proteins exhibit variations in the number of SRCR domains.  
Deleted in Malignant Brain Tumors 1 (DMBT1) is involved in host defense by pathogen binding. Recently, 
we noted genetic polymorphism within DMBT1. These polymorphisms lead to DMBT1-alleles giving rise to 
polypeptides with interindividually different numbers of SRCR domains, ranging from 8 SRCR domains 
(encoded by 6kb DMBT1 variant) to 13 SRCR domains (encoded by the 8kb DMBT1WT variant) within the 
SRCR/SID region. In numerical terms reduction from 13 to 8 amino-terminal SRCR domains is predicted to 
lead to a 38% reduction of bacterial binding. Quantification of bacterial binding of DMBT1-variants isolated 
from donors with the respective genotypes confirmed this prediction. This is the first study to explore 
polymorphism of a SRCR protein, demonstrating a functional significance for SRCR domain repetition. 
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INTRODUCTION 
 
The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of highly conserved 
glycoproteins exclusively occurring in multicellular animal organisms with earliest appearance in the sponges 
(1-5). The SRCR-superfamily comprise cell membrane-anchored proteins as well as secretory proteins. SRCR 
proteins are characterized by the presence of multiple SRCR domains showing broad-spectrum ligand binding. 
SRCR domains are approximately 110 amino acids long and are classified into group A and B based on the 
number of conserved cysteine residues (six for group A, eight for group B) (1;5). Genetic analysis has 
demonstrated that Deleted in Malignant Brain Tumors 1 (DMBT1) at chromosome 10q25.3-q26.1 is a member 
of the group B SRCR superfamily (6-10). DMBT1 is composed of 13 highly homologous SRCR domains 
(1;11), separated by SRCR-interspersed domains (SIDs), two CUB (C1r/C1s Uegf Bmp1) domains (12;13), 
separated by a 14th SRCR domain, and a Zona Pellucida domain (14;15). Salivary agglutinin (SAG) and lung 
gp-340 represent the DMBT1-isoforms secreted into saliva (DMBT1SAG) and the lung fluid (DMBT1GP340), 
respectively (6-10). 
The highly conserved SRCR domains in DMBT1 and DMBT1 homologues have been shown to play an 
important role in bacterial binding (16, 21). Although, the precise role of many other SRCR proteins e.g. the 
macrophage scavenger receptor, Mac2-binding protein, CD5, CD6, WC1, has still to be elucidated. These 
proteins have generally been implicated into host defense systems (1;2;6;9;10;17-21). 
We recently have discovered genetic polymorphism within DMBT1 (22;23) resulting in DMBT-1 alleles 
encoding polypeptides having different (8-13) numbers of SRCR domains within the SRCR/SID region. This 
SRCR/SID region does not include the carboxy-terminal SRCR domain, which is located in between the CUB 
domains. This 14th SRCR domain does not show exhibit bacterial-binding activity (21). Based on analogies to 
mucins, we have proposed that these polymorphisms may lead to a differential efficacy in mucosal protection 
(24-26).  
In the present study we demonstrate that genetic polymorphism results in a 40% reduction of the SRCR 
domains and SIDs of DMBT1, leading to a corresponding reduction of the protein size. We consistently 
observed that, compared to wild-type DMBT1 (8kb, 13 SRCR domains in the SID/SRCR region), the short 
DMBT1-variant (6kb, 8 SRCR domains in the SID/SRCR region) displays 30 - 45% reduced capacity in 
binding to bacteria. 
 
EXPERIMENTAL PROCEDURES 
 
Southern blotting 
Genomic DNA from healthy volunteers (ethnic background: Caucasian) was extracted from peripheral blood 
leukocytes (PBL) according to standard procedures. Collection of blood samples and genetic analyses were 
approved by the ethics committee of the University Heidelberg. Twenty µg genomic DNA was digested 
overnight with the restriction enzyme RsaI (Roche Diagnostics; 10 U/µg DNA), ethanol-precipitated and 
resuspended in a total volume of 40 µl H2O. The digested DNA was separated for 20-22 h on 1.2% (w/v) 
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agarose gels at 45 V. From this point on, everything was exactly done as described previously (22), with the 
exception that exclusively probe DMBT1/sr1sid2 was used. 
 
Bacteria 
Streptococcus mutans (Ingbritt), Streptococcus gordonii (HG222) and Escherichia coli (F7) were cultured on 
blood agar plates under anaerobic conditions with 5% CO2 at 37 ºC for 24 h. Subsequently, single colonies 
were cultured in Todd Hewitt medium and in Luria Broth (Oxoid, Hampshire, United Kingdom) for S. mutans, 
S. gordonii and E. coli, respectively, overnight in air/CO2 (19:1), at 37 ºC. Cells were harvested and washed 
twice in TTC buffer (TBS-Tween-Calcium buffer: TBS, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4; 0.01% (v/v) 
Tween 20 (polysorbate, Merck-Schuchardt, Germany); 1 mM calcium). Helicobacter pylori (NCTC 11637) 
was cultured on selective Dent plates (Oxoid) at 37 ºC for 72 h. H. pylori was harvested by wiping off the 
plates and washed twice in NTC buffer (100 mM Sodium acetate, pH 4.2, 0.01% (v/v) Tween 20, 
supplemented with 1 mM calcium). Bacteria were diluted in buffer to a final OD700 of 0.5, corresponding with 
approximately 5 x 108 cells/ml.  
 
Collection of DMBT1SAG and determination of relative concentration 
Human parotid saliva was collected from four healthy donors with a Lashley cup, under stimulation by 
chewing on sugar-free chewing gum. Twenty-five ml of parotid saliva was kept on ice water for 30 min, to 
promote the formation of a precipitate. This precipitate was collected by centrifugation at 5,000 x g at 4 ºC for 
20 min. The resulting pellet was dissolved in 2.5 ml TBS. The pellet was approximately ten-fold enriched in 
DMBT1SAG, designated as crude DMBT1SAG.  
For qualitative adhesion assays with DMBT1SAG, crude DMBT1SAG samples from different saliva donors were 
titrated against monoclonal antibody (mAb) DMBT1h12. The antibody recognizes a non-repetitive, non SRCR 
domain, peptide epitope (amino acid 26-40), which is present within all known DMBT1 variants and locates 
outside the region that shows germline deletions (Fig. 2A, 24). High affinity microtiter plates (Greiner-F, 
Polysorp, Nunc, Kamstrup, Denmark) were coated with crude DMBT1SAG, obtained from four saliva donors, 
in coating buffer (100 mM sodium carbonate, pH 9.6) for 2 hr at 37º. This incubation and all the following 
steps were carried out in a volume of 100 µl per well at room temperature, and all washes and incubations 
were carried out in TTC Buffer. Plates were incubated for 1 h with 1:500 mAb DMBT1h12. After washing, 
the plates were incubated at 37 °C for 1 h with a rabbit anti-mouse IgG-HRP conjugate (dilution 1:2,000 in 
TTC; DAKO A/S, Denmark). Subsequent to three washes with TTC, 100 µl TMB-solution (3,3`,5,5`-
Tetramethyl-benzidine; 125 µg/ml in citrate buffer pH 4.5 with 0.05% v/v H2O2) was added, and after 
incubation at RT for 10-15 min, the reaction was stopped by the addition of 50 µl 2 M sulphuric acid per well. 
The absorbance was read at 405 nm on a Dynatech MR7000 plate reader (Billington, UK). The results of the 
ELISA were used to dilute the different DMBT1SAG samples to obtain solutions containing comparable 
concentrations of the unique DMBT1 epitope, which is not the SRCR-epitope. For the adhesion assay these 
equalized DMBT1SAG solutions were coated onto microtiterplates.  
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Adhesion assays 
Bacterial adhesion was examined using a microtiter plate method based on labeling of microorganisms with 
SYTO13, a cell-permeable DNA-binding probe, essentially as previously reported (16;27) except that bacteria 
were dissolved in TTC buffer, for S. mutans, S, gordonii, E. coli, and in NTC buffer for H. pylori, 
respectively. These experiments were repeated at least four times. 
  
SDS-PAGE and Western blotting  
7.5% SDS-PAGE and Western blotting was performed exactly as described previously (28). For immuno-
enzymatic detection of DMBT1SAG mAb DMBT1h12 was used. . 
 
RESULTS 
 
Determination of interindividual polymorphism of DMBT1 
Recently, we discovered genetic polymorphism within DMBT1 (22;23) (Fig. 1). This lead us to hypothesize 
that this polymorphism results in a differential efficacy in mucosal protection. In order to answer this 
hypothesis we first screened 200 persons for genetic DMBT1 polymorphism. We found two persons (donor A 
and C) that were homozygous for the smallest DMBT1 variant of 6kb. Furthermore we found two persons 
(donor B and D) that were homozygous for the largest DMBT1 variant of 8kb (Fig. 1). 
Now that DMBT1 polymorphism was found on a genetic level, we wanted to confirm these findings on the 
polypeptide level. For this, we collected DMBT1SAG from the four donors and analyzed protein size by SDS-
PAGE and subsequent Western analysis, using mAb DMBT1h12 for immunodetection. In SDS-PAGE 
DMBT1SAG of donor A and C migrated to a position corresponding with an apparent molecular mass of 
approximately 255 kDa. DMBT1SAG of donor B and D migrated in SDS-PAGE to a position corresponding 
with an apparent molecular mass of approximately 340 kDa. These data agreed with the genetic analysis (Fig. 
1), revealing that on the one hand donor A and C express the ‘short’ DMBT1SAG of 255kDa, which putatively 
contains 8 SRCR domains in the SID/SRCR. At the other hand, donor B and D express the ‘long’ DMBT1SAG 
isoform, which putatively contains the SID/SRCR region with 13 SRCR domains (Fig. 1 and 2A). This 
SRCR/SID region does not include the carboxy-terminal SRCR domain, which is located in between the CUB 
domains. 
 
DMBT1 polymorphism leads to differential bacterial binding 
To examine whether this polymorphism would affects biological relevant function of DMBT1, we compared 
the bacteria-binding properties of two different genetic variants. Because of the variations in DMBT1SAG 
concentration, direct comparison of bacteria-binding properties of the isolated preparations using the solid-
phase adherence assay was not feasible. Therefore, first the DMBT1SAG content of the various preparations 
was quantified in ELISA using mAbDMBT1h12. The antibody recognizes a non-repetitive peptide epitope 
(amino acid 26-40), which is present within all known DMBT1 variants and locates outside the SRCR/SID 
region that shows germline deletions. So the crude DMBT1SAG samples could be diluted to equimolar amounts 
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without interference of the variable SRCR domains. Then each sample was diluted so that the preparations 
matched each other in epitope concentration, as was verified by western analysis using mAb DMBT1h12 (Fig. 
1B). The solutions subsequently were used to coat microtiter plate wells. By ELISA it was confirmed that the 
coating densities of the different DMBT1 preparations indeed were comparable. 
 
 
 
Figure 1. DMBT1 polymorphism leads to different length DMBT1 polypeptides. A, Schematical presentation of the 
exon-intron structure within the relevant region of DMBT1 with resulting RsaI restriction fragment sizes depicted below. 
Gray boxes denote restriction fragments hybridizing with the probe DMBT1/sr1sid2. SR: exons coding for scavenger 
receptor cysteine-rich domains. The hypothetical configurations within the proteins are depicted below. In the carboxy-
terminal part of the protein resulting from the deleted allele, it cannot be discerned between a loss of either SR9, SR10 or 
SR11. Only one of the possibilities is shown. Pink triangle: signal peptide; blue box: motif without homology; SRCR: 
scavenger receptor cysteine-rich domains; CUB: C1r/C1s-Uegf-Bmp1 domains; ZP: zona pellucida domain; EHD: 
Ebnerin-homologous domain; orange ovals: SRCR interspersed domains (SIDs); TTT and STP are threonine and serine-
threonine-proline-rich domains, respectively. B, Top panel: Southern blot analysis of the DMBT1 genomic configuration 
in four individuals (A-D) selected from the panel. Band sizes and exons loacting on the restriction fragments are depicted 
at the left. Bottom panel: Western blot analysis of DMBT1SAG protein sizes in the partially purified and concentration-
adjusted saliva samples of the four probands. The arrowhead denotes the position of the 220-kDa marker band. 
DMBT1SAG was collected from saliva donors that were homozygous for DMBT1WT/8kb (donors A and C), homozygous 
for DMBT1/6kb (donors B and D). Crude DMBT1SAG from the four donors samples were separated on 7.5 % 
polyacrylamide gels, transferred to nitrocellulose and immunoblotted with mAb DMBT1H12. Lane 1, donor A; lane 2, 
donor B; lane 3, donor C; lane 4, donor D. DMBT1SAG of donors A and C migrated at a position corresponding to an 
apparent molecular mass of approximately 340kDa. DMBT1SAG  of donors B and D runs at a position corresponding to 
approximately 255kDa. 
 
The wells coated with a dilution series of DMBT1SAG were incubated with various bacterial species, including 
S. mutans, S. gordonii, E. coli, and H. pylori for 1 h. After washing and addition of the fluorogenic probe, the 
number of adhering cells was quantified by fluorescence (Fig. 2). The results indicated that wells coated with 
the short variant DMBT1SAG 6kb bound, on a molar base, significantly less bacteria, than those coated with the 
CHAPTER 6             
 76
long-variant DMBT1SAG 8kb. The relative difference in binding for the bacteria tested were 42,4 % (+/- 11,7) 
for S. mutans, 32,5% (+/- 2,7) for S. gordonii , 44,3% (+/- 15,5) for E. coli and 35,1% (+/- 16,0) for H. pylori 
(Fig. 2B). 
 
 
Figure 2. Bacterial binding is dependent on DMBT1 polymorphism. A, Domain structure of the DMBT1-variant 
expressed from the largest (wild-type) DMBT1 allele (DMBT1wt/8kb, 13 SRCR domains within the SRCR/SID region) 
and the smallest DMBT1 allele (DMBT1/6kb, 8 SRCR domains within the SRCR/SID region).  Pink triangle: leader 
peptide; blue box: sequence contains unique epitope for mAb DMBT1H12; red ovals: SRCR domains; orange ovals: 
SRCR interspersed domains (SIDs); purple boxes: C1r/C1s-Uegf-Bmp1 domains; green oval: zona pellucida domain; 
EHD: Ebnerin-Homologous Domain. B, Bacterial binding to DMBT1wt/8kb and DMBT1/6kb (A) was semi-quantified 
using S. mutans (S.m), S. gordonii (S.g.), E. coli (E.c.) and H. pylori (H.p.). Relative to the wild type DMBT1SAG/8kb we 
found, on a molecular base, a decrease in bacterial binding to DMBT1SAG/6kb. Error bars represent the standard error of 
the mean (SEM), P≤0.05. 
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 DISCUSSION 
 
The scavenger receptor cysteine-rich (SRCR) proteins are an archaic group of proteins exclusively occurring 
in multicellular animal organisms with earliest appearance in the sea urchin (2;4;5). SRCR proteins contain 1-
20 SRCR domains, but the exact functions of the SRCR proteins as a whole and the SRCR domain itself are 
generally unknown. Perhaps one of the best-studied members of these SRCR superfamily is DMBT1. DMBT1 
is known to bind a number of bacteria (9;10;16;28). In addition DMBT1 is proposed to be involved in 
epithelial differentiation and to act as tumor suppressor in brain, lung, gastrointestinal tract, and salivary 
glands (7;22;25;26;30-37).  
Previously, we noted genetic polymorphism within DMBT1(22;23). It has also been reported for other SRCR 
proteins as well, and seems to be an overall characteristic feature of members of the SRCR superfamily. 
Genetic polymorphism for SRCR proteins has been reported e.g. for human CD5 (38), human CD163 sponge 
Aggregation Receptor (AR, (3;39)), and sheep T19 (40). We are the first linking genetic polymorphism to 
functionality i.e. bacterial binding properties of the polypeptide of DMBT1.  
In this study we demonstrated that genetic polymorphism i.e. a reduction of the tandem repeat of the SRCR 
domains and SIDs of DMBT1, results in a corresponding reduction of the protein size (Fig. 1 and 2A). In a 
previous study, we used an ELISA based adherence assay in which we analyzed the bacteria-binding spectrum 
of DMBT1SAG (16). We immobilized DMBT1SAG on black high-affinity microplates and tested a variety of 
fluorescent-labeled bacteria for DMBT1SAG binding (3;16;27). This not only learned us that DMBT1 displays 
binding to a wide variety of bacteria, but also offered us a valid and reliable in vitro system for semi-
quantitative studies on DMBT1-bacterial interaction. Using this assay we quantified bacterial binding of 
DMBT1-variants isolated from donors with different genotypes virtually exactly confirmed our prediction. 
Based on the assumption that a single SRCR domain contains a single bacterial binding site, located in a 
putative cleft (3;16), 8 SRCR within the SRCR/SRCR region domains should theoretically contain 38% less 
binding capacity than 13 SRCR domains. We consistently observed that, compared to wild-type DMBT1 (8kb, 
13 SRCR domains in the SID/SRCR region), the short DMBT1-variant (6kb, 8 SRCR domains in the 
SID/SRCR region) displayed an about 30-45% reduced capacity to bind Gram positive and Gram–negative 
bacteria. Based on the present results, we predict that genetic polymorphism of DMBT1 impairs its protective 
functions, as supported by complete inactivation in DMBT1-knockout mice (41).  
Next to its role in bacterial defense DMBT1 has been proposed to act as tumor suppressor (7;22;25;26;30-37). 
Small mutations in DMBT1, such as single base substitutions, are thought not play a major role in the 
inactivation of DMBT1 (34;42-45). These findings are supported by mutational analysis on the macrophage 
scavenger receptor 1 (MSR1), which is a SRCR protein that is putatively involved in prostate cancer (46;47). 
Prostate cancer risk is associated with germline mutations of (MSR1) and independent of the effect of the 
known rare mutations.  
The present data suggest that the SRCR/SID region defines a complex multi-allele system that represents a 
possible basis for the variability in human susceptibility to infection and, consequently, also to infection-
induced cancer (48) as suggested in earlier papers (23;45). 
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Chapter 7 
 
Pathogen Recognition by the DMBT1/agglutinin Pathogen-Binding Site is Unique in the Scavenger 
Receptor Cysteine-Rich Superfamily  
 
Based on:  
DMBT1 Is a Dual-Specific Pattern Recognition Receptor, which Pathogen-Scavenging Efficacy Is Impaired 
by Germline Deletions 
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C. I. Veerman, Marcus Renner, Gaby Bergmann, Jolanda M. A. de Blieck-Hogervorst, Rainer Wittig, Petra 
Kioschis, Mathias Haffner, Arie V. Nieuw Amerongen, Annemarie Poustka, and Jan Mollenhauer 
 
Submitted 
 
The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of proteins, which are divided 
into group A and B based on the number of conserved cysteine residues (six for group A, eight for group B). 
They occur in multicellular animals with earliest appearance in the sponge. The exact functions of the SRCR 
proteins and the SRCR domains are unknown, but they are generally involved in ligand binding. Deleted in 
Malignant Brain Tumors 1 (DMBT1), which is identical to salivary agglutinin (SAG) and lung gp-340, 
belongs to the group B of the SRCR proteins and is involved in host defense by pathogen binding. In our 
previous study we used non-overlapping synthetic peptides, covering the SRCR consensus sequence, to 
identify a 16 amino acid peptide bacteria binding protein loop (peptide SRCRP2; QGRVEVLYRGSWGTVC).  
In this study, using overlapping peptides, we pinpointed the minimal bacterial-binding site on SRCRP2, and 
thus DMBT1, to an 11 amino acids motif (DMBT1 pathogen binding site 1, DMBT1pbs1; 
GRVEVLYRGSW). Subsequently, essential amino acids in this motif were identified. Our results suggest that 
limited amino acid variation is tolerated within the DMBT1pbs1 amino acid sequence. In addition, the 
homologous sequences of DMBT1pbs1 present in other SRCR proteins were designed, created and analyzed 
for pathogen interaction. It is demonstrated that bacterial binding, mediated by this 11 amino acid motif, is 
strictly limited to DMBT1 and DMBT1 orthologs.   
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INTRODUCTION 
 
The Scavenger Receptor Cysteine-Rich (SRCR) proteins are an archaic group of proteins occurring in 
multicellular animals with earliest appearance in the sponges (1-5). This group of glycoproteins comprises cell 
surface molecules as well as secreted proteins that are characterized by the presence of multiple SRCR 
domains. SRCR domains consist of about 110 amino acids and are divided into group A and B based on the 
number of conserved cysteine residues (six for group A, eight for group B).  
Group A SRCR domains have been found in phyla ranging from the vertebrates to the most primitive metazoa 
(1-5). The best studied members of the group A SRCR proteins are the macrophage scavenger receptor 
(MSR1), Mac2-binding protein (Mac-2bp) and MARCO. Both MSR1 and MARCO are known to interact with 
bacteria (6;7). In contrast to MARCO (8), the SRCR domain of MSR1 does not seem to be involved in 
bacterial binding (9;10). So far, group B SRCR proteins have only been found in vertebrates and are generally 
related to innate immunity. The group B SRCR proteins have been divided on the basis of their structure and 
sequence homology into three subgroups (11): The first subgroup includes CD5 (12), CD6 (13), and SPα (14). 
CD5 and CD6 have an extracellular domain that is composed of three SRCR domains, a transmembrane 
domain, and a cytoplasmatic region. SPα lacks the latter two domains but contains three SRCR domains that 
are highly homologous to those of CD5 and CD6. CD5 and CD6 are mainly expressed by thymocytes, T-cells 
and B-cells (12;13). SPα transcripts are found in human bone marrow, spleen, lymph nodes, thymus and fetal 
liver. Although CD5, CD6 and SPα are structurally closely related, their ligands are quite different. The 
second subgroup of SRCR group B molecules is the Workshop Cluster 1 (WC1) family, including WC1, 
CD163 and M160 (11;15). These molecules are primarily related to monocyte and macrophage cell lineages 
but the function of the WC1 family remains mysterious. The third subgroup of group B SRCR proteins 
includes human Deleted in Malignant Brain tumors 1 (DMBT1) (16-21), with homologues in the rat (Ebnerin) 
(22) mouse (CRP-ductin) (23) and rabbit (Hensin) (24). Besides, bovine gallbladder mucin (25) and Pema-
SREG from the sea lamprey Pertromyzon marinus (26) are included in this subgroup. These molecules are 
associated with host defense e.g. by pathogen binding. In addition, it has been are suggested that they play a 
role in epithelial differentiation. These molecules are expressed by epithelial cells in the gastrointestinal tract 
and in the ducts of the exocrine glands (also see (27)).  
Salivary agglutinin (SAG), and lung gp-340 are encoded by DMBT1 at chromosome 10q25.3-q26.1 
(17;19;21;28;29). These proteins, which are identical, represent the DMBT1-isoforms secreted in the saliva 
(DMBT1SAG) and the lung fluid (DMBT1GP340), respectively. For about two decades, DMBT1SAG, which 
manifests a broad bacterial-binding specificity, has intensively been investigated in regard to its role in caries 
prevention, by binding to and agglutination of cariogenic bacteria in the oral cavity (30;31). DMBT1GP340 is 
putatively involved in respiratory tract protection, because it interacts with the defense collectins surfactant 
protein D (SP-D) and A (SP-A) and is able to stimulate alveolar macrophage migration (17;32). 
7 
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Despite the fact that the exact functions of the SRCR proteins and the SRCR domains are not fully understood, 
various A and B group SRCR proteins are associated with host defense systems and show broad ligand 
binding spectra (1;4). It has been reported that bacterial binding by MARCO (group A) is mediated by the 
RXR motif (6). Accordingly, by initial protein digestion and utilization of non-overlapping synthetic peptides, 
we recently identified a protein loop in the SRCR domains of DMBT1 (group B) that was able to bind to 
various bacteria (16). The use of synthetic peptides thus offered us a simple in vitro system to explore 
fundamental aspects of DMBT1 and SRCR-mediated bacterial binding in general.  
In this study we have defined the minimal bacterial-binding motif on tDMBT1 as an 11 amino acid peptide 
DMBT1pbs1 (DMBT1 pathogen-binding site 1) as being the minimal site required for bacterial binding and 
agglutination. These data were confirmed by successive amino- and carboxy-terminal truncations of the 
DMBT1pbs1 motif. Next, substitution of most amino acids within DMBT1bps1 greatly reduced its binding 
and agglutination capacity pointing to limited acceptance of sequence variation. Accordingly, none of the 
consensus peptides derived from the DMBT1pbs1-corresponding regions of other SRCR proteins, other than 
DMBT1 and DMBT1 orthologs, showed significant bacterial binding and agglutination capacity.  
 
EXPERIMENTAL PROCEDURES 
 
Purification of DMBT1SAG 
DMBT1SAG purified exactly as described previously (16), except that DMBT1SAG was eluted from a column 
with either PBS or Tris-buffered saline (TBS: 150 mM NaCl, 10 mM Tris-HCl, pH 7.4) 
 
Bacteria  
Streptococcus mutans (Ingbritt), Streptococcus gordonii (HG222) and Escherichia coli (OM36-1) were 
cultured on blood agar plates under anaerobic conditions with 5% CO2 at 37 ºC for 48 h. Subsequently, single 
colonies of S. mutans and S. gordonii were cultured in Todd Hewitt medium (Oxoid, Hampshire, United 
Kingdom). Single colonies of E. coli were cultured in Luria Broth (Oxoid) at 37 ºC for 24 h in air/CO2 (19:1). 
Cells were harvested and washed twice in TTC buffer (TBS Tween Calcium buffer: TBS, 150 mM NaCl, 10 
mM Tris-HCl, pH 7.4; 0.01% (v/v) Tween 20 (polysorbate, Merck-Schuchardt, Germany); 1 mM CaCl2). 
Helicobacter pylori (NCTC 11637) was cultured on selective Dent plates (Oxoid) at 37 ºC for 72 h. H. pylori 
was harvested by wiping off the plates and washed twice in NTC buffer (100 mM NaAc, pH 4,2, 0.01% (v/v) 
Tween 20, 1 mM CaCl2). Bacteria were diluted in buffer to a final OD700 of 0.5, corresponding with 
approximately 5 x 108 cells/ml.  
 
Peptide design, synthesis and purification 
All synthetic peptides were SRCR domain consensus-based and designed as described previously using 
alignment software (DNASTAR, Lasergene Inc., Madison, WI, U.S.A.) (16). For determination of the 
minimal bacterial / pathogen-binding site (DMBT1pbs1) we designed overlapping peptides covering the 
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SRCR consensus sequence ranging from 6 amino acids towards the amino-terminus (peptide SRCRP+6N) to 6 
amino acids towards the carboxy-terminus (SRCRP2+6C), relative to SRCRP2 (Fig. 1A).  
To study the role of the individual amino acids within DMBT1pbs1 in pathogen binding we generated 
peptides with alanine substitutions for each amino acid (Fig. 3).  
To test bacterial binding of other SRCR proteins we used the Pfam (Protein family) database on the World 
Wide Web, located at http://www.sanger.ac.uk/Software/Pfam/index.shtml. As keyword we used the 
abbreviation ‘SRCR’, or Protein Database (PDB) accession code 1by2, which led us to the SRCR superfamily 
database. The present known SRCR amino acid sequences were used as template for the design of peptides of 
other SRCR proteins, which amino acid sequence corresponds to the DMBT1pbs motif. So, analogous to 
DMBT1, we designed peptides, representing consensus sequences of various other SRCR proteins (Table 1A) 
SRCR proteins in species, families, genera and orders (Table 1B). The amino acid motif, homologous to 
DMBT1pbs1 in DMBT1, was calculated as a consensus sequence for each SRCR protein, exactly as described 
previously (16). Peptides were generated either by solid phase synthesis using Fmoc chemistry on a MilliGen 
9050 peptide synthesizer (MilliGen/Biosearch, Bedford, MA, USA) according to the manufacturer’s 
procedures or purchased from Eurogentec (Seraing, Belgium). The authenticity of the peptides was confirmed 
by quadrupole-time of flight mass spectrometry (Q-TOF MS) on a tandem mass spectrometer (Micromass 
Inc., Manchester, United Kingdom) as described previously (33). The purity of the peptides was at least 90%, 
except those for taxonomical analysis (Fig. 3A and B), having a purity of at least 70%. 
 
Adhesion assays  
Bacterial adhesion was examined using a microtiter plate method based on labeling of microorganisms with 
cell-permeable DNA-binding probes, as reported earlier (16;34). Microtiterplates Fluotrac 600, (Greiner, 
Recklinghausen, Germany) were coated with various amounts of either synthetic peptides, or purified 
DMBT1SAG. The peptides were dissolved in coating buffer (100 mM sodium carbonate, pH 9.6) to a starting 
concentration of 40 µg/ml and diluted twofold serially. After incubation for 16 h at 4 ºC, plates were washed 
twice with the relevant buffers. Subsequently, 100 µl of a bacterial suspension (5 x 108 bacteria/ml TTC) were 
added to each well and incubated at 37 ºC for 2 h. Plates were washed three times with the same buffer using a 
plate washer (Mikrotek EL 403, Winooski, VT). Bound bacteria were detected using 100 µl/well of 1 mM 
SYTO-9 solution (Molecular Probes, Leiden, The Netherlands), a cell-permeable fluorescent DNA-binding 
probe. Plates were incubated in the dark for 15 min at ambient temperature and washed three times with the 
same buffer. Fluorescence was measured in a fluorescence microtiter plate reader (Fluostar Galaxy, BMG 
Laboratories, Offenburg, Germany) at 488 nm excitation and 509 nm emission wavelengths. These 
experiments were repeated at least three times. 
 
Agglutination assays  
100 µl of a bacterial suspension (5 x 108 bacteria/ml) were mixed with 20 µl peptide solution at final peptide 
concentrations of 0-200 µg/ml in a 48-wells microtiter plate (Faclon, New Jersey, U.S.A.), and incubated at 37 
°C for 5-15 min. Agglutination was analyzed by visual observation and quantified as positive (+, 
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agglutination) or negative (-, no agglutination). Turbidometric analysis of the agglutination process was 
carried out using a spectrophotometer (UVICON 930, Kontron Instruments, Watford, United Kingdom), as 
described earlier (16), using 150 µM peptide. The optical density of the bacterial suspensions was monitored 
at 700 nm for 60 min at 37 ºC. These experiments were repeated at least three times. 
 
RESULTS 
 
Determination of the minimal pathogen-binding site of DMBT1  
By the utilization of non-overlapping peptides we previously identified the bacterial binding site of DMBT1. 
This 16 amino acid peptide sequence, SRCRP2, represents a protein loop spanning residue 18-33 of the SRCR 
domain consensus sequence (QGRVEVLYRGSWGTVC) (16). Now using overlapping peptides we further 
defined the exact/minimal bacterial-binding site. We tested 16 amino acid peptides shifting up six amino acids 
from the amino-terminus (SRCRP2+6N) to six amino acids beyond the carboxy-terminus (SRCRP2+2C), 
relative to SRCRP2 for bacterial binding (Fig. 1A). First, we immobilized peptides on microtiterplates. By the 
adherence of bacteria that were labeled with a fluorescent DNA-binding probe, we could determine the 
relative amount of bound bacteria. Only the peptides SRCRP+4 – SRCRP2+C1 were able to bind bacteria 
(Fig. 1B). All the other peptides showed no bacterial affinity at all. Of the bacterial binding peptides the 
overlapping sequence was reconstructed as an 11-mer (GRVEVLYRGSW, Fig. 1C). This 11-mer showed 
bacterial binding suggesting that this 11 amino acid sequence is the minimal bacterial binding site (Figs. 1C, 
2A and B, 3A). These data were confirmed by successive amino- and carboxy-terminal truncations of 
DMBT1pbs1 (Fig. 1C). Peptides containing the motifs RVEVLYRGSW (amino-terminus truncated), and 
GRVEVLYRGS (carboxy-terminus truncated) motif did not show any bacterial affinity at all (Fig. 1C).  
This 11-mer, designated DMBT1pbs1, was able to interact with both Gram-positive as well as Gram-negative 
bacteria in solid and liquid phase (Figs. 1 and 2). Like peptide SRCRP2 and the native DMBT1 DMBT1pbs1 
binds bacteria. All synthetic peptides were analyzed for both bacterial-adherence and bacterial agglutination 
and no contradictory results were found. 
 
SRCRP2 vs. DMBT1pbs1  
In our previous study we showed that peptide SRCRP2 was able to induce bacterial agglutination. In order to 
compare DMBT1pbs1 with SRCRP2 for bacterial agglutination, both peptides were mixed with standardized 
bacterial suspensions. We incubated the mixture for 1 h to allow precipitation of aggregates formed. 
Agglutination was studied by turbidometric analysis. Both peptides were able to aggregate S. mutans in the 
presence of 1 mM Ca2+ (Fig. 2A). Using peptide SRCRP2 bacterial aggregates were detected after 
approximately 30 min of incubation. Strikingly, using corresponding concentrations of peptide DMBT1pbs1 
bacterial agglutination was detected already after 2-3 min. Apparently DMBT1pbs1 interacts stronger with S. 
mutans than SRCRP2. In parallel with SRCRP2, DMBT1pbs1 has affinity for both Gram-positive and –
negative pathogens such as S. mutans and S. gordonii (Gram-positive), E. coli and H. pylori (Gram-negative) 
(Fig. 2B).  
CHAPTER 7           
 86
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Comp arison of SRCRP 2- and DMBT1pbs1-medi ated bac terial agglu tination .  A, turbidometric 
measurements showed that S. mutans agglutination could be mediated by both SRCRP2 and DMBT1pbs. DMBT1pbs1 
mediated agglutination could be detected at 2-3 minutes, while SRCRP2 mediated agglutination was observed not earlier 
than 20-30 minutes. These results suggest that DMBT1pbs1 interacts significantly stronger with S. mutans than SRCRP2. 
B, DMBT1pbs1 could mediate bacterial agglutination and binding (not shown) of both Gram-positive (S. mutans, S. 
gordonii) as well as Gram-negative bacteria (E. coli, H. pylori), and therefore harbors a broad bacterial binding spectrum, 
as was determined for SRCRP2 previously (16). 
 
Determinati on of essential amino acids of DMBT1pbs1   
In order to identify essential amino acids for pathogen interaction within DMBT1pbs1 peptides were created 
that were identical to the DMBT1pbs1 motif, except that for each peptide single a amino acid was substituted 
by alanine (Fig. 3). These peptides were immobilized on a microplate and analyzed for binding to fluorigenic 
bacteria. In general, peptides other than DMBT1pbs1 were strongly reduced in pathogen interaction pointing 
to limited acceptance of sequence variation (Fig. 3). Substitution of most amino acids within DMBT1bps1 
greatly reduced the ability of the peptides to agglutinate bacteria (not shown). Particularly the substitution of 
the negatively charged glutamic acid (E4A) and adjacent residues (V3A, V5A and L6A) strongly reduced 
pathogen adherence (Fig. 3). Furthermore, substitution of the hydrophobic and aromatic thryptophan (W11A) 
at the carboxy-terminus of DMBT1pbs1 completely destroyed pathogen interaction. These results point to an 
essential role of these residues in bacterial binding. 
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 Figure 3: Determination of essential amino acids of DMBT1pbs1. Analysis of critical amino acid residues in 
DMBT1pbs1. The graph at the right displays the impact of amino acid substitution by alanine in DMBT1pbs1. Binding 
activity to S. mutans is expressed as percent compared to DMBT1pbs1, which served as positive control. SRCRP1, (14) 
without substantial binding activity, was included as negative control. Error bars are SEM. Substitution of the amino 
acids Val3, Glu4, Val5, Leu6 and Trp11 by alanine in DMBT1pbs1 revealed a significant decrease in pathogen binding. 
All other positions seem to tolerate an alanine substitution. 
 
Pathogen interaction in the SRCR superfamily according to the DMBT1pbs1 motif  
DMBT1 is able to bind bacteria, via a specific bacterial binding site, located in a putative cleft in the SRCR 
domains (Fig. 1A) (see also 16; 43; 44). This bacterial binding site is represented by the 11 amino acid peptide 
DMBT1pbs1 (GRVEVLYRGSW). The amino acid sequence of the SRCR domains is highly conserved across 
species and family boundaries. Therefore we hypothesized that bacterial binding, which is mediated by this 
particular amino acid motif in DMBT1, might also be conserved in SRCR proteins other that DMBT1.  
Using a widely used Pfam (Protein family) database on the World Wide Web 85 amino acid sequences of 
group A and B SRCR proteins were found at http://www.sanger.ac.uk/cgi-bin/Pfam/getacc?PF00530. In total, 
these 85 proteins comprised 301 SRCR domains, ranging from 1 – 20 SRCR domains per protein. The amino 
acid motif, homologous to DMBT1pbs1 in DMBT1, was calculated for each SRCR protein. Besides, in order 
be able to possibly limit bacterial binding to separate species, the consensus sequence of all SRCR proteins 
within single species was calculated. This was also done for families, genera, orders and phyla. Of all 
DMBT1pbs1 homologous motifs we synthesized a representative number of 37 peptides consisting of 11 
amino acids, including: 4 peptides representing all 14 SRCR domains of DMBT1 and 20 peptides representing 
the consensus sequence of 20 different SRCR proteins (Table 1A). 13 peptides represent the consensus 
sequence of all SRCR domains within 13 different species; 2 peptides representing the consensus sequence of 
  N-term              C-term 
DMBT1pbs1        G R V E V L Y R G S W 
SRCRP1 neg. contr.  G S E S S L A L R L V N G G D R C 
DMBT1pbs1 G1A        A R V E V L Y R G S W 
DMBT1pbs1 R2A        G A V E V L Y R G S W 
DMBT1pbs1 V3A        G R A E V L Y R G S W 
DMBT1pbs1 E4A        G R V A V L Y R G S W 
DMBT1pbs1 V5A        G R V E A L Y R G S W 
DMBT1pbs1 L6A        G R V E V A Y R G S W 
DMBT1pbs1 Y7A        G R V E V L A R G S W 
DMBT1pbs1 R8A        G R V E V L Y A G S W 
DMBT1pbs1 G9A        G R V E V L Y R A S W 
DMBT1pbs1 S10A        G R V E V L Y R G A W 
DMBT1pbs1 W11A        G R V E V L Y R G S A 
PATHOGEN BINDING BY THE SAG PATHOGEN-BINDING SITE IS UNIQUE IN THE SRCR SUPERFAMILY 
 89
all SRCR domains within 2 families; 2 peptides representing the consensus sequence of all SRCR domains 
within 2 genera; 6 peptides representing the consensus sequence of all SRCR domains within an order, 
infraorder, superorder, phylum, subphylum and infraclass; and one peptide representing the consensus 
sequence of all SRCR domains within the SRCR superfamily (Table 1B). Note that some peptides represent 
more than one SRCR protein or taxonomical subgroups. Approximately equal numbers of peptides represent 
either group A or B SRCR proteins and taxonomical subgroups.  
All peptides were immobilized on microplates and tested for binding of fluorigenic bacteria. Sequence 
variations of DMBT1pbs1 were blasted against all SRCR amino acid sequences and revealed that specifically 
the amino acid sequences that are present in DMBT1 and DMBT1 orthologs: mouse CRP-ductin, rat Ebnerin, 
and rabbit Hensin, retained the property to interact with bacteria (Table 1A). Corresponding motifs in most 
other group B SRCR proteins and all group A SRCR proteins and taxonomical subgroups did not show any 
bacterial binding activity (Table 1A and B). 
 
 
 
 
 
 
 
 
 
 
 
Table 1 (next two pages): Pathogen interaction in the SRCR superfamily according to the DMBT1pbs1 motif. (B) 
and (A) denote group B and group A SRCR proteins, respectively. (+) Binding and agglutination activity and (-) no 
binding and agglutination activity with both Gram-positive S. mutans Gram-negative E. coli. A, the panel summarizes the 
results of DMBT1pbs1-homologous motifs in other SRCR proteins. Amino acids diverging from DMBT1pbs1 are in 
italic. Boxed residues are compatible substitutions. None of the consensus peptides representing the DMBT1pbs1-
homologous regions of other SRCR proteins from various species, other than DMBT1 homologues, showed significant 
bacterial binding and agglutination capacity. Asterisks mark consensus sequences only, other sequences are both 
consensus sequences and actual sequences within the SRCR proteins. Quantitative differences were found between the 
DMBT1pbs1-motifs present in the various SRCR domains of DMBT1. Motifs present in SRCR1-13 exerted bacterial 
binding and aggregation activity. While the motif in the carboxy-terminal SRCR14 exerted no activity at all. B, The panel 
summarizes the results from DMBT1pbs1-homologous motifs of SRCR proteins in particular species, families, and 
orders. Additional to Table 1A, only the overall SRCR consensus sequence peptide revealed that substitution of arginine 
and glutamic acid, by asparagine at position eight is tolerated. None of the other consensus peptides showed significant 
bacterial binding and agglutination capacity, with a sequence other than revealed in Table 1A. Overall, sequence 
variation in DMBT1pbs1 was limited to Val5Ile, Tyr7Phe, and Arg8Gln/Asn. 
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 DISCUSSION 
 
The scavenger receptor cysteine-rich (SRCR) proteins are an archaic group of proteins occurring in 
multicellular animals with earliest appearance in the sponge (1;4). The exact functions of the SRCR proteins 
and the SRCR domain itself are still mysterious. Both group A SRCR proteins MSR1 and MARCO and group 
B DMBT1 are known to bind bacteria (6;7;16;21;30). Furthermore DMBT1 was proposed to act as tumor 
suppressor in brain, lung, gastrointestinal tract and salivary glands and play to a role in epithelial 
differentiation (18;24;35-42). The goal of this study was to determine the minimal bacterial binding site of 
DMBT1. Moreover we aimed at tracing down structural related functional parallels of the minimal bacterial 
binding site of DMBT1 in other SRCR proteins.  
Based on the bacterial binding protein loop of the SRCR domains of DMBT1 i.e. SRCRP2 (16), and the use of 
a series of overlapping synthetic peptides the minimal bacterial binding site was defined. 16-mer peptides 
containing amino- and carboxy-flanking sequences of SRCRP2 were tested for bacterial binding. Remarkably, 
peptide SRCRP2+1N exhibits clear decreased bacterial binding, when compared to its neighboring peptides 
SRCRP2 and SRCRP2+2N (Fig. 1B). Compared to SRCRP2+2N, SRCRP2+1N contains no amino-terminal 
arginine residue, and so lacks a positively charged residue, when compared with SRCRP2+2N. This may 
explain a decreased bacterial-binding capacity. SRCRP2 and SRCRP2+1N share an identical amino acid 
sequence, except for the position of the cysteine residue. SRCRP2 contains an amino–terminal cysteine 
residue, whereas SRCRP2+1N contains a carboxy-terminal cysteine residue. Differential bacterial binding to 
these peptides suggests an important role of the exact position of the cysteine residues in these peptides. Thus, 
possibly, the amino acid sequence plays a crucial role in bacterial recognition and is not per se related to the 
amino acid composition. In order to answer these questions peptides with reverse sequences to be tested and 
compared for qualitative bacterial binding.    
The in vitro binding studies, especially the impact of substitutions by alanine (Fig. 3), strongly indicated that 
pathogen interaction by DMBT1pbs1 does not only rely on ionic interaction, but might also include 
hydrophobic interactions, hydrogen-bonding and possible steric requirements. In concordance, only limited 
sequence variation is tolerated in the DMBT1pbs1 motif in other SRCR consensus sequences in regard to 
pathogen interaction (Table 1A and B). Accordingly, the amino acid substitutions that are tolerated are 
structurally highly related. At first, both valine and isoleucine at position 5 are hydrophobic, uncharged and 
aliphatic. Secondly, at position 7 tyrosine and phenylalanine are permitted, which are hydrophobic, uncharged 
and aromatic. Finally, position 8 bears the hydrophilic arginine, glutamine and asparagine. Seemingly, the 
positive charge on arginine does not play a key-role in pathogen recognition.  
In principle, the use of consensus-based synthetic peptides, as done with DMBT1, offered us a simple in vitro 
system to explore fundamental structural-related functional aspects of SRCR proteins in general. However, not 
all SRCR proteins share as high amino acid identities as DMBT1 (identity of SRCR domains 1-13 in DMBT1 
= 87-100%) (16;19;29). This results in consensus sequences that do not represent actual sequences of at least 
one of the SRCR domains, as is the case for CD6 (Table 1A). Computer-based calculation of the CD6 
consensus sequence results in GRVEVLYFGSW, while the actual sequences of CD6 of the putative binding 
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sites are, GRVEMLEHGEW, GQVEVHFRGVW and GTVEVRLEASW, as CD6 harbors three different 
SRCR domains. Therefore, bacterial adherence may not be allocated to CD6 but only to its consensus 
sequence. So far, this method only leads to false positives, which can easily be traced back by comparing the 
peptide sequence to the actual protein amino acid sequence. Thus, this system still offers a sophisticated in 
vitro model to study fundamental and structural-based functional studies on amino acid substitution tolerance 
within DMBT1pbs1.  
As the group B SRCR domains are considered to share a conserved overall structure, these data suggest that 
bacterial binding by this motif, locating in a putative cleft (16;43;44), is an evolutionary invention unique to 
DMBT1. This is in agreement with the fact that DMBT1 and its homologues in other species represent the 
only known group B SRCR proteins secreted onto epithelial surfaces and into body fluids, which represent the 
primary sites of pathogen contacts (11;27;29;39;45).  
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Chapter 8 
 
DMBT1/agglutinin Recognizes Sulfate and Phosphate Groups on Bacteria and Host Components 
 
Based on:  
DMBT1 Is a Dual-Specific Pattern Recognition Receptor, which Pathogen-Scavenging Efficacy Is Impaired 
by Germline Deletions 
 
Floris J. Bikker, Caroline End, Antoon J. M. Ligtenberg, Stephanie Blaich, Kamran Nazmi, Stefan Lyer, Enno 
C. I. Veerman, Marcus Renner, Gaby Bergmann, Jolanda M. A. de Blieck-Hogervorst, Rainer Wittig, Petra 
Kioschis, Mathias Haffner, Arie V. Nieuw Amerongen, Annemarie Poustka, and Jan Mollenhauer 
 
Submitted 
 
DMBT1 belongs to the Scavenger Receptor Cysteine Rich (SRCR) superfamily. Generally, members of this 
protein family are involved in host defense and ligand binding. Salivary agglutinin (SAG) and lung gp-340 are 
the DMBT1 (Deleted in Malignant Brain Tumors1)-isoforms secreted into saliva (DMBT1SAG) and lung fluid 
(DMBT1GP340), respectively. DMBT1 plays a role in host defense by exhibiting a broad bacterial-binding 
spectrum. Recently, we have identified the bacterial binding site on DMBT1, and narrowed it down to an 11 
amino acid peptide designated DMBT1pbs1 (DMBT1 pathogen binding site 1). The structural features of 
ligands of DMBT1 and DMBT1pbs1 are unknown.  
Dmbt1-knockout mice show impaired protection against epithelial damage and inflammation induced by 
dextran sulfate (DSS). Therefore binding of DMBT1 to DSS is a possible mechanism for protection against its 
cytotoxic effect. In the present study we started the ligand characterization with DMBT1SAG binding to DSS. 
By ELISA and inhibition assays of bacterial agglutination it was demonstrated that DMBT1SAG and 
DMBT1pbs1 bound to sulfate groups on DSS. In addition, it was demonstrated that DMBT1SAG and 
DMBT1pbs1 bound to sulfated and phosphorylated structures including heparan sulfate, phospholipids and 
DNA, as well as to ubiquitous bacterial surface structures including lipoteichoic acid (LTA) of Gram-positive 
and lipopolysaccharide (LPS) of Gram-negative bacteria. Furthermore, it was demonstrated that phosphate 
groups on LPS from Salmonella strains were essential for binding.  
These results indicate that DMBT1 binds to sulfate and phosphate groups on their cognate ligands. This 
binding is mediated by a peptide domain of the tandem repeats / SRCR domains of DMBT1, which is also 
involved in pathogen recognition.  
 
CHAPTER 8           
 98
INTRODUCTION 
 
The human oral cavity and gastrointestinal tract are in a permanent state of defense in order to prevent 
microbial invasion. This involves both adaptive and innate immune system (1-6). Whereas adaptive immunity 
is only found in vertebrates and depends on genetic rearrangements, innate immunity is a universal, germline 
encoded and evolutionary ancient defense system that gives a rapid and relatively non-specific response to 
pathogen invasion (7-9). An important mechanism of the innate immune system is the ability to recognize 
specific (non-self) structures, a mechanism called pattern recognition (10;11).  
The patterns on invading pathogens that are recognized by the immune system are called pathogen-associated 
molecular patterns (PAMPs). These PAMPs encompass a variety of vital and conserved structures of the 
microbial cell, such as mannans and zymosan of the yeast cell wall (12;13), lipoteichoic acid (LTA) of Gram-
positive bacteria and lipopolysaccharide (LPS) of Gram-negative bacteria (14-17), peptidoglycan, and 
bacterial DNA (7;18). PAMPs are recognized by host proteins, designated Pattern Recognition Receptors 
(PRRs). Generally, PRRs are membrane anchored on epithelial cells, macrophages, granulocytes and dendritic 
cells or are present in the mucosal fluid.  
Proteins of the archaic SRCR (Scavenger Receptor Cysteine-Rich) superfamily (19-21) are generally related 
to host defense systems due to their ligand-binding characteristics (22;23). SRCR proteins contain 1-20 SRCR 
domains each comprising approximately 110 amino acid residues. Based on the numbers of conserved 
cysteine residues SRCR domains are divided in group A (six cysteine residues) and B (eight SRCR residues) 
(24;25). DMBT1 (Deleted in Malignant Brain Tumors1) belongs to the group B SRCR proteins. Salivary 
agglutinin (SAG) and lung gp-340 represent the DMBT1 isoforms secreted into saliva (DMBT1SAG) and the 
lung fluid (DMBT1GP340), respectively (26-29). DMBT1 plays a role in host defense by exhibiting a broad 
bacterial-binding spectrum (29-31). Besides, it binds to defense components, such as SP-D, SP-A (2;26;27;32) 
and IgA (33;34). On the other hand DMBT1 has been proposed to play a role in epithelial differentiation and 
tumorigenesis in various types of cancer (28;35-43). In vitro studies demonstrated that the rabbit homologue 
of DMBT1 triggers epithelial differentiation, when interacting with galectin-3 in the extra cellular matrix 
(ECM) (36;39;42;44). Furthermore, different tumors display loss of DMBT1 expression, apparently depending 
on the time point of DMBT1 localization in the ECM during ontogenesis (38). 
Recently, we have identified the bacterial binding site on DMBT1 (30), and narrowed it down to an 11 amino 
acid sequence, designated DMBT1pbs1 (DMBT1 pathogen binding site 1). This 11 amino acid sequence is 
localized in the repeated SRCR domain of DMBT1 (amino acids 19-29) (45). DMBT1pbs1, synthesized as an 
11 amino acid peptide, is able to mediate bacterial agglutination (45).    
In another study, we demonstrated that Dmbt1-knockout mice show impaired protection against epithelial 
damage and inflammation induced by dextran sulfate (DSS) (46), a common model system for colitis and for 
inflammation-induced cancer (47). Dmbt1-knockout mice were more severely affected by tissue damage, 
inflammation, and macroscopic symptoms (weight losses and colon length reduction) than Dmbt1-wild type 
mice. Thus, it is possible that DMBT1 may act as a scavenger against potential noxious agents like DSS, 
thereby protecting the gastro-intestinal tract The present study was undertaken to investigate whether DSS 
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indeed acts as a ligand for DMBT1, and furthermore, which part of the molecule is involved. In addition, other 
bacterial and host structures, including LPS, LTA, DNA and heparan sulfate have been tested. It was found 
that these molecules can act as ligands for DMBT1, and furthermore, that this binding is mediated by the 
DMBT1pbs1, the previously identified bacteria-binding domain. 
 
EXPERIMENTAL PROCEDURES  
 
Peptide design, synthesis and purification 
The synthetic peptides, DMBT1pbs1 and SRCRP2 were SRCR domain consensus-based and designed as 
described previously using alignment software (DNASTAR, Lasergene Inc., Madison, WI, U.S.A.) (30; 45). 
The peptides were generated by solid phase synthesis using Fmoc chemistry on a MilliGen 9050 peptide 
synthesizer (MilliGen/Biosearch, Bedford, MA, USA) according to the manufacturer’s procedures.  
The purity of the peptides was analyzed by a Reversed Phase HPLC on a JASCO HPLC System (Tokyo, 
Japan). Peptides were dissolved in 0.1% trifluoroacetic acid (TFA) and applied on a VYDAC C18-column 
(218TP, 1.0 x 25 cm, 10 µm particles, Hesperia, CA), equilibrated in 0.1% TFA. Elution was performed with 
a linear gradient, from 30-45% acetonitrile containing 0.1% TFA in 20 min at a flow rate of 4 ml/min. The 
absorbance of the column effluent was monitored at 214 nm and peak fractions were pooled, lyophilized, and 
reanalyzed by RP-HPLC and by capillary electrophoresis on a Biofocus 2000 apparatus (Bio-Rad 
Laboratories). The purity of the peptides was at least 90%. 
The authenticity of the peptides was confirmed by quadrupole-time of flight mass spectrometry (Q-TOF MS) 
on a tandem mass spectrometer (Micromass Inc., Manchester, United Kingdom) as described previously (61). 
 
Specification of tested substances  
Sucrose, maltose, dextrose, and the various salts tested were standard reagents obtained from Merck (NJ, 
U.S.A.) or Sigma-Aldrich (Zwijndrecht, the Netherlands). Dextran sulfate was obtained from ICN 
Biomedicals Aurora (Monrovia, CA, U.S.A.), and was the same as used in the animal experiments studying 
the effect of DSS in DMBT1-/- mice (46). The following chemicals were purchased from Sigma-Aldrich 
Corp. (St. Louis, Mo, U.S.A.): heparan sulfate (H-7640), chondroitin sulfate B (C-3788), Streptococcus 
sanguis LTA (L-3765), Staphylococcus aureus LTA (L-2515), Escherichia coli LPS (L-3012), Klebsiella 
pneumoniae LPS (L-1770), Salmonella typhimurium LPS (L-6511), Salmonella minnesota LPS (L-9391), L-
alpha-phosphatidylcholine (P-4279). CUROSURF with 80 mg/ml phospholipids from pig surfactant (mainly 
phosphatidylcholine) was obtained from Dey (Napa, CA, U.S.A.). s-IgA was purchased from Dako (Glostrup, 
Denmark). dNTPs and dNTP-Mix were from Roche Diagnostics BV (Woerden, the Netherlands), while the 
DNA used in all experiments was the plasmid pE6FP-N1 from Clontech (CA, U.S.A.). 
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Recombinant expression and purification of salivary human DMBT1 
Salivary DMBT1 (DMBT1SAG) was obtained from parotid saliva of a healthy volunteer and purified 
essentially as previously described (30) except that DMBT1SAG was eluted from an UNO Q-6 column (Bio-
Rad) with either PBS or Tris-buffered saline (TBS: 150 mM NaCl, 10 mM Tris-HCl, pH 7.4). Purity of the 
final preparation was approximately 95%.  
Detailed protocols on molecular cloning, the generation of stable transfected cell lines and purification of 
recombinant DMBT1 (rDMBT1) will be published elsewhere (C. End et al., in preparation). Briefly, the 
largest known DMBT1 open reading frame corresponding to the DMBT1/8kb.2 variant (EMBL Accession 
number AJ243212) was cloned into the pT-REX-DEST30 vector (Invitrogen) under the control of a 
tetracycline-inducible promoter. The plasmid was transfected into the cell line T-REX-CHO (Invitrogen, 
Karlsruhe, Germany), which constitutively expresses the Tet-repressor protein, by lipofection using Fugene 6 
(Roche Diagnostics). Stable transfectants were selected by addition of 1 mg/ml G418 and 0.001 mg/ml 
blasticidin. Subcloning was done by low-density plating (20 cells per 50 cm2) and picking of single colonies 
after 15 d under selection. After expansion, the cell clones were grown for 48 h in DMEM/F12 medium 
containing 10 µg/ml tetracycline. rDMBT1 expression was assayed by Northern blot analysis of 15 µg total 
RNA using probe DMBT1/8kb-3.8 DMBT1 and by Western blot analysis using the monoclonal antibody anti-
DMBT1h12 as described before (36). Among the clones with predicted transcript and protein sizes, clone 
CHO-DMBT1/8kb.2-T3 displayed highest expression levels and was selected for the production of rDMBT1. 
For the production of rDMBT1, supernatants were collected after 48 h growth in DMEM/F12 containing 10 
µg/ml tetracycline followed by 24 h of growth in Fetal Calf Serum (FCS)-containing medium (10%) without 
tetracycline. The supernatant was filtered by 0.22 µm bottle top filters and rDMBT1 was purified using a 
computer-monitored FPLC system (Biologic HR Chromatography System; Bio-Rad, Hercules, Ca) and a 
Resource Q column (Amersham). Proteins were eluted with a linear gradient (0.00-0.04 M NaCl). rDMBT1 
containing fractions were pooled and loaded on a Sephacryl S-300 High Resolution (Amersham, Piscataway, 
NJ) gel permeation chromatography column (d = 2.6 cm; h = 57 cm). Proteins were eluted with a linear flow 
of 15 cm/h PBS. rDMBT1 containing fractions were pooled and monitored for purity (about 90-95%) and 
integrity on silver-stained protein gels. Protein concentrations were determined using either Bradford reagent 
with bovine serum albumin as the standard or using the BCA Protein Assay Kit (Pierce Chemical Co., 
Rockford, Ill.) according to the instructions of the manufacturer. 
 
Bacteria 
Streptococcus gordonii (HG222), Escherichia coli (OM36-1), Salmonella typhimurium SF 1399 (smooth, wild 
type), Salmonella typhimurium SF 1195 (Rc chemotype), Salmonella typhimurium SF 1567 (Rd1 chemotype), 
Salmonella typhimurium SF 1398 (Re chemotype) were cultured on blood agar plates under anaerobic 
conditions with 5% CO2 for 48 h at 37 ºC. All Salmonella strains were kindly provided by Dr. B. J. Appelmelk 
from the department of Medical Microbiology of the VUMC, Amsterdam, the Netherlands. Subsequently, 
single colonies were cultured in Todd Hewitt medium (Oxoid, Hampshire, United Kingdom) for S. gordonii 
and in Luria Broth (LB, Oxoid) for E. coli and Salmonella strains, respectively in air/CO2 (19:1), at 37 ºC for 
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24 h. Cells were harvested and washed twice in TT buffer (TBS Tween buffer: TBS; 0.01% (v/v) Tween 20 
(polysorbate, Merck-Schuchardt, Germany); supplemented with 1 mM calcium chloride when indicated (TTC 
buffer). Bacteria were diluted in buffer to a final OD700 of 0.5, corresponding to approximately 5 x 108 
cells/ml.  
 
Turbidometric assays 
The binding of DMBT1 and DMBT1pbs1 to DSS was monitored by examining the inhibitory effects of DSS 
on the DMBT1- and DMBT1pbs1-mediated bacterial agglutination, as described (45). Turbidometric analysis 
of the agglutination process was carried out using a spectrophotometer (UVICON 930, Kontron Instruments, 
Watford, UK) as described (30). 200 µg/ml peptide DMBT1pbs1 and 2 µg/ml of purified DMBT1SAG and 
rDMBT1 in TTC was used. The optical density of the bacterial suspensions was monitored at 700 nm at 37 ºC 
in intervals of 1 min for 60-200 min. These experiments were repeated at least three times.  
To test a large number of potential ligands for DMBT1pbs1, semi-quantitative high-throughput inhibition 
assays were applied. 20 µl of the respective component, potential inhibitor or ligand for DMBT1pbs1, was 
mixed with 20 µl DMBT1pbs1 solution in a 48-wells microtiter plate (Falcon, NJ). The final peptide 
concentration was 200 µg/ml. As positive control served 20 µl peptide mixed with 20 µl of the solvent of the 
respective substances treated in the same manner. 
After 5 min 100 µl of an S. gordonii or E. coli suspension (5 x 108 bacteria/ml) was added to each well. Then, 
plates were incubated at 37 °C for 5 to 15 min. DMBT1pbs1-mediated bacterial aggregation was scored by 
visual inspection as follows: (+++) agglutination comparable to the positive control; (++) onset of aggregation 
delayed by 3-5 min compared to reference; (+) onset of aggregation delayed by 10 min compared to reference; 
(-) no aggregation after 10-15 min.  
 
Adhesion assays / ELISA 
Binding of purified rDMBT1 and DMBT1SAG to various components was examined in ELISA. High affinity 
microtiter plates (Microlon Greiner-F, Polysorp, Nunc, Kamstrup, Denmark) were coated with various 
substances in coating buffer (100 mM sodium carbonate, pH 9.6) at 4 º C for 16 hr. This incubation and all the 
following steps were carried out in a volume of 100 µl per well at room temperature (RT), and all washes and 
incubations were carried out in TTC buffer. After adding purified rDMBT1 and DMBT1SAG and subsequent 
washing, plates were incubated for 1 h with mAb 143 (48) directed against the polypeptide chain of DMBT1 
(diluted 1:10.000 in TTC buffer). After washing, the plates were incubated for 1 h with rabbit anti-mouse IgG-
HRP conjugate (dilution 1:2.000 in TTC; DAKO A/S Denmark). After three washes with TBS-TC, 100 µl 
TMB-solution (3,3`,5,5`-tetramethyl-benzidine; 125 µg/ml in citrate buffer pH 4.5 with 0.05% v/v H2O2) was 
added and incubated at room temperature for 10-15 min. The reaction was stopped by adding 50 µl 2 M 
sulfuric acid. The absorbance was read at 405 nm in a Dynastic MR7000 plate reader (Billington, UK).  
Inhibition of bacterial adhesion to purified rDMBT1 and DMBT1SAG by various substances was examined 
using a microtiter plate method based on labeling of microorganisms with cell-permeable DNA-binding 
essentially as reported previously (30). These experiments were repeated at least three times.  
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RESULTS 
 
DMBT1 binds to DSS 
In a previous study, Dmbt1-knockout mice show impaired protection against epithelial damage and 
inflammation induced by DSS (46). Thus, direct binding of DMBT1 to DSS is a possible mechanism for 
protection against its harmful effect. To examine the binding of DMBT1 to DSS, DSS was immobilized on 
microtiterplates and rDMBT1 and DMBT1SAG were added and tested for binding to DSS, in ELISA. Both 
rDMBT1 and DMBT1SAG bound DSS. Increasing amounts of immobilized DSS bound to increasing amounts 
of DMBT1SAG and rDMBT1 (Fig. 1A). 
 
 
Figure 1. Binding of DMBT1SAG and rDMBT1 to sulfated substances. A, DMBT1SAG binding to DSS. Note that 
DMBT1 and rDMBT1 showed virtually identical binding properties. B, DMBT1 interaction with heparan sulfate. DSS 
and heparan sulfate did not bind to the antibody. 
 
DMBT1 binds to DSS via DMBT1pbs1, its pathogen binding site 
DMBT1pb32s1, an 11 amino acid peptide, represents the pathogen-binding site of DMBT1 and exhibits 
functional characteristics of DMBT1 like bacterial agglutination. Binding of DMBT1pbs1 to DSS was tested 
by evaluating the inhibitory effect of DSS on the DMT1pbs1-mediated agglutination of S. mutans: 
DMBT1pbs1 was preincubated with various concentrations of DSS and subsequently mixed with an S. mutans 
suspension. Aggregation by DMBT1pbs1 and DMBT1SAG were carried out as a control. All DSS 
concentrations tested inhibited both DMBT1SAG -mediated bacterial agglutination (Fig. 2A) and DMBT1pbs1-
mediated bacterial agglutination (Fig. 2B). These results confirm the results of the DSS binding by 
DMBT1SAG and rDMBT1 (Fig. 1A). Thus, DMBT1SAG and DMBT1pbs1 showed virtually identical bacterial 
agglutination characteristics (Fig. 2), which, in both cases, could be inhibited by DSS.  
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Figure 2. DSS inhibits DMBT1SAG and DMBT1pbs mediated bacterial agglutination. A, Purified DMBT1 was 
preincubated with various concentrations of DSS and mixed with a standardized bacterial suspension of S. mutans to a 
final optical density of 0.5 at 700 nm, representing 8 x 105 cells/ml. In a dose-dependent manner, increasing amounts of 
DSS decreased the capacity of DMBT1SAG to agglutinate bacteria. B, DMBT1pbs1, the 11 amino acid bacterial binding 
domain reconstructed as 11-mer peptide, mediated bacterial agglutination. This was inhibited by all concentrations of 
DSS tested. 
 
DMBT1pbs1-mediated bacterial agglutination is inhibited by sulfated components 
In order to specify the exact chemical group of DSS involved in binding to DMBT1pbs1 dextran and sulfate, 
were tested separately. For this we preincubated DMBT1pbs1 with various concentrations of dextran and 
disodium sulfate and subsequently mixed the solutions with a suspension of the Gram-positive S. gordonii, 
and a suspension of the Gram-negative E. coli. With none of the neutral carbohydrates tested (dextran, sucrose 
or maltose) any inhibition of the DMBT1pbs1-mediated bacterial agglutination occurred (Table 1), suggesting 
that the inhibition by DSS did not involve the dextran moiety of the molecule. On the other hand, inorganic 
sulfate ions, as well as sulfate-containing biopolymers, including heparan sulfate and chondroitin sulfate 
exerted inhibitory effects (Table 1) suggesting that the sulfate groups of DSS are involved in the interaction 
with the peptide. Besides to DSS (Fig. 1A) DMBT1SAG bound to heparan sulfate (Fig. 1B), which is a 
biopolymer with another carbohydrate backbone than DSS but also containing a great number of sulfate 
residues. 
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Table 1. Identification of candidate DMBT1 ligands by competition of DMBT1pbs mediated bacterial 
agglutination. Candidate ligands were mixed with a DMBT1pbs1 solution, added to standardized E. coli and S. gordonii 
suspensions and incubated at 37 ° C for 5-15 min. Peptide mediated bacterial aggregation was compared to the reference, 
where no competitor was included, by visual inspection. The scoring system was: (+++) simultaneous aggregation 
compared to reference meaning no binding of DMBT1bs1 to the tested substance; (++) onset of aggregation delayed by 
3-5 min compared to the positive control; (+) onset of aggregation delayed by 10 min compared to the positive control;   
(-) no aggregation after 10-15 min meaning strong, competitive binding of the tested substance to DMBT1pbs1. All 
assays were repeated al least three times. 
 
Substances Concentration Aggregation of 
  S. gordonii E. coli 
Carbohydrates       
Sucrose 1 mM (+++) (+++) 
Maltose 1mM (+++) (+++) 
Dextrose 10 mg/ml (+++) (+++) 
    
Sulfate groups       
Dextran sulfate sodium (DSS) 10 mg/ml (-) (-) 
Heparan sulfate 1 mg/ml (-) (-) 
Chondroitin sulfate B 1 mg/ml (-) (-) 
Na2SO4 1 mM (+) (+) 
 10 mM (+/-) (+/-) 
 50 mM (-) (-) 
    
Phosphate groups       
DNA 5 µg/ml (+/-) (+/-) 
DNA 10 µg/ml (-) (-) 
dNTP-Mix 8mM (++) (++) 
dATP 8mM (++) (++) 
dTTP 8mM (++) (++) 
dCTP 8mM (++) (++) 
dGTP 8mM (++) (++) 
CUROSURFTM  1 % v/v (+/-) (+/-) 
 (pig surfactant phospholipids)    
    
Bacterial cell wall components       
LTA (Streptococcus sanguis) 1 mg/ml (-) (-) 
LTA (Staphylococcus aureus) 1 mg/ml (-) (-) 
LPS (Escherichia coli) 1 mg/ml (-) (-) 
LPS (Klebsiella pneumoniae) 1 mg/ml (-) (-) 
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Figure 3. DMBT1SAG binding to PAMPS. A, DMBT1 interaction with lipopolysaccharide (LPS) of Salmonella 
minnesota (Corresponds to the Rd1 chemotype in Fig. 4A), Klebsiella pneumoniae and Salmonella typhimurium 
(Corresponds to wild type in Fig. 4A). Note that DMBT1 more efficiently bound to LPS from S. minnesota chemotype 
Rd1 than to wild-type LPS from S. typhimurium. B, DMBT1 binding to lipoteichoic acid (LTA) of S. sanguis and S. 
aureus. LPS and LTA did not bind the antibody. 
 
Figure 4. DMBT1s pathogen-scavenging efficacy depends on the accessibility and availability of phosphorylated 
carbohydrates. A, Schematic presentation of the LPS structure of Salmonella (Adapted from Lüderitz et al., Pharmac. 
Ther. 15: 383-402 (1982)). A-D: carbohydrate residues; AraN: 4-amino-L-arabinose; EtN: ethanolamine; Gal: D-
galactose; Glc: D-glucose; GlcNAc: N-acetyl-D-glucosamine; Hep: L-glycero-D-manno-heptose; KDO: 2-keto-3-deoxy-
manno-octonate; P: phosphate; Ra to Re are incomplete forms present on the different chemotypes. B, Enhanced binding 
of the Rd1 and Re chemotype to DMBT1SAG (left panel) and the DMBT1pbs1-containing peptide SRCRP2 (right panel), 
wt: wild type. 
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DMBT1 and DMBT1pbs1 bind to typical bacterial phosphorylated PAMPs: LPS and LTA 
Besides binding to noxious agents like DSS DMBT1SAG exerts a broad bacterial binding spectrum. In order to 
determine the bacterial binding targets for DMBT1 we tested typical bacterial phosphorylated PAMPs, 
including LTA (Fig. 3A) and LPS (Fig. 3B) for DMBT1 binding. Wild type LTA from S. sanguis and S. 
aureus, wild type LPS from K. pneumoniae, S. typhimurium, and truncated LPS of S. minnesota (Rd-
chemotype, Fig. 4A) were tested for DMBT1SAG binding. DMBT1SAG showed interaction with all LTA 
structures (Fig. 3A) and LPS structures (Fig. 3B) tested. DMBT1 showed strongest interaction with the 
truncated LPS of S. minnesota. In parallel, DMBT1pbs1 mediated bacterial agglutination could be inhibited by 
LTA from S. sanguis and S. aureus and LPS from E. coli and K. pneumoniae (Table 1) pointing to similar 
binding specificities of DMBT1 and DMBT1pbs1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DMBT1 binds to phosphorylated components 
To further analyze the binding of DMBT1SAG to LPS various S. typhimurium chemotypes, expressing 
truncated LPS structures (Rb, Rc, Rd1 and Re as shown in Fig. 4A) were tested for binding to the whole 
DMBT1SAG-molecule as well as to SRCRP2, a DMBT1pbs1 containing peptide (30;45). DMBT1 showed 
highest affinity for S. typhimurium chemotype Rd1, which exposes phosphorylated carbohydrates at its surface 
(Fig. 4A, B). These results were comparable to those found in the binding studies (Fig. 3A) where the 
truncated LPS (Rd chemotype) showed higher affinity to DMBT1SAG than the wild type LPS. In concordance, 
peptide SRCRP2 also showed highest affinity for the S. typhimurium Rd1 chemotype (Fig. 4B). These results 
suggest that DMBT1 shows affinity for phosphorylated components and underline again that DMBT1 and 
DMBT1-derived peptides exhibit similar binding specificities. Also other phosphorylated components 
Figure 5. Binding of DMBT1SAG to phosphorylated 
substances. A, DMBT1 interaction with immobilized 
DNA. B, DMBT1 binding to phospholipid L-alpha-
phosphatidylcholine. C, Interaction of DNA with 
immobilized rDMBT1. The immobilized substances did 
not bind the antibody. 
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including DNA and phosphatidylcholine exhibited binding to DMBT1 and DMBT1pbs1 (Fig. 5, Table 1) In 
contrast to DNA, dNTPs did not inhibit DMBTpbs1 mediated bacterial agglutination. This suggests that the 
affinity for arrayed monophosphates in DNA is higher than for phosphate ions in the dNTPs (Table 1). 
 
DISCUSSION 
 
In the present study, we show that DMBT1 and DMBT1pbs1 recognize sulfate and phosphate groups on DSS, 
bacterial structures and host components. DMBT1 functions in pathogen-defense (29-31) and epithelial 
differentiation (36; 39;42). Sulfate and phosphate binding could provide a uniform and simple mechanistical 
basis clarifying the dualistic functions of DMBT1 and DMBT1 orthologs (45;49).  
For about two decades, DMBT1SAG has intensely been investigated with regard to its role in binding and 
aggregation of Streptococci in relation to oral health. Until now, studies dealing with SAG-bacteria 
interactions on bacterial receptors mainly focused on the characterization of antigen I/II / P1/ Pac, a ubiquitous 
surface adhesin on Streptococci, which had been identified as a specific DMBT1SAG binding protein (50-56). 
Recently, we and others found that DMBT1SAG is identical to the lung glycoprotein gp-340 (27;29). This has 
altered the view on SAG extensively. Genetic analysis revealed that both SAG and gp-340 are encoded by the 
DMBT1 gene, which is localized on chromosome 10q25.3-26.1, and represent isoforms that are secreted into 
saliva (DMBT1SAG) and lung fluid (DMBT1GP340), respectively (26;28;57). Besides, DMBT1 was found to be 
secreted into the gastrointestinal tract and has repeatedly been proposed to be involved in epithelial 
differentiation (26;36;37;42). 
It was demonstrated that DMBT1SAG exhibits a broad binding specificity to bacteria, including oral bacteria 
such as Streptococci, Actinobacillus actinomycetemcomitans, Peptostreptococcus micros and Prevotella 
intermedia but also H. pylori, S. aureus, Bacillus fragilis, Moraxella catarrhalis, Lactobacillus casei, E. coli 
(29;30) and Salmonella spp (this study). These findings were supported by Madsen and co-workers, who 
discovered that CRP-ductin (Dmbt1), the mouse homologue of DMBT1, contains the capacity to bind Gram-
negative as well as Gram-positive bacteria (49).  
In the present study we have demonstrated that DMBT1SAG and DMBT1pbs1 are able to bind typical bacterial 
PAMPs, including LPS and LTA (Fig. 3). Binding to these ubiquitous bacterial surface molecules is a 
plausible explanation for the broad-spectrum binding properties of DMBT1s broad bacterial binding spectrum. 
Phosphate groups seem to play a crucial role in LPS binding.(Fig. 4)  
Overviewing DMBT1s characteristics we argue that DMBT1 exhibits typical PRR characteristics in innate 
immunity. First, DMBT1 binds to typical PAMPs. Secondly, DMBT1 is germline encoded, in contrast to the 
immunoglobulins, which are involved in the acquired immune system. Third, like many PRRs, DMBT1 is 
present on host–pathogen interacting (mucosal) surfaces (in saliva, lungfluid, tear fluid, gastrointestinal tract 
fluid) (36;37;58-60). Finally, DMBT1 belongs to a well conserved protein family, which orthologs exert 
bacterial binding in other species as well (45;49).  
In parallel to DMBT1SAG, other soluble defense factors i.e. salivary proteins such as lactoferrin, 
lactoperoxidase, cystatins, histatins, lysozyme (6) might have pathogen contacts prior to these membrane–
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anchored PRRs, and subsequently may recruit the cells with these PRRs. We speculate that, as being a 
secreted protein in the oral cavity, DMBT1SAG does not only inhibit bacterial colonization but also PRR-
mediated inflammatory responses. 
Furthermore, our results suggest that DMBT1SAG binds to the sulfate group of DSS. This could be a plausible 
mechanism for protection against the cytotoxic effect of DSS in Dmbt1-knock out mice. Sulfate binding could 
also be deduced for binding to heparan sulfate. We speculate that, DMBT1 secreted into the ECM, might 
interact with sulfated polysaccharides, such as heparan sulfate, which could also be of importance for shifting 
polarity and consequent epithelial differentiation.  
In summary, we have demonstrated that DMBT1 acts as receptor for (poly)anionic substances. These include 
sulfate and phosphate groups on ‘nonself’ structures (LPS, LTA, DSS, foreign DNA) and ‘self’ structures 
(DNA, cell membrane and surfactant phospholipids, sulfated cell surface and extra cellular matrix 
polysaccharides i.e. heparan sulfate). Therefore, we believe that it is appropriate to propose DMBT1 as a 
typical PRR recognizing sulfate and phosphate groups. 
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Background 
The oral cavity harbors an enormous diversity of micro-organisms potentially giving rise to commensal 
infection. For example, accumulation of bacteria on tooth surfaces may cause dental caries and induce 
inflammation of gingival tissues. Chronic gingival inflammation and continuous exposure to virulent bacteria 
may eventually lead to periodontitis, a severe degradation of tooth supporting tissues. Saliva plays an 
important role in the protection of oral tissues against micro-organisms, which is illustrated by people 
suffering from xerostomia (dry mouth syndrome). Besides severe complaints of soreness and mucosal 
ulceration these people show a higher prevalence of dental caries and oral infections, due to an increase in the 
number of cariogenic bacteria and other pathogenic micro-organisms, like streptococci and Candida spp. (1-
3).  
To protect the oral tissues against microbial invasion and infection, saliva contains numerous antimicrobial 
proteins. These include lysozyme, lactoferrin, cystatins and histatins, which exhibit bacteriostatic, bactericidal 
and fungicidal activity (4). Other proteins, including immunoglobulins, the high and the low molecular weight 
mucins MUC5B and MUC7, respectively, and salivary agglutinin (SAG) agglutinate a number of oral 
bacterial species promoting their removal from the oral cavity (4).  
SAG is a 300-400 kDa glycoprotein, 25 % of its molecular mass consists of carbohydrate residues. Potentially, 
SAG contains 14 N-glycosylation sites and 449 O-glycosylation sites (5;6). SAG primarily has been studied 
for its aggregating properties of oral streptococci in parotid saliva. Due to its ability to bind and agglutinate the 
cariogenic bacterium Streptococcus mutans, SAG has been considered to play an important role in the innate 
protection against dental caries (7-9). For the last two and a half decades, studies dealing with SAG-bacteria 
interactions have been focused mainly on the characterization of bacterial receptors (10-14), and identification 
of their cognate carbohydrate ligands on SAG (6;12;15;16). These studies revealed that carbohydrate residues 
play only a partial role in binding and aggregation of bacteria by SAG (12;15;16). For example, chemical 
modification of the carbohydrate residues of SAG only slightly impaired its agglutinating properties (16). On 
the other hand, treatments affecting the polypeptide moiety abolished binding to S. mutans completely, 
suggesting a dominant role for peptide domains (6;15;16). SAG was known to bind to antigen I/II, which is 
also known as antigen PAc and B, a surface receptor on streptococci (11-13). Members of the antigen I/II 
family of cell surface proteins are highly conserved, multifunctional adhesins that mediate interactions with 
SAG, but also of oral streptococci with other oral bacteria, and with cell matrix proteins, such as type I 
collagen (14). The interaction of SAG with S mutans requires an alanine-rich repetitive domain (A-region) of 
antigen I/II that is highly conserved in all members of this family of proteins (14). 
Protective factors at the interfaces between the human organism and the environment represent the first 
frontline of defense against infection-, tissue-damage-, inflammation-, and even cancer-inducing stimuli. 
Understanding the mechanisms of host-pathogen interactions and innate defense systems creates the 
opportunity to combat infectious diseases, to develop new drugs, and to understand the genetic basis of human 
susceptibility to infectious diseases. The aim of this study was to unravel (structurally related) functional 
properties of the bacterial binding activity of SAG and to deepen our understanding in the role of SAG in the 
oral defense. 
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SAG is not limited to the oral cavity 
The identification of SAG was initiated when monoclonal antibodies evoked against the polypeptide chain of 
SAG showed cross reactivity with gp-340, a 300-400 glycoprotein from the lung, which is a receptor for SP-D 
(5;17;18). By sequence analysis it was proven definitely that SAG and gp-340 contain an identical amino acid 
sequence (18). In line, gp-340 and SAG bound in a similar way to S. mutans and surfactant protein D. This 
way, the genomic structure and amino acid composition of SAG were recovered; SAG/gp-340 is encoded by 
the DMBT1 gene (Deleted in Malignant Brain Tumors 1) (19;20). SAG, gp-340 and DMBT1 contain an 
identical polypeptide chain. Post-translational processes, such as glycosylation of the polypeptide chain 
probably are tissue specific. In order to indicate that the amino acid sequence of these proteins is identical 
SAG and gp-340 are also denoted as DMBT1SAG and DMBT1GP340, respectively. Thus SAG and gp-340 
represent the isoforms of DMBT1 secreted into saliva and lung fluid, respectively.  
The DMBT1 gene was first studied by Mollenhauer and co-workers (19), who correlated its loss of 
heterozygosity to the occurrence of certain brain tumors. Genetic studies revealed that the DMBT1 gene is 
located on chromosome 10q25.3-26.1, containing 59 highly homologous introns, which possibly cause its 
genetic instability (20). Furthermore, DMBT1 expression was proposed to be involved in epithelial 
differentiation (21) and as putative tumor-suppressor in the gastrointestinal tract and the lung (21;22). For 
example, immunohistochemical studies in situ demonstrated that an up-regulation of DMBT1-expression 
occurred in the tumor-flanking epithelium. Lung carcinomas show decreased DMBT1 levels compared to that 
of tumor-flanking tissue (22). SAG in salivary gland tumors resembles the changes of expression levels known 
from DMBT1 in tumors in other cancer types. All salivary gland tumors displayed decreased SAG expression 
compared to either the flanking normal tissues or healthy tissues (23;24) (Chapters 3 and 4). Only secretory 
cells were SAG-positive. In particular, in tumor-flanking tissues SAG/DMBT1 expression was significantly 
upregulated in cell types that were SAG-negative in normal salivary gland tissues (Chapter 3). Besides, a 
strong staining of the luminal content in the tumor and/or the tumor-flanking tissue was observed. This 
suggests that, in addition to its role in caries defense, SAG may serve as potential tumor indicator and/or 
tumor suppressor in the salivary glands. 
 
SAG and bacterial binding 
SAG/DMBT1 is a member of the SRCR superfamily, which is characterized by the presence of multiple 
SRCR domains (5;19). These domains contain approximately 110 amino acids and harbor a complex tertiary 
structure which is stabilized by multiple three or four disulfide bonds (Fig. 1) (25). The polypeptide chain of 
SAG/DMBT1 is composed of fourteen SRCR domains that are separated by SRCR-interspersed domains 
(SIDs), two CUB (C1r/C1s Uegf Bmp1) domains and a Zona Pellucida domain (Fig. 2A) (5;19). Except for 
the SIDs, these domains are all known to be involved in ligand binding (26-31). 
Generally, SRCR proteins are involved in ligand binding (28;29), but structural-related functional studies on 
SRCR proteins are scarce. So far, MARCO (macrophage receptor with collagenous domain) is one of the best-
characterized SRCR proteins. MARCO is able to scavenge bacteria, by binding to polyanionic bacterial 
structures such as LTA and LPS apparently by an RXR motif (32-36).  
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Figure 1. Schematic representation of an SRCR domain. A model of the SRCR domain of the Mac-2 binding protein 
(Protein Data Bank accession code 1BY2) was constructed using RasWin Molecular Graphics (25). DMBT1pbs1, the 
bacterial binding site, is marked. 
 
 
 
Figure 2. Determination of the minimal bacterial binding site of SAG. A, SAG. The polypeptide chain of SAG 
contains fourteen SRCR domains, two CUB domains and a ZP. B, a digested SAG fragment containing exclusively 
SRCR domains and SIDs still exhibited bacterial binding. C, typical SRCR domain and SID. D, Peptides covering the 
complete SRCR and SID sequence. E, Of all peptides only a 16 mer, SRCRP2, bound bacteria. F, the minimal bacterial 
binding site of SAG :essential amino acids are underlined. 
 
The role of the SRCR domains of SAG in ligand binding was unknown. Cleavage of the SRCR/SID region of 
SAG in the C-terminal CUB domain (Fig. 2B) resulted in a protein fragment of 1722 amino acids that was still 
able to bind to S. mutans (37). This suggested that, in parallel to MARCO, bacterial binding was mediated 
through the SRCR domains. The involvement of SRCR domains was supported by earlier studies where 
treatments affecting the polypeptide moiety showed a complete abolishment of bacterial binding (6;15). 
For the first time, synthetic peptides were used to pinpoint the ligand binding site on a SRCR protein (Chapter 
5) (37). Due to the high identity of the SRCR domains (87-100%) (17;19) consensus-based peptides of a 
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typical SRCR domain of SAG were used to study the SRCR domains of SAG as a whole (Fig. 2C, D). 
Initially, the bacterial binding site of SAG was determined to a sixteen mer peptide 
(QGEVEVLYRGSWGTVC, Chapter 5) (37). In parallel with SAG, this sixteen amino acid peptide was also 
able to bind and agglutinate S. mutans and a number of other bacterial species including Streptococcus 
gordonii, Staphylococcus aureus, Escherichia coli and Helicobacter pylori. Subsequently, the minimal 
bacterial binding site on SAG was pinpointed to an eleven amino acid sequence (Fig. 1F, GRVEVLYRGSW, 
denoted as DMBT1pbs1, Chapter 7) (38). By the synthesis and subsequent analysis of DMBT1pbs1-variants 
we found that the amino acids valine at position 3 (V3), glutamic acid at position 4 (E4), valine at position 5 
(V5) and thryptophan at position 11 (W11) (GRVEVLYRGSW) are essential for bacterial binding (Fig. 1F, 
Chapter 7) (38).32 
The repeated presence of this peptide in the native molecule endows SAG/DMBT1 with a general bacterial 
binding feature with a multivalent character. Experimental evidence confirmed this prediction. DMBT-1 
exhibits genetic polymorphism, giving rise to polypeptides with different numbers of SRCR domains These 
polymorphisms lead to DMBT1-alleles giving rise to polypeptides with interindividually different numbers of 
SRCR domains, ranging from eight SRCR domains (encoded by 6kb DMBT1 variant) to thirteen SRCR 
domains (encoded by the 8kb DMBT1WT variant) within the SRCR/SID region. In numerical terms reduction 
from thirteen to eight amino-terminal SRCR domains is predicted to lead to a 38% reduction of bacterial 
binding (Chapter 6) (38). Quantification of bacterial binding with the Gram-positive bacteria S. mutans, S. 
gordonii, and the Gram-negative bacteria E. coli and H. pylori to SAG/DMBT1-variants isolated from donors 
with the respective genotypes confirmed this prediction. It remains to be investigated whether this 
heterogeneity in bacterial binding will result in enhanced/reduced susceptibility to infectious disease like, for 
example, caries. 
The SRCR superfamily is an archaic group of proteins (Fig. 3). They occur in multicellular animals along the 
entire animal kingdom with earliest appearance in the sponge (26;28;29;39;40). During evolution the SRCR 
family has retained enormous sequence homology among its members (28;29). Since use of synthetic peptides 
had offered us a simple and reliable method to study SAG-bacterial interactions the same method was used to 
study bacterial binding to the homologous domain of DMBT1pbs1 of other SRCR proteins. It was found for 
this eleven amino acid motif that bacterial binding was strictly limited to DMBT1 and DMBT1 orthologs. 
including Crp-ductin (mouse), Ebnerin (rat) and Hensin (rabbit) (Chapter 7) (17;38).  
 
SAG/DMBT1 is a pattern recognition receptor 
Innate immunity is a universal, ancient defense system and, in contrast to adaptive immunity, germline 
encoded (41-43). This system enables a rapid and relatively non-specific response to pathogen invasion. 
Besides, it might prevent overloading the adaptive immunity and chronic inflammatory conditions. An 
important tool of innate immunity is pattern recognition (44;45). Pathogens are characterized by a variety of 
vital and conserved structures of the microbial cell called pathogen-associated molecular patterns (PAMPs). 
PAMPs include mannans and zymosan of the yeast cell wall, and various bacterial cell-wall components, such 
as lipoteichoic acid (LTA) of Gram-positive bacteria and Gram-negative lipopolysaccharide (LPS) (46-49),  
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Figure 3. Phylogenetic tree indicating the prevalence of SRCR proteins. Gene names are italic.  
Source: http://www.sanger.ac.uk/Software/Pfam. 
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and bacterial DNA (44;50). In the human body, PAMPs are recognized by receptors called pattern recognition 
receptors (PRRs). Generally, PRRs are found on host–pathogen interacting surfaces and expressed by 
epithelial cells, macrophages, granulocytes and dendritic cells or as secretory product present in mucosal 
fluids (45;51-53).  
Macrophages contain a set of PRRs that can directly recognize pathogen-associated common structures, 
including the mannose receptor, CD14, Toll-like receptors, scavenger receptors (SRs), such as SR-AI and SR-
AII and MARCO (36;44;45;51-53). MARCO has certain structural similarities with the class A scavenger 
receptors SR-AI and SR-AII, which are generally expressed in macrophages of different tissues (54-56). SR-
AI and SR-AII, which are products of the same gene generated through alternative splicing of primary 
transcript (57), differ from each other in that SR-AII lacks the SRCR domain. SR-AI and SR-AII have been 
associated with the binding of oxidized LDL and the process of atherosclerosis (58;59). Similarly to MARCO, 
SR-AI and SR-AII may also be involved in the removal of bacterial pathogens. Both SR-AI and SRAII bind a 
large number of polyanionic molecules, including typical PAMPs as including LPS and LTA (60;61). 
Furthermore, Suzuki et al. (62) reported that mice homozygous for a disrupted SR-A gene are more 
susceptible to bacterial and viral infections than wild-type mice. This finding, together with the data that SR-A 
binds bacterial cell-wall components, clearly indicates a role for SR-A in the innate immune system.  
In parallel, our data indicate a clear role for SAG as PRR in innate immunity. Evidence was obtained from 
Dmbt1-knockout mice, showing impaired protection against epithelial damage and inflammation when fed 
with dextran sulfate (DSS) (63). It was shown that DSS binding could explain the protective effect of DMBT1 
(Chapter 8) (38). It had been demonstrated that SAG bound specifically to the sulfate group and not the 
dextran backbone of DSS. These results were confirmed by the finding that SAG/DMBT1 bound to another 
sulfated biopolymer, namely heparan sulfate, an extra cellular matrix (ECM) constituent. Moreover, 
SAG/DMBT1 and the peptide DMBT1pbs1 bound to typical PAMPs including LTA and LPS (Chapter 8) 
explaining its broad bacterial binding spectrum (37;64). It was noted that SAG showed highest affinity to a 
truncated LPS structure (Rd1 chemotype of Salmonella spp) which exposes phosphate groups to the surface. 
In parallel SAG and peptide SRCRP2 were shown to exhibit highest affinity to Salmonella typhimurium 
expressing the Rd1 chemotype. Thus, these results suggested that phosphate groups are essential for binding. 
Phosphate binding was confirmed by the fact that, SAG/DMBT1 bound also to other phosphorylated 
biopolymers including phospholipids and DNA Altogether, these results indicate that SAG/DMBT1 bound to 
sulfate and phosphate groups on their cognate ligands (Chapter 8). Overviewing SAG/DMBT1’s 
characteristics we argue that SAG/DMBT1 exhibits typical PRR characteristics in innate immunity, which is 
not limited to the oral cavity. 
 
Concluding remarks 
We have shown that the polypeptide chain of SAG plays a dominant role in binding to a broad spectrum of 
bacteria (18;37). These findings are comparable for MUC7, another salivary glycoprotein, that is involved in 
defense of oral surfaces by bacterial binding. Similar to SAG, binding of purified MUC7 to S. mutans in vitro 
was abolished by reduction and alkylation, suggesting an important role for the polypeptide chain of MUC7 
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(65-67). However, pathogen-binding by SAG/DMBT1 is not limited to bacteria. SAG also binds to viruses, 
including HIV (68) and influenza A (69). In contrast to bacterial binding, viral-binding seems to be 
carbohydrate-mediated. SAG has been found to inhibit specifically HIV-1 infectivity and to bind to the virus 
through the envelope protein gp120. Inhibition by monoclonal antibodies specific to carbohydrates implicates 
the involvement of carbohydrates in the interaction between SAG and gp120 (68). Besides, SAG/gp-340 had 
been shown to inhibit the hemagglutination activity and infectivity of influenza A (69). The antiviral effects of 
SAG/gp-340 are mediated by calcium-independent interactions between the virus and sialic acid-bearing 
carbohydrates on SAG/gp-340. The presence of carbohydrate residues might also effect the conformation of 
SAG. Compared to the SRCR domains the SIDs contain a high density of potential O-glycosylation sites (17). 
Thus, putatively the glycosylated regions are predominantly present in the SIDs (37). Presumably, the high 
density of glycans will force these regions in an extended conformation, thus creating a molecule with 
alternating stretched SIDs and globular SRCR domains exposing its bacterial binding site, DMBT1pbs1, and 
promoting multivalent interaction. Moreover, it can be speculated that the presence of carbohydrates also will 
prevent self-adhesion of SRCR domains to other parts of the molecule, since it has been shown that the SRCR 
domains themselves do not bind to carbohydrates.  
DMBT1 germline deletions, i.e. polymorphism, are predicted to impair interaction with any of the ligands 
identified in the present study. Based on the strategical location of SAG/DMBT1 on mucosal surfaces and 
body fluids (tear fluid, saliva, lung fluid) (4;17;70), i.e. at the major sites of contact with harmful 
environmental stimuli, a systemic and pleiotropic effect of SAG/DMBT1 germline deletions might be 
predicted. This includes a contribution to human susceptibility to infection, inflammation, and even the 
development of cancer. For example, decreased scavenging activity for Helicobacter pylori could contribute 
to tip the balance towards the development of gastric ulcers, gastritis and downstream gastric cancer. This is 
supported by the SAG/DMBT1-related protein MUC1, showing that shortened MUC1 alleles are considered 
to render humans susceptible to Helicobacter pylori-induced gastritis and gastric cancer (71-73). It will be 
clear that epidemiological studies are imperative to substantiate this suggestion. 
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SUMMARY 
 
The oral cavity harbors an enormous diversity of micro-organisms. Accumulation of bacteria on tooth surfaces 
may cause dental caries and induce inflammation of gingival tissues. Chronic gingival inflammation and 
continuous exposure to virulent bacteria may eventually lead to periodontitis, a severe degradation of tooth 
supporting tissues. 
Numerous antimicrobial proteins are present in human saliva. These include lysozyme, lactoferrin, cystatins 
and histatins, which exhibit bacteriostatic, bacteriocidic and fungicidal activity. Other proteins, including 
immunoglobulins, mucins and salivary agglutinin (SAG) play a role in the oral clearance of bacteria. By 
mimicking adhesive sites on oral tissues, these proteins interfere with receptors on the microbial cell wall. The 
aim of this study was to unravel (structurally related) functional properties SAG-bacterial interactions and to 
deepen our understanding in the role of SAG in the oral defense. 
 
SAG is not specific for the oral cavity 
In Chapter 2 is shown that SAG is identical to gp-340, a 300-400 kDa glycoprotein present in lung fluid, that 
was co-purified with the surfactant protein SP-D, as confirmed by the following characteristics. First it was 
found that SAG and gp-340 have an identical molecular mass. Second, amino acid sequence analysis of SAG 
by mass spectrometry confirmed identity with gp-340. Third, monoclonal antibodies directed against gp-340 
reacted with SAG and vice versa. In line, gp-340 and SAG bound in a similar way to Streptococcus mutans 
and surfactant protein D. A search in the human genome revealed that SAG and gp-340 are encoded by the 
gene DMBT1 (Deleted in Malignant Brain Tumors 1), a candidate tumor-suppressor. In other words, SAG, gp-
340 and DMBT1 are genetically identical. This way, we had recovered the genomic structure and amino acid 
composition of SAG.  
 
Immunohistochemical localization of SAG in the salivary glands 
For further characterization SAG was immunolocalized in the human salivary glands (Chapter 3). For this, 
first two monoclonal antibodies (mAb), directed against gp-340, were characterized. The first mAb, 213-1, 
reacted with sialic acid containing epitopes, cross-reacting with MUC7. Thus mAb 213-1 was unsuitable to 
localize SAG in the submandibular and labial salivary gland. The reaction with the second mAb, 213-6, 
disappeared after reduction suggesting that a protein epitope was recognized. Using this mAb we were able to 
localize SAG, on a cellular level in the salivary glands. 
In the parotid gland SAG was immunolocalized exclusively in the duct cells. In the submandibular gland and 
labial gland both serous acini and demilune cells were labeled with mAb 213-6. In addition, in the labial gland 
labeling was found in the duct cells. Thus in different salivary glands SAG was localized in distinct cell-types 
but in the respective glandular secretions no differences in electrophoretic behavior were observed. 
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SAG (DMBT1SAG) and salivary gland tumors 
SAG represents the salivary variant of DMBT1, a candidate tumor-suppressor in the brain, lung and 
gastrointestinal tract. We analyzed SAG expression in salivary gland tumors and tumor-flanking tissues by 
immunohistochemistry (Chapter 4). All 20 salivary gland tumors displayed decreased DMBT1SAG expression 
compared to positive structures in either the tumor-flanking tissues or healthy tissues. Furthemore, in tumor-
flanking tissues SAG/DMBT1 expression was significantly upregulated in cell types that were SAG-negative 
in normal salivary gland tissues (Chapter 3). Besides, a strong staining of the luminal content in the tumor 
and/or the tumor-flanking tissue was observed. This suggests, that in addition to its role in caries prevention, 
SAG may serve as potential tumor indicator and/or tumor suppressor in the salivary glands. 
 
Identification of the bacterial-binding site on SAG 
We have searched for the peptide domains of SAG responsible for bacterial-binding (Chapter 5). Protein 
digestion resulted in a protein fragment containing SRCR domains and SID domains. This protein fragment 
was still able to bind to S. mutans. To define more closely the S. mutans binding domain consensus-based 
peptides of SRCR domains and SIDs were designed and synthesized. Only one of the SRCR peptides, 
designated SRCRP2 (QGRVEVLYRGSWGTVC), and none of the SID peptides bound to S. mutans. In 
parallel with SAG, this 16 amino acid peptide was also able to bind and agglutinate S. mutans and a number of 
other bacteria, including Escherichia coli, Staphylococcus aureus, and Helicobacter pylori. Moreover, peptide 
SRCRP2 inhibited bacterial-binding to SAG, indicating that the bacterial-binding amino acid sequence on 
SAG and the peptide were identical. Our studies demonstrated for the first time that the polymorphic SRCR 
domains of SAG/DMBT1, mediate ligand interactions. 
 
The efficacy of bacterial-binding to SAG is related to genetic polymorphism  
DMBT1 polymorphisms lead to DMBT1-alleles giving rise to polypeptides with interindividually different 
numbers of SRCR domains, ranging from 8 SRCR domains (encoded by 6kb DMBT1 variant) to 13 SRCR 
domains (encoded by the 8kb DMBT1WT variant) within the SRCR/SID region. In numerical terms reduction 
from 13 to 8 amino-terminal SRCR domains is predicted to lead to a 38% reduction of bacterial-binding 
(Chapter 6). Quantification of bacterial-binding, with the Gram-positive bacteria S. mutans and S. gordonii, 
and Gram-negative E. coli and H. pylori to SAG/DMBT1-variants isolated from donors with the respective 
genotypes confirmed this prediction. This was the first study to explore polymorphism of a SRCR protein, 
demonstrating a functional significance for SRCR domain repetition. 
 
Identification of the minimal bacterial-binding site of SAG 
In order to pinpoint the minimal bacterial-binding site of SAG a set of overlapping peptides was generated 
(Chapter 7) and tested for bacterial-binding. All peptides that contained the sequence GRVEVLYRGSW 
(underlined in the SRCRP2 sequence: QGRVEVLYRGSWGTVC) contained the ability to bind and 
agglutinate S. mutans. Subsequently, a peptide containing exclusively this 11 amino acid sequence was 
generated. This peptide agglutinated and bound to both Gram-positive and Gram-negative bacteria, but N-, 
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and C-terminally truncated peptides: RVEVLYRGSW and GRVEVLYRGS did not show this behavior. Thus, 
the 11-mer peptide containing the sequence GRVEVLYRGSW, further on denoted as DMBT1pbs1 (DMBT1 
pathogen binding site 1), represents the minimal bacterial-binding site on SAG. Variants of DMBT1pbs1 
revealed that the amino acids valine at position 3 (V3), glutamic acid at position 4 (E4), valine at position 5 
(V5) and tryptophan at position 11 (W11) (GRVEVLYRGSW) are essential for bacterial-binding. 
 
Bacterial-binding by the SAG/DMBT1-pathogen-binding site is limited to DMBT1 and DMBT1 
orthologs  
SAG is a member of the SRCR superfamily, an archaic group of proteins. They occur in multicellular animals 
with earliest appearance in the sponge. We designed a set of 37 peptides, representing current known 
homologous sequences of DMBT1pbs1 present in other SRCR proteins. These peptides were analyzed for 
binding to bacteria (Chapter 7). It was demonstrated that bacterial-binding, mediated by this 11 amino acid 
motif, is strictly limited to DMBT1 and DMBT1 orthologs: Crp-ductin (mouse), Ebnerin (rat) and Hensin 
(rabbit).  
 
SAG/DMBT1 binds to sulfated components 
Human and mouse DMBT1 are luminally secreted by the colon surface epithelium. Dmbt1-knockout mice 
showed impaired protection against epithelial damage and inflammation when fed with dextran sulfate (DSS). 
Therefore binding of DMBT1 to DSS is a possible mechanism for protection against its cytotoxic effect. We 
showed that both SAG/DMBT1 and peptide DMBT1pbs1 bound to DSS (Chapter 8). Furthermore, our 
results suggested that both SAG/DMBT1 and the peptide specifically bound to the sulfate group and not to the 
dextran compound of DSS. These results were confirmed by the finding that both SAG/DMBT1 and the 
peptide bound to another sulfated biopolymer heparan sulfate, an extra cellular matrix (ECM) constituent. We 
speculate that, SAG/DMBT1 secreted into the ECM, might interact with sulfated polysaccharides, such as 
heparan sulfate, which could also be of importance for shifting the cellular polarity and consequent epithelial 
differentiation.  
 
SAG/DMBT1 binds to phosphate groups on typical PAMPS  
SAG binding was tested to ubiquitous bacterial PAMPS, including LPS and LTA (Chapter 8). It was shown 
that both SAG/DMBT1 and the peptide bound to LTA of Streptococcus sanguis and S. aureus and LPS of 
Klebsiella pneumoniae and Salmonella strains (wt, and Rd1-chemotype). SAG showed the highest affinity to a 
truncated LPS structure (Rd1 chemotype), which exposes phosphate groups to the surface. These results were 
confirmed because SAG and peptide SRCRP2 were shown to exhibit the highest affinity to Salmonella 
typhimurium expressing the Rd1 chemotype. Phosphate binding was also confirmed by the fact that both 
SAG/DMBT1 and the peptide were observed to bind to other phosphorylated biopolymers including 
phospholipids and DNA. Altogether, these results indicated that both SAG/DMBT1 and the peptide bound to 
both sulfate and phosphate residues on their cognate ligands. 
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Conclusions 
SAG/DMBT1 is involved in innate immunity by exhibiting a broad bacterial-binding spectrum. In addition to 
its role in caries defense, SAG/DMBT1 may serve as potential tumor indicator and/or tumor suppressor in the 
salivary glands. We have shown that the polypeptide chain of SAG/DMBT1/gp-340 plays a dominant role in 
bacterial-binding. The use of synthetic peptides had offered us a simple and reliable method to study SAG-
bacterial interactions. This way we were able to pinpoint the minimal bacterial-binding site of SAG, an 11 
amino acid sequence. The repeated presence of this peptide in the native molecule endows SAG/DMBT1 with 
a general bacterial-binding feature with a multivalent character. 
DMBT1 germline deletions i.e. polymorphism, are predicted to impair interaction with any of the ligands 
identified in the present study. Based on the strategical location of SAG/DMBT1 on mucosal surfaces and 
body fluids (tear fluid, saliva, lung fluid), i.e. at the major sites of contact with harmful environmental stimuli, 
a systemic and pleiotropic effect of SAG/DMBT1 germline deletions might be predicted. This includes a 
contribution to human susceptibility to infection, inflammation, and even cancer.  
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SAMENVATTING VOOR NIET BIOLOGEN 
 
Speeksel en speeksel agglutinine (SAG) 
In de mondholte is een enorme verscheidenheid aan bacteriën aanwezig. In grote hoeveelheden kunnen ze 
schade veroorzaken aan tanden en kiezen (cariës), het tandvlees en zelfs het kaakbot. Speeksel speelt een 
belangrijke rol bij de afweer tegen bacteriën. Dit is goed merkbaar bij mensen die door ziekte, of door het 
gebruik van bepaalde medicijnen, of door bestraling geen of weinig speeksel kunnen aanmaken. Tanden en 
kiezen worden daardoor gevoeliger voor slijtage en cariës, en de zachte weefsels, zoals de tong, verhemelte en 
wangen, worden gevoeliger voor bacteriële infecties. 
Speeksel bevat verschillende eiwitten die betrokken zijn bij de afweer. Dit zijn eiwitten die bacteriën kunnen 
doden of hun groei kunnen remmen, zoals lysozym, lactoferrine, cystatinen en histatinen. Daarnaast bevat 
speeksel eiwitten die door binding en samenklontering (agglutinatie) de aanhechting van bacteriën aan 
bijvoorbeeld het tandoppervlak kunnen remmen of voorkomen. Voorbeelden van bacteriebindende eiwitten 
zijn immunoglubulinen, mucinen en agglutinine (SAG).  
De bacterie Streptococcus mutans is de belangrijkste veroorzaker van cariës, daar deze bacterie suikers omzet 
tot melkzuur en dat uitscheidt op het tandoppervlak. Omdat SAG het belangrijkste S. mutans bindende eiwit in 
speeksel is, wordt SAG met name onderzocht om zijn rol bij de handhaving van mondgezondheid en de 
afweer tegen cariës te analyseren. 
 
SAG is niet specifiek voor de mondholte 
Oorspronkelijk werd aangenomen dat SAG specifiek aanwezig zou zijn in de speekselklieren en speeksel. 
Later bleek dat SAG ook in andere weefsels aantoonbaar is. In longvocht komt een eiwit voor, genaamd gp-
340, dat identiek bleek te zijn met SAG. Evenzo is in hersenweefsel een eiwit aanwezig, met de aanduiding 
DMBT1 (Deleted in Malignant Brain Tumors 1), dat eveneens identiek met SAG bleek te zijn (hoofdstuk 2). 
Net als SAG speelt gp-340, door binding aan bacteriën en andere eiwitten, een rol in de afweer in longweefsel. 
DMBT1 werd voor het eerst onderzocht in de hersenen omdat het daar in sommige kwaadaardige 
hersentumoren afwezig bleek te zijn. Dit kan erop duiden dat DMBT1 de groei van bepaalde hersentumoren 
voorkomt. Mogelijk speelt DMBT1 ook een rol bij het voorkomen van longtumoren en tumoren in het 
maagdarmkanaal.  
Omdat SAG in de speekselklieren wordt aangemaakt (hoofdstuk 3), hebben we bestudeerd welke rol SAG in 
speekselkliertumoren speelt (hoofdstuk 4). We vonden overeenkomstig met DMBT1, dat SAG in sommige 
speekselkliertumoren afwezig bleek te zijn. Echter, de aanmaak van SAG in speeksel werd door het gezonde 
tumoraangrenzende weefsel juist verhoogd. Dus, mogelijk verraden verhoogde concentraties SAG in speeksel 
de aanwezigheid van een speekselkliertumor.  
 
Identificatie van het bacteriebindende gedeelte op SAG 
In hoofdstuk 5 is onderzocht met welk gedeelte van het eiwit SAG aan bacteriën kan binden. SAG is een eiwit 
dat bestaat uit een keten van 2413 aminozuren. Deze keten is opgebouwd uit 14 SRCR domeinen, 11 SIDs, 2 
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CUB domeinen, en één ZP domein (Fig. 1A). Om te onderzoeken of de SRCR domeinen een rol spelen bij 
bacteriebinding is een eiwitfragment van 13 SRCR domeinen en 11 SIDs losgeknipt (Fig. 1B). Dit grote 
eiwitfragment, bestaande uit 1722 aminozuren, was net als het oorspronkelijke SAG, in staat aan bacteriën te 
binden. Daarom veronderstelden we dat de bacteriebindende plaats op SAG gelegen zou kunnen zijn op een 
SRCR domein of een SID. 
Alle 13 SRCR domeinen zijn nagenoeg hetzelfde. Daarom kon een typische aminozuurvolgorde van een 
SRCR domein worden berekend (Fig. 1C). Dit is ook gedaan voor de SIDs (Fig. 1C).  
Om nu de precieze bacteriebindende plaats op het SRCR domein te bepalen, of om te zien of de SIDs daarbij 
betrokken zijn, zijn er zeven korte aminozuurketens (peptiden) gemaakt die met elkaar het SRCR domein 
beslaan, én twee peptiden die de SIDs vertegenwoordigen. Deze peptiden varieerden in lengte van 10 tot 22 
aminozuren (Fig. 1D). Van deze negen peptiden bleek er slechts één peptide te zijn, namelijk peptide 
SRCRP2, dat nog in staat was om, net als SAG, bacteriën te binden. Peptide SRCRP2 bestaat uit zestien 
aminozuren (Fig. 1E). Echter, we vonden dat slechts elf van de zestien aminozuren nodig zijn voor 
bacteriebinding (Fig. 1F) (hoofdstuk 7). Deze volgorde van elf aminozuren (peptide DMBT1pbs1) is de 
minimale aminozuurvolgorde op een SRCR domein van SAG die nodig is om bacteriën te kunnen binden en 
komt op elk SRCR domein slechts eenmaal voor Op deze manier hebben we uit 2413 aminozuren een gedeelte 
van 11 aminozuren gevonden dat belangrijk is voor bacteriebinding en samenklontering. 
 
 
 
Figuur 1. Bepaling van de minimaal bacteriebindende aminozuurvolgorde van SAG. A, SAG. De aminozuurketen 
van SAG is georganiseerd in SRCR (14), SID (11), CUB (2) en ZP (1) domeinen. B, een eiwitfragment van SAG 
bestaande enkel uit SRCR domeinen en SIDs. C, een typisch SRCR domein en SID. D, peptiden die samen een typisch 
SRCR domein en SID vertegenwoordigen. E, Alleen peptide SRCRP2 bindt aan bacteriën. F, de minimale 
aminozuurvolgorde van SAG die nodig is om aan bacteriën te kunnen binden. 
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SAG varianten en bacteriebinding 
Van SAG bestaan er korte en lange varianten. Een lang, oorspronkelijk SAG, heeft veertien SRCR domeinen. 
Sommige mensen maken een kortere variant aan met negen SRCR domeinen. In hoofdstuk 6 wordt 
aangetoond dat de kortste variant van SAG 30 tot 45% minder aantallen bacteriën kan binden dan de lange, 
oorspronkelijke variant.  
 
De bacteriebindende aminozuurvolgorde is uniek voor SAG/DMBT1  
Er bestaan naast SAG ook andere eiwitten met SRCR domeinen. Deze eiwitten komen niet alleen in de mens 
voor maar ook in een groot aantal diersoorten, zoals de spons, de fruitvlieg, de kip en het rund. Hoewel alle 
SRCR eiwitten sterk op elkaar lijken laten we in hoofdstuk 7 zien dat de bacteriebindende aminozuurvolgorde 
van SAG (peptide DMBT1pbs1) alleen voorkomt op SAG, in direct aanverwante SRCR eiwitten in de muis, 
rat en het konijn. 
 
SAG/DMBT1 bindt aan typische bacteriële structuren 
SAG kan aan veel verschillende soorten bacteriën binden. Hoewel deze bacteriën allemaal verschillend zijn, 
zijn er structuren die op alle bacteriën aanwezig zijn. Dit zijn lipopolysacchariden en lipoteichonzuur In 
hoofdstuk 8 laten we zien dat SAG, specifiek via fosfaatgroepen op deze bacteriële structuren, bacteriën kan 
binden. Deze eigenschap is typerend voor veel eiwitten die een rol spelen in de zogenaamde aspecifieke 
afweer. Antilichamen kunnen één ziekteverwekker herkennen, maar deze eiwitten herkennen een heel scala 
aan ziekteverwekkers.  
 
Conclusies en aanbevelingen 
Door de ontdekking dat SAG niet alleen in speeksel voorkomt, maar ook o.a. in de longen (gp-340) en de 
hersenen (DMBT1), werden nieuwe inzichten te verkregen over de eigenschappen van SAG. Zo hebben we 
ontdekt dat SAG niet alleen aan bacteriën bindt die in de mondholte voorkomen, maar in principe aan alle 
bacteriën bindt. Ook hebben we ontdekt dat SAG mogelijk een rol speelt het voorkomen van 
speekselkliertumoren. 
Omdat de aminozuurvolgorde van gp-340 en DMBT1, en dus ook SAG, bekend was, werden we in staat 
gesteld om de bacteriebindende aminozurenvolgorde op SAG de identificeren. In dit onderzoek bleek het 
gebruik van peptiden erg nuttig en waardevol.  
De SAG-peptiden die bacteriën binden zouden de aanhechting van schadelijke bacteriën aan tanden of andere 
oppervlakten kunnen remmen. Zo kunnen ze mogelijk in de vorm van een toevoeging in mond-, en 
spoeldranken, tandpasta, tandvernis, kauwgom, speekselsubstituten, zalf, neus- , en oogdruppels etc. worden 
ingezet.  
SAG bestaat in lange en korte varianten, waarvan de korte varianten 30-45% minder bacteriën kunnen binden. 
Aangezien SAG wordt uitgescheiden in speeksel, maar ook in andere mucosale vloeistoffen (slijmlaag van het 
maagdarmkanaal, longvocht, traanvocht) zou onderzocht kunnen worden of deze variatie in de lengte van 
SAG gerelateerd kan worden aan de gevoeligheid voor infecties, bijvoorbeeld cariës.  
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